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The Multiple Breath Washout (MBW) test is increasingly being recognised as a sensitive 
method of detecting early small airways lung disease. Indices of MBW include lung clearance 
index (LCI), Scond and Sacin. Factors that affect MBW variability have not been fully 
established. This thesis presents five studies which examine MBW repeatability in children 
with and without cystic fibrosis (CF) or asthma. 
 
MBW was performed using 0.2% sulphur hexafluoride and the modified Innocor (Innovision). 
Testing was performed at the Clinical Research Facility of the Royal Hospital for Sick 
Children in Edinburgh.  
 
(1) MBW and spirometry were performed in children with and without CF (n=20 in each 
group), initially while sitting and then 30 minutes after assuming a supine posture. 
LCI was found to significantly rise on lying supine in healthy children (p<0.01) and 
children with CF (p=0.03). 
 
(2) Thirty two children with CF performed MBW and spirometry on four study visits, 
results were correlated with findings from high resolution chest computed tomography 
scans taken on the first visit. LCI showed the strongest correlation with extent and 
severity of bronchiectasis (r=0.66, p<0.01 and r=0.69, p<0.01 respectively). 
Variability of LCI was similar to FEV1 over the 4 visits. 
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(3) MBW and spirometry of 66 healthy children were compared to 63 children with stable 
asthma; lung function of asthmatic children was related to symptoms and medication 
use. LCI was higher in the asthmatic group (6.7 vs 6.3, p<0.01); within the asthmatic 
group LCI was significantly higher if asthma was less well controlled (p=0.02). 
 
(4) Children with and without asthma (n=21 in each group) performed MBW and 
spirometry before and after exercise and again after salbutamol, symptom data was 
collected from asthmatic children. Baseline LCI was abnormal in the asthmatic group 
who had severe exercise induced bronchospasm during testing. 
 
(5) Asthmatic children admitted to hospital due to exacerbation performed MBW and 
spirometry. Mean (SD) LCI was abnormally high at 8.5 (1.7) in the nine patients 
recruited and returned to normal 6.7 (0.6) in three patients who attended follow up. 
 
I have presented evidence that LCI is repeatable and sensitive to early disease in CF and 
asthma. I have described for the first time the effects of exercise and exacerbation on 
MBW indices in asthmatic children. MBW is potentially a very useful tool in paediatrics; 




The Multiple Breath Washout (MBW) test measures lung function and is easy for children of 
all ages to perform. It is proving to be a sensitive way of detecting early disease in conditions 
such as cystic fibrosis (CF). Its use had previously been limited as it required bulky and 
expensive equipment. More portable, less expensive equipment has now been developed and 
the test is growing in popularity. 
 
Although there is evidence that the test could be very useful in a range of diseases we still have 
limited information regarding the factors which might affect test results. We need to know 
what affects MBW results so that changes can be interpreted meaningfully for the patient. In 
my thesis I have presented five studies in which different variables are examined.  
 
The effect of body position on MBW in children with and without CF was examined. The 
variability in MBW results over several visits in children with CF was studied and related to 
disease identified by lung CT. MBW results were compared between healthy children and 
children with asthma. The effects of exercise in children with and without asthma was 
investigated. MBW was also performed in children admitted to hospital due to an exacerbation 
of asthma. 
 
We found that change in posture does alter MBW test results. Results can reliably be repeated 
in children with CF over several visits. Children with asthma have different results compared 
to healthy children and asthmatic children with abnormal results are more likely to have 
exercise induced symptoms. MBW results are abnormal in children suffering an exacerbation 
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1.1 Small Airways Disease 
The lung has a surface area of over 100m2, which is necessary for efficient gas exchange. To 
achieve this large surface area the human airway branches into 23 generations to supply more 
than 300 million alveoli. The first 16 airway generations are termed conducting airways and 
generations 17-23, intra-acinar airways. There are approximately 20-30,000 acini which 
consist of terminal respiratory bronchioles and alveolar ducts and sacs. Small airways are 
defined as those with a luminal diameter of less than 2mm, and these correspond to airway 
generations 8-23 (1). 
 
Figure 1: Illustration of the airway tree including airway generations. Broken lines denote the 
total airway cross-sectional area which increases dramatically in the lung periphery (1). 
 
Gas flows at high velocity through conducting airways by linear convection. As the airways 
divide, linear gas flow velocity declines. In the acinus gases mix by diffusion. The entry of the 
acinus marks the point at which the contribution of diffusion and convection to gas flow are 
equal, this has been termed the “diffusion convection front”.  
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Small airways disease is an important component of many serious paediatric respiratory 
conditions including cystic fibrosis (CF), asthma, bronchopulmonary dysplasia and 
obliterative bronchiolitis. Conventional lung function testing often has a low sensitivity for 





1.2 Lung Function Testing In Children 
 
Lung function testing is an objective tool in the assessment of patients with respiratory disease. 
In the research setting, lung function testing is used to understand the natural history of disease 
and lung development and to measure outcome in clinical trials. Clinically, tests are used to 
assess disease severity, predict prognosis and aid treatment decisions. Testing in children 
differs from that in adults because of apparatus requirements, compliance with testing and in 
interpretation of results with growth.  
 
To ensure reproducibility and repeatability of testing the American Thoracic Society (ATS) 
and European Respiratory Society (ERS) have produced joint guidelines for the 
standardisation of some lung function tests (including spirometry and the measurement of lung 
volumes) in adults and children (2-7). The reliability of a physiological test can depend on 
knowing what factors cause variability in its results. Standardisation of testing ensures that 
variance is minimised so that testing is comparable and can be used to identify deterioration 
or improvement in disease. 
 
Most lung function tests including spirometry, the forced oscillation technique, the interrupter 
technique and plethysmography measure resistance to flow across airways. Resistance is 
raised in conditions which cause airways obstruction and is largely dependent on obstruction 
to medium and large airways. Airways of less than 2mm in diameter are estimated to contribute 
10% of total airways resistance, despite a cross sectional area many magnitudes greater than 
that of larger airways (8). Measures of airways resistance may therefore be insensitive in 
detecting early peripheral airway disease.  
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Children with lung disease can often have normal conventional lung function. Many children 
with CF have normal FEV1 (9, 10); however some of these children will have structural lung 
damage detected using CT scanning (11, 12). Most children with chronic persistent asthma 
have normal FEV1 (13, 14) in whom symptoms correlate poorly with both FEV1 and FEF25-75 
(13, 15). Disease in these groups may be missed because it exists within the small airways, a 
method of detecting this disease is required to improve understanding of pathogenesis, guide 




Spirometry is the most commonly used lung function test in paediatric respiratory clinics. 
Testing has been standardised by an ATS/ERS task force (3). Standardisation ensures that 
variability of results is minimised, accuracy is improved and abnormalities may be more easily 
detected. 
 
Indices of lung function derived from spirometry need to be interpreted in the context of patient 
age, sex, height and race. The Global Lung Function Initiative (GLI) have compiled over 
160,000 results from healthy non-smokers in 33 countries to produce continuous prediction 
equations for spirometric indices throughout growth (16). There are limitations within these 
equations, there are only 4 ethnic groups represented, Caucasian, African-American, North 
Asian and South East Asian; individuals who are not represented or who are of mixed race use 
a composite equation. The use of reference equations is dependent on accurate height and age, 
Quanjer et al demonstrated bias in results derived from inaccuracies in these variables, which 
is most pronounced in children (17).  
 
In clinical practice spirometry is commonly presented as a percentage of predicted value. 
Interpretation of percentage of predicted values is difficult because the variability of 
spirometry changes with age. The ATS and ERS define the lower limit of normal for 
spirometry as the 5th centile of normal distribution or a z score of -1.64 (16). The GLI 
demonstrated variability in spirometry with age and showed that although a FEV1 of 80% 
predicted may be abnormal in some children, in younger children it might fall within normal 




Figure 2: Percentage of healthy male and female non-smokers (n=74,187) in whom FEV1 is 
<80% predicted in the GLI cohort (16). 
 
Spirometry is volitional and requires a coordinated effort from the patient. The participant 
must sit and wear a nose clip, inspire to total lung capacity (TLC) and exhale forcefully to 
residual volume (RV). Exhalation must continue until no longer possible; to terminate the test 
no change (<0.025L) in volume for ≥1 second must occur. Exhalation must last for ≥3 seconds 
if the child is <10 years old and ≥6 seconds if older than 10 years. There should be no leak, 
the patient must exhale continuously and any tests in which a cough occurs in the first second 
should be discarded. An adequate test requires a minimum of 3 acceptable manoeuvres, the 
difference between the largest and next largest FVC and FEV1 should be ≤0.150L unless FVC 
is less than 1.0L in which case the difference should be ≤0.10L. Testing can be repeated if 
these criteria are not met within the first 3 tests but should generally not exceed 8 manoeuvres 
(3). Testing is generally felt to be possible from the age of 5-6 years. Spirometry in children 
as young as 2 years of age can be made possible using incentive spirometry but testing in pre-





1.2.1.1 Forced Vital Capacity (FVC) 
 
FVC is the maximal volume of air exhaled with maximally forced effort from a maximal 
inspiration expressed in litres, at body temperature and ambient pressure saturated with water 
vapour (BTPS). Volumes measured by spirometry are corrected for BTPS to reflect actual 
lung volumes. 
 
1.2.1.2 Forced expiratory volume in 1 second (FEV1) 
 
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a 
position of full inspiration, expressed in litres at BTPS.  
Figure 3: Flow Volume Loop (Wikimedia) 
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FEV1 is a measure of airway obstruction and is widely used in clinical medicine as a diagnostic 
and monitoring tool in a wide range of respiratory diseases. It is accepted as a biological 
marker; a decline in FEV1 is understood to directly indicate worsening disease. FEV1 is also 
the most commonly used measure of lung function in research studies.  
 
The largest FVC and FEV1 are recorded even if they do not come from the same curve. 
 
1.2.1.3 Mean forced expiratory flow during the middle half of the FVC (FEF25-75) 
 
Also known as the maximal mid-expiratory flow, FEF25-75 is taken from the expiratory flow 
with the largest sum of FEV1 and FVC. FEF25-75 has been shown to be a more sensitive marker 
of small airway disease than FEV1 (19). However, it is highly dependent on the validity of the 
FVC measurement and the level of expiratory effort. The GLI found the coefficient of variation 
(CV) of FEF25-75 to be between 20 and 33% in healthy people aged <20 years (16). The very 
high CV limits its clinical utility; another more repeatable yet sensitive test of small airways 




1.2.2 The Multiple Breath Washout Test 
 
The Multiple Breath Washout (MBW) test is a non-volitional lung function test that was first 
described in the 1950s, it is facing renewed interest because of its sensitivity in detecting small 
airways disease. MBW detects small airways disease by measuring efficiency of gas mixing 
within the lung by analysing the elimination of an inert gas during tidal breathing. Gas mixing 
is essential for effective respiration and requires efficient ventilation; inspired gas must reach 
areas of gas exchange and resident gas must be expired. Small airways disease disturbs 
ventilation to parts of the lung, due to inflammation, scarring, mucus or changes in airway tone 
or compliance. Obstructed alveoli can receive ventilation through collateral channels (8) but 
this consists of existing alveolar (not freshly inspired) air, thus reducing the efficiency of gas 
mixing.   
 
Various MBW methods exist but all measure the efficiency of clearance of an inert marker gas 
from the lungs. The gas should be safe to inhale, not participate in gas exchange and not be 
absorbed or excreted by the body in significant amounts. Gases which have been used include 
nitrogen (N2), argon, helium (He), methane and sulphur hexafluoride (SF6). Different gases 
will convey information about different zones of the lung. Heavier gases such as SF6 diffuse 
less readily than lighter gases and when used in MBW convey information from deep within 
the acini. Lighter gases such as helium diffuse more quickly and in MBW give information 
regarding more proximal regions. Comparison of the indices generated by simultaneously 




In N2 washouts resident N2 is cleared from the lung with 100% oxygen (O2). Advantages of 
N2 washouts include the widespread availability of 100% O2, lack of a wash-in phase (required 
with exogenous gases) and complete starting equilibrium of N2 throughout the lung. N2 is 
becoming the most commonly used gas in MBW because of newly developed commercially 
available washout systems which utilise N2 and reduce the greenhouse burden of SF6. A 
disadvantage of N2 is that N2 is excreted by the body in small amounts; the amount is not 
thought to significantly affect washouts in healthy subjects but in longer tests in diseased lungs 
may cause an over-estimation of functional residual capacity FRC (20, 21). 100% O2 can affect 
breathing pattern in infants although it is not thought to significantly alter breathing pattern in 
older children (21).  
 
SF6 has been used in 4% and 0.2% concentrations for MBW. It is completely inert, not being 
absorbed or excreted by the body. There is some evidence that SF6 in high concentrations 
(>56%) can cause temporary reductions in mental and psychomotor performance (22). In 






The lack of a commercially available validated system for performing MBW has been a factor 
preventing its widespread use. Commercially available devices have now become available. 
The device must continuously measure and record inert gas concentrations and synchronise 
this with respiratory flow to determine inspired and expired inert gas volumes.  Several 
different devices have been and are being used to perform MBW. Figure 4 shows a table 
detailing the characteristics of some current washout systems.  
 
MBW has traditionally been performed using the respiratory mass spectrometer (RMS). It can 
measure multiple gases simultaneously, the sample flow is low so only a small sample is 
required which does not interfere with respiratory volumes and it has a short response time 
allowing accurate synchronisation with flow (23). However it is a large and highly expensive 
machine to buy and maintain. 
 
More recently commercially available ultrasonic flowmeters (USFM) have been developed 
that measure SF6 or N2 indirectly. Indirect measurement is performed either through changes 
in molecular mass or using simultaneous oxygen and carbon dioxide measurement and 
Dalton’s law of partial pressures to calculate N2 concentration (24). The mainstream USFM 
has been validated against the RMS in measuring FRC in infants (25) but a lack of validated 
BTPS correction algorithms have limited its use beyond this age group. USFM sidestream 
systems with the use of nafion tubing avoid problems with temperature and humidity and have 
been validated against the RMS in older children (21, 24), the dead space of sidestream USFMs 
precludes their use in infants. Indices of phase III slope analysis have not been reported from 
USFM molecular mass washouts but are possible with indirect nitrogen washouts using 
simultaneous oxygen and carbon dioxide analysis. 
 25
 
Figure 4: The characteristics of some currently available MBW systems - extracted from the 
2013 ERS Consensus Statement on inert gas washout measurement (21). 
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Research performed at Edinburgh’s Royal Hospital for Sick Children and Western General 
Hospital has adapted the Innocor (Innovision, Denmark) device, a photoacoustic analyser 
originally designed to measure cardiac output, to perform MBW (26). The adaptions described 
below were made in consultation with Innovision and other centres performing MBW.  
 
 
Figure 5: Innocor with adapted patient interface 
 
The patient interface (or rebreathing valve unit) supplied with the Innocor is replaced (see 
figure 6). A mouthpiece fitted with a flowmeter and gas sampling port is connected to a 
detachable flow past tube which is used to supply tracer gas during the wash-in and is then 
removed at the start of washout. Pre sampling capillary equipment dead space is 36mls; 
ATS/ERS guidelines recommend a maximum apparatus dead space of 2ml/kg body weight 
(27) meaning this set up would be unacceptable for use in infants.   
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Figure 6: Patient interface used for inert gas washout with Innocor gas analyser (26). 
 
Nafion tubing is used to connect the sampling capillary to the Innocor. Nafion equilibrates the 
humidity of the sampled gas so that gas concentrations do not change on route to the analyser. 
The minimum length of nafion that equilibrates humidity is used (40cm) because longer 
lengths allow more spreading of the gas which causes a slower rise time within the analyser. 
 
The Innocor uses photoacoustic spectrospcopy to measure gases including SF6 and carbon 
dioxide. The Innocor is a highly sensitive analyser and the signal: noise ratio is better than the 
RMS (944:53 vs 200:13 respectively) meaning that lower concentrations of inert gas can be 
accurately measured (26). In SF6 Innocor washouts 0.2% SF6 can be used as opposed to the 
4% SF6 required for the RMS, reducing the burden of this greenhouse gas on the environment.  
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The sample rate of the Innocor is higher than that of the RMS (100Hz vs 33Hz respectively) 
(21); a minimum of 100Hz has been recommended for use in infants to accurately detect 
changes in breathing pattern and reconstitute breathing pattern.  The sample flow of the 
Innocor is higher than that of the RMS (120mL/min vs 20mL/min) but the sampling capillary 
is placed distal to the flowmeter to prevent volume recordings being affected. 
 
Synchronisation of flow and gas concentration is integral to accurate volume calculation. 
Factors such as the delay between the transit of gas between sampling site and analyser and 
the analyser response time need to be considered and corrected for. Mainstream analysers 
reduce the impact of transit time, however mainstream analysers increase dead space which 
may affect ventilation, particularly in children.  The length of analyser rise times are more 
important in faster breathing patterns, more often seen in young children. Changes to signal 
alignment in a mainstream N2 ultrasonic MBW system have demonstrated significant 
alterations in calculated volumes and thereby MBW derived indices (28).  A decrease in gas 
concentration delay time by 40ms lead to a mean increase in lung clearance index (LCI) of 
12%, an increase in delay time by 40ms lead to a decrease in LCI of 9%. 
 
The response time of the Innocor to a step change in SF6 concentration is longer than the RMS 
(154 vs 64ms respectively). A response time of less than 100ms is recommended by the 
ERS/ATS expert group to prevent errors in calculation of gas volumes (21). To allow for the 
more prolonged response time, gas concentration and flow signals are offset by an additional 
50ms during analysis. The accuracy of the modified Innocor system in integrating flow and 
gas signals with this offset has been validated using gas calibration syringes set to deliver 
different volumes of SF6 (26).  To improve the response time the oxygen analyser which is 
positioned in series, proximally to the photoacoustic analyser within the Innocor can be 
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bypassed. This prevents the spreading of gas within the oxygen analyser and improves the 
system rise time from 154ms to 97ms.  
 
The Innocor is much less expensive and more portable than the RMS, and like the RMS it 





1.2.4 Performing MBW 
 
 
There are two phases in exogenous inert gas MBW, wash-in and washout. In the wash-in 
phase, the patient breaths in the inert gas through a mouth piece until it is evenly distributed 
throughout the lung (as determined by its equal concentration during inspiration and 





Figure 7: Flow and SF6 concentration throughout a washout (Software courtesy University of 
Gothenburg)  
 
The washout phase begins with the disconnection of the gas supply. This must occur during 
expiration so that the first breath of the washout does not contain an unknown volume of inert 
gas which subsequently makes calculation of MBW indices impossible. The patient can either 
be encouraged to achieve set tidal volumes throughout the washout or to breathe normally with 
the aid of some distraction (most commonly an age appropriate video). Flow and tracer gas 
concentration are displayed throughout the washout. The test is terminated when the maximum 
SF6 Concentration 
Flow Wash-In: Equilibration of SF6 Concentration Start of Washout phase 
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end expiratory gas concentration falls to less than 1/40th of that at the end of the wash in phase. 
This is a historical threshold set due to the resolution of the gas analyser at the time. 
 
The test is performed three times at each visit. Each test takes approximately 5-10 minutes 
depending on the degree of lung disease. There is slower clearance of gas in more severe 
disease meaning a longer testing duration. 
 
MBW can be performed in preschool children and infants. As discussed, equipment needs to 
be suitable for use in small children with a small dead space and fast rise time. A face mask 
can be used instead of a mouthpiece; sedation may be necessary in infants.  
 
Testing is operator dependant and adequate training is essential. The set-up of the equipment 
and observation of the patient throughout testing requires appreciation of the factors that might 
influence test results. I was trained by my predecessors within the UK Cystic Fibrosis Gene 
Therapy Consortium who adapted the Innocor for MBW and wrote a consortium wide standard 






Several indices of ventilation distribution inhomogeneity derived by performing MBW have 
been described. These include the Lung Clearance Index (LCI), which is a measure of overall 
ventilation inhomogeneity and indices of phase 3 slope analysis Scond and Sacin, which localise 
problems to either conducting airways or the acinar region respectively. Moment ratios are 
briefly discussed but have not been investigated within this thesis.  
 
1.2.5.1 Functional Residual Capacity (FRC) 
 
FRC is the volume of air present in the lungs at the end of passive expiration, it is mainly 
governed by the interaction between the elastic recoil of the chest and that of the lungs. FRC 
can be measured using plethysmography, helium dilution or MBW. 
 
Figure 8: Static lung volumes and capacities based on a volume–time spirogram of an 
inspiratory vital capacity (IVC). IRV: inspiratory reserve volume; VT: tidal volume (TV); ERV: 
expiratory reserve volume; RV: residual volume; IC: inspiratory capacity; FRC: functional 
residual capacity; TLC: total lung capacity (4). 
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FRC is calculated during a washout by dividing the volume of expired inert gas (VGAS) by the 
difference between end tidal gas concentrations at the start (CINIT) and end (CEND) of washout. 
  FRC = VGAS / CINIT- CEND 
FRC calculated using MBW or gas dilution excludes obstructed non ventilated regions of lung. 
In patients with severe airways obstruction FRC will be lower when calculated using MBW 
or helium dilution compared to plethysmography derived FRC (4). 
 
1.2.5.2 Lung Clearance Index (LCI) 
 
LCI reflects overall ventilation inhomogeneity. In most published MBW studies and this thesis 
it corresponds to the number of lung volume turnovers required to clear inert alveolar gas to 
1/40th of its starting concentration. Alveolar gas concentration is estimated using end tidal 
concentration (Cet); Cet is dependent on accurate identification of the end of the breath. Recent 
studies have found that LCI calculated using the number of lung volumes required to clear 
inert gas to 1/20th of initial concentration was repeatable in patients with and without CF 
disease and shortened duration of testing (29, 30). However there is some evidence that 
shortening the test may make it less sensitive to increasing disease severity in children with 
CF (31). 
 
LCI is calculated by dividing the cumulative expired volume (CEV) required to clear the inert 
gas by the functional residual capacity (FRC). LCI will rise with delayed inert gas clearance 
from the lung due to ventilation heterogeneity. LCI will depend on the choice of inert gas; 
heavier gases such as SF6 generate higher values compared to lighter gases such as He. N2 
MBW generates higher LCIs than SF6, possibly because it is an endogenous gas (32). 
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  LCI = CEV / FRC 
LCI is reported as the mean of 2-3 technically acceptable manoeuvres in which the FRC differs 
by less than 10%. 
 
1.2.5.3 Phase III slope Analysis 
 
A tidal breath can be divided into three phases if inert gas concentration is plotted against 
expired volume, as illustrated in figure 9. During phase I the inspired gas sitting in anatomical 
dead space is expired. Phase II corresponds to a transition phase in which inspired gas mixes 
with alveolar gas. During phase III at typically 65-95% of expired volume, alveolar gas is 
expired and it is this phase III slope which can be analysed to assess ventilation heterogeneity. 
Individuals with diseased lungs and inhomogeneous gas mixing have steeper phase III slopes 
than those with heathy lungs. The first breath in a washout reflects gas flow from better 





Figure 9: Concentration of tracer gas versus expired tidal volume (33)  
In phase III slope analysis progressive change in the alveolar or phase III slope of each breath 
throughout the washout is examined. To allow comparison of progression each phase III slope 
(SIII) is normalised for mean tracer gas concentration over the slope (SnIII) and plotted against 
lung volume turn over (TO). SIII will depend on the tracer gas, higher SIII is seen with use of 
heavier gases in healthy people, but this may reverse in diseased lungs (21). 
 
The site of ventilation inhomogeneity can be determined by the analysis of SnIII against TO 
(34). Abnormal compliance and resistance in the conducting airways are believed to cause 
convection dependent inhomogeneity (CDI), which causes a steady increase in SnIII 
throughout the washout and is measured by Scond. Scond is calculated by determining the 
increase in SnIII between TO 1.5 and 6.0.  
Scond = delta SnIII (1.5-6.0 TO) 
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Structural asymmetries in the acini cause diffusion-convection dependent inhomogeneity 
(DCDI), and this is measured by subtracting the contribution of the conducting airways from 
the SnIII of the first breath to produce Sacin (35).  
Sacin = first breath SnIII – (first breath TO x Scond) 
The value of Scond or Sacin increase as ventilation heterogeneity in the corresponding lung zone 
increases. 
 
Figure 10: Conceptual illustration of calculation of phase III slopes. SnIII (O) for each breath 
plotted against corresponding TO value. Scond is calculated by the increase in SnIII between 
TO 1.5 and 6.0 (       ). DCDI for each breath (    ) =SnIII-CDI contribution. Sacin (    ) = first 
breath DCDI (1) 
 
Fluctuating tidal volume affects SIII, therefore for optimum phase III slope analysis a fixed 
tidal volume and respiratory rate are set. However, set tidal volumes are impractical in some 
children and to attempt to correct for fluctuating tidal volumes and to allow comparison 
between individuals SnIII is multiplied by tidal volume. If tidal volumes fall below a certain 
minimum, identification of the phase III slope is impossible (35). For this reason Aurora’s 
 37
group stipulate a minimum expired breath volume of (3.5 x body weight (kg) + precapillary 
dead space) x2 (ml). This assumes the SnIII slope starts at double the airway and instrument 
dead space. Breaths below this threshold are excluded from analysis (35). Breaths in which 
SIII is unidentifiable due to a breath hold or cough should also be excluded; washouts in which 
>3rd of breaths are excluded should not have phase III slope indices reported (21). I was unable 
to exclude breaths with the software I had to my disposal. 
 
1.2.5.4 Moment Ratios 
 
Moment Ratios (MDM) relate to the mean number of lung TOs that a molecule remains in the 
lung. Disease skews the washout curve to the right with slower peripheral release of inert gas 
and MDMs describe the degree of skewness. Concentration normalised end tidal inert gas 
concentration (Cnet), Cnet*TO and Cnet*TO2 are plotted against TO and moments 0, 1 and 2 
are calculated by determining the area under the each curve respectively. MDM1 is the ratio 
between 1st and 0th moments of the washout and MDM2 the ratio between the 2nd and 0th 
moments. Truncation of the washout at either 6 or 8 TOs is recommended to allow comparison 
between subjects. Moment ratios are useful in children with variable respiratory rate and tidal 
volume but healthy children may require longer washouts to achieve 6-8 turnovers and low 
gas concentrations require very accurate analysers (21). Moment ratios are measures of overall 
ventilation heterogeneity and are not thought to offer additional information to LCI, which is 
more widely reported in the literature (1). 
 
1.2.5.5 Trapped gas volume (VTG) 
Gas trapping occurs due to airway closure in regional lung units and increases in conditions 
which cause peripheral airways obstruction. Gas trapping can be measured following 
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termination of standard MBW testing by asking the patient to take five inspiratory capacity 
breaths and measuring the volume of lung recruited. Only the regions which can be 
unobstructed by performing a large breath will be measured, regions which remain obstructed 
will not be measured. 
 
1.2.6 Single Breath Washouts 
 
Single breath washout (SBW) measures gas mixing within a single breath. The most 
commonly used SBW test uses N2. The patient performs a vital capacity (VC) manoeuvre at 
constant low flow (400-500mL-s); following exhalation to residual volume (RV), the patient 
inhales 100% oxygen (O2) to total lung capacity (TLC) and then exhales back to RV. The 
phase III slope of N2 concentration over the mid portion of the exhalation from TLC to RV is 
measured (36). Other inert gases can be used and are washed in during inspiration between 




Figure 11: Example of a typical single-breath washout (SBW) trace. Nitrogen gas (N2) 
expirogram showing calculation of phase III slope (SIII) in a vital capacity.  SIII is calculated 
between 25% and 75% of the expired volume (SIII 4.4%·L−1), to avoid the contribution of phase 
IV (21). 
 
Peripheral airway contribution to VC SBW is unclear. VC SBW is thought to be more 
influenced by inter regional differences in gas distribution and airway closure during 
inspiration compared to tidal breathing techniques. The technique can be modified so that 
initial wash in occurs from FRC to TLC or a volume above FRC, which may better detect 
peripheral airway ventilation inhomogeneity (21). A SBW test using a single inert gas cannot 
localise the site of inhomogeneity. Recently, SBW with the simultaneous use of more than one 
inert gas with different molecular masses has made localisation of the site of inhomogeneity 
with SBW possible (37).   
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1.3 Variability of MBW derived indices in Children 
 
1.3.1 Healthy population – Normal values 
 
MBW testing is not standardised and reported healthy values vary between centres. Factors 
which are likely to affect normal values include the choice of inert gas, equipment and 
software.   
 
Ranges of normality for MBW derived indices from infancy through to adulthood differ 
slightly (26, 35, 38, 39). MBW derived indices appear to decline through infancy and early 
childhood and then slowly increase in the elderly (40, 41). In pre-school children LCI is 
dependent on height but once children have obtained approximately 115cm in height at around 
6 years of age height appears to become insignificant (41). In healthy people there are minimal 
gender differences in LCI (26, 41, 42). There have been no published studies regarding 
differences in normative values between ethnic groups. 
 
In Edinburgh normative values for LCI using the modified Innocor and 0.2% SF6 were derived 
in 48 healthy adults (aged 19-58 years) as 5.9 - 7.5 and from 12 healthy children (aged 6-16 
years) as 5.3 - 7.3 (26). This was a small study but the range obtained was in concordance with 
the following published studies which used 4% SF6. The upper limit of normal for LCI was 
reported as 7.23 in a UK study of 33 healthy controls aged 6-16 years, in whom testing was 
performed using a mass spectrometer (43). The normal range for LCI of pre-school children 
was determined from a group of 37 healthy children (mean age 4.2 years) in London using a 
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mass spectrometer as 6.0-7.8 (39). The upper limit of normal in a German/Austrian study using 
the ultrasonic flow sensor was 7.0 (44). 
 
In healthy children LCI does not appear to correlate with FEV1 (43). As described earlier FEV1 
is a measure of airway resistance and LCI a measure of ventilation heterogeneity of the small 
airways.  
 
Reported healthy ranges for indices of phase III slope analysis vary; measurement has not been 
standardised and values appear dependant on the choice of inert gas, testing protocol and 
analysis. Verbanck et al performed N2 MBW on two groups of 10 adults (with no respiratory 
disease) with a targeted one litre tidal volume; they reported mean Scond as 0.031-0.033L-1 and 
mean Sacin as 0.067-0.075L-1; the upper limit of normal for Sacin was described as 0.11-0.13 L-
1 (45). The group performed a larger study in 63 healthy adults using the same technique and 
found mean (SD) Scond was 0.028 (0.001) and Sacin was 0.072 (0.003) (46). In Downie et al’s 
study which included 17 healthy adults and used N2 MBW with a N2 analyser and set tidal 
volume of 1-1.3L, mean (SD) Scond was 0.019L-1 (0.01), with an upper limit of normal of 
0.037L-1, Sacin mean (SD) was 0.094L-1 (0.03) (47).  
 
Gustafsson studied N2 RMS MBW in a group of 18 children (mean age 15 years) with relaxed 
tidal breathing and reported mean (SD) Scond as 0.045L-1  (0.021) and Sacin as 0.090L-1 (0.022) 
(48). Sonnappa et al performed SF6 MBW with a RMS in 65 healthy pre-school children (aged 
4-6 years) and mean (95% CI) Scond was reported as 0.010L-1 (0.007-0.014), the upper limit of 
normal was 0.045L-1; mean Sacin was 0.042L-1 (95% CI 0.035-0.051) (49). In Edinburgh the 
modified Innocor, 0.2% SF6 and relaxed tidal breathing was used in a study of 29 healthy 
children, mean (SD) Scond was 0.017L-1 (0.02) and Sacin was 0.12L-1 (0.06) (50). Phase III 
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slope indices appear dependent on testing protocol and seem to be different in children 





1.3.2 Evidence of repeatability and reproducibility in healthy children 
 
LCI has good intra and inter visit reproducibility in healthy volunteers (26). Forty nine healthy 
adults and 13 healthy children were studied in Edinburgh using the modified Innocor and 0.2% 
SF6 in order to assess the intra and inter visit reproducibility of LCI. Participants were non-
smokers with no history of significant respiratory disease. Tests were excluded if FRC varied 
by more than 10% from both the other 2 tests. The mean (SD) coefficient of variation (CV) 
for LCI was 3.6 (2.1) % for healthy adults and 5.4 (3.8) % for healthy children. In 16 
participants testing was repeated after a mean of 36 days, the 95% limits of agreement for LCI 
were -0.78 to 0.46 (26).  
 
A German and Austrian collaborative showed LCI to be highly repeatable with good short and 
long term reproducibility in healthy children and adolescents (44). Fuchs et al used the 
sidestream ultrasonic flow sensor to study 44 volunteers aged 5.3 to 20.3 years. All participants 
did the first set of 3 tests, 22 did a second set an hour later and 34 returned 6-15 months later 
for a 3rd set of testing. Mean (SD) LCI was 6.2 (0.4), 6.3 (0.4) and 6.0 (0.4) at the 1st, 2nd and 
3rd set of tests respectively. The mean within set CV for LCI was 5.1%. Short term (set 1 to 2) 
repeatability, assessed using a mean intra individual CV was 4.2% with a mean difference of 
-0.13 (95% CI -0.35; 0.087) over the 2 sets. Long term (set 1 to 3) repeatability had a mean 
CV of 5.1% with a mean difference of 0.017 (95% CI -0.16; 0.348). 
 
Age does not appear to affect the repeatability of testing for LCI. In studies of both pre-school 
and school aged children in London using a mass spectrometer the mean within subject intra-
visit CV was 5.2% (39, 43).  
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LCI results from different countries appear to be very similar (43). Results from 33 children, 
aged 5.9-16.8 years in the UK were compared to those obtained in Sweden from 24 healthy 
children aged 7.6-15.7 years. The mean (SD) LCI in the UK was 6.45 (0.49) compared to 6.33 
(0.46) in Sweden (43). In Fuchs et al’s study of the reproducibility and repeatability of LCI, 
subjects in Germany had a mean (SD) LCI of 6.13 (0.3) and in Austria mean (SD) LCI was 
6.27 (0.5), there was no statistical difference between the two groups (44). 
 




It is possible to perform MBW in people of all ages. In preschool children a face mask can be 
used instead of the standard mouthpiece (39). Infants may require sedation (51, 52). LCI was 
initially thought to be independent of age in healthy children (42, 43), however there is 
increasing evidence that infants and preschool children have slightly higher ranges of 
normality (35, 41, 53).  
 
MBW performed on the first day of life has demonstrated increased ventilation inhomogeneity 
which subsequently improves over the first day and week of life (51). This may be due to 
retention of fluid within the lung, or alveolar stabilisation and establishment of the FRC (51). 
 
Infants have been shown to have slightly higher LCI than older children (35). There are several 
potential reasons for this: it could be an artefact due to the relatively larger apparatus dead 
space. It may alternatively be due to less negative end expiratory intra pleural pressure caused 
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by a more compliant chest wall resulting in a tendency for peripheral airway closure during 
tidal breathing. The difference nevertheless is small; the mean LCI of a group of 14 infants 
assessed by Aurora et al was 7.2, which lies within the healthy reference range for an adult 
(35).  
 
Healthy preterm infants have been shown to have greater ventilation inhomogeneity than term 
babies (52). Gas mixing improves between 34 and 40 weeks post menstrual age but remains 
poorer than in babies born at term when tested at 40 weeks. It is postulated that this is because 
preterm birth impairs the formation of alveoli and decreases lung tissue elasticity. 
 
Lum et al collected MBW data from 497 healthy subjects aged 2 weeks to 19 years from three 
centres using mass spectrometry and SF6 (41). They found that age and height were 
independent predictors for FRC but that once height was excluded using multivariate analysis, 
age was no longer predictive for LCI. They found a small reduction in LCI throughout 
childhood but once children had attained a height of approximately 115cm (at around 6 years 
of age) changes were minimal. The higher LCI in younger children is postulated by the authors 
as being due to asymmetrical branching in the acinar region of lungs undergoing rapid 
alveolisation. 
 
The range of normality for LCI is similar for healthy children and adults. Horsley et al. found 
a weak correlation between LCI and age in their study of healthy children and adults (Pearson 
r2= 0.16, p<0.002). However, the normal ranges for children (≤16 years) and adults overlapped 
markedly (5.3-7.3 and 5.9-7.5 respectively) (26).  
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Aurora et al reported that Scond and Sacin were independent of age in children from birth to 16 
years (35). Verbanck et al have more recently reported small increases in LCI, Scond and Sacin 
with age in adults aged 25-65 years (40). 
 
Longitudinal studies of healthy individuals are required to definitively define the effect of age 
on MBW results. The evidence suggests that although the effects of age and height on MBW 
may be small they do need to be considered when interpreting results particularly when 
studying infants and pre-school children. The use of age and height matched control groups in 
pre-school studies could limit the influence of age and height on results. Reference equations 
to standardise LCI to z-scores in pre-school children have been published (41). However the 
patient cohort from which these equations were derived is limited (compared to cohorts used 
to determine reference equations for other tests including spirometry) by the number of 
subjects (497), testing centres (3) and ethnicity (80% white European). In addition testing was 
performed using a RMS and 4% SF6 and equations would not be applicable to a different 
system. The European Cystic Fibrosis Society Clinical Trial Network Standardisation 
Committee have published LCI reference ranges for different equipment, gases, method of 
analysis, software and patient age (54).  
 
1.3.3.2 Tidal Volume 
 
Fluctuating tidal volumes throughout a washout may affect MBW indices. Large inspiratory 
breaths can release trapped gas, small inspiratory and expiratory breaths lead to steeper phase 
III slopes and expiration beyond FRC can lead to phase IV (21). Studies in adults have 
implemented set tidal volumes, often of 1 litre. However, this is not feasible in some children 
who may have difficulty achieving a set tidal volume throughout a washout.  
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Changes in breathing pattern can affect FRC and LCI. Yammine et al asked children with and 
without CF to perform MBW with normal tidal breathing and again with tidal volumes of 1 
Litre. They found that FRC fell and LCI rose significantly with the fixed 1 litre breathing 
pattern in both groups (55). In children with CF, mean (SD) LCI increased from 11.0 (2.2) to 
13.0 (2.6) (p=0.011) and in healthy children LCI rose from 6.8 (0.5) to 7.7 (1.4) (p=0.004).  
 
Identification of the phase III slope can be impossible if the tidal volume falls too low, Aurora 
et al stipulated a minimum tidal volume of (3.5 x body weight (kg) + precapillary dead space) 
x2 (ml) (35). Fluctuating tidal volumes particularly in younger children who are especially 
susceptible to variable breathing patterns can affect indices of phase III slope analysis. The 




Change in posture is likely to affect ventilation heterogeneity. As described previously LCI is 
a function of the total volume of gas expired during a washout, divided by the functional 
residual capacity (FRC); LCI should logically be indirectly affected by variable FRC. The 
supine posture is associated with elevation of the diaphragm, pressure of the heart on 
pulmonary structures and increased sequestration of blood in the gravity dependent thorax, all 
of which cause a reduction in residual lung volumes in adults and children (56, 57). In adults, 




Imaging studies using MRI and CT have demonstrated atelectasis in children’s lungs when 
lying supine (59, 60); obstruction of small airways will affect gas mixing and MBW indices. 
However, these imaging studies were performed in sedated and ventilated children (as 
necessary for imaging) which may be responsible for some of this effect.   
 
Gustafsson studied the effect of posture on ventilation inhomogeneity in asthmatic and healthy 
children using N2 MBW (57). Ten asthmatic children (aged 10-17 years) and 12 healthy 
subjects (aged 11-18 years) were recruited. The participants all initially performed spirometry, 
followed by 2 MBW tests and then 3 measurements of inspiratory vital capacity (VC) while 
sitting. Participants then lay down and performed one MBW test at 0, 30 and 60 minutes 
following assumption of the supine position. VC was measured after each test. In both the 
asthmatic and control groups FRC fell immediately on lying by 21% and 24.9% respectively. 
There was no further change in FRC in the control group over the supine hour. In the asthmatic 
group FRC fell significantly further over 60 minutes to 24.7% less than sitting FRC. VC fell 
slightly in both groups. LCI did not significantly change in either group. This small study 
demonstrated an effect of posture on FRC in healthy and asthmatic children which was not 
translated into any change in LCI. MBW testing may have been affected by performing 
spirometry before MBW (the effects of forced manoeuvres on ventilation heterogeneity are 
unclear) and by only performing one MBW test at each time point as opposed to the standard 
three tests. 
 
Gronkvist et al. studied 11 healthy men using a mass spectrometer. They found a rise in Scond 
in the supine position but no change in Sacin or LCI (p<0.001) (58). Bouhuys et al studied 6 
healthy men using nitrogen washout and found that their LCI increased in the supine position 
(61). In their analysis of MBW results from almost 500 children Lum et al found no difference 
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in LCI measurements made supine (in sedated children <2yrs) and older children studied 
sitting (CI -0.07, 0.34) when corrected for height (41). However, Lum’s study was comparing 
two different groups of children using different methodologies (the supine group were sedated 
and used a face mask). 
 
In young children and infants it is necessary to perform MBW while the child is lying supine. 
In older children, however, the test is performed with the child sitting; for results to be 
comparable across age groups it is imperative that any effects posture may have on LCI are 
known. More research into the effects of posture on ventilation heterogeneity in healthy 
children and those with disease including CF and asthma is necessary. 
 
1.3.3.4 Forced Airway Manoeuvres 
 
Deep inspirations are thought to affect airway diameter during subsequent tidal breathing (39). 
Forced airway manoeuvres include activities that recruit lung volume by inspiring to total lung 
capacity, such as spirometry or some methods of physiotherapy. Physiotherapy in children 
with CF has been found to improve indices of phase III slope analysis measured by single 
breath washout (62). Performing physiotherapy or spirometry may transiently normalise 
inhomogeneity, by opening atelectatic regions (51, 63). For this reason MBW testing has not 
been performed directly after these manoeuvres in our centre.  
 
However, in 2010 Fuchs et al published a study in which physiotherapy performed 
immediately before MBW in children with CF did not alter the repeatability of LCI (64). They 
studied 32 children, aged 5.7-15.9 years. MBW testing was performed twice with an interval 
 50
between testing of 90 minutes. Sixteen patients performed 30 minutes of physiotherapy 
between the tests, 11 did not. In the physiotherapy group intra individual coefficient of 
variation (CV) was 6.1% at the first test and 6.5% post physiotherapy. This was compared to 
the control group in which CV was 4.2% and 7.1% in the 2 tests. There was no consistent 
difference in LCI between the tests in either group. Reproducibility was assessed using the CV 
of LCI over the two tests for each patient. Mean inter-test CV was reported as 4.6% in the 
physiotherapy group and 2.6% in the control group. This study’s authors concluded that there 
are no consistent effects of physiotherapy on the variability of LCI; however children with CF 
had a mean initial LCI of only 7.76 suggesting mild disease and further study of more severely 
affected children may draw different conclusions. The study did not assess effects of 





1.4 MBW in Disease 
 
MBW can detect abnormalities in gas mixing in diseases including CF, asthma, COPD and 
bronchiolitis obliterans (65).  
 
Ventilation inhomogeneity is also found in healthy preterm infants (52) and babies with 
respiratory distress syndrome. In ventilated infants with respiratory distress syndrome 
ventilation inhomogeneity improves after administration of surfactant (51). MBW is abnormal 
in chronic lung disease and can differentiate between mild, moderate and severe disease (51).  
 
The degree of abnormality generally reflects the extent of disease. However, in patients with 
severe disease, variability in MBW derived indices may be worse due to intermittent 
obstruction of badly affected peripheral lung regions (66). Washout traces from patients with 
collapse of part of their lungs or widespread peripheral airway closure may be misleading. A 
normal LCI and a low FRC may be seen in these patients when the rest of the lung is ventilated 
evenly (35). 
 
Reports of the within visit variability of MBW appear to be greater in patients with disease 
compared to healthy individuals (39, 43, 51). In Aurora et al’s study of school aged children 
with CF, the healthy control group had a within subject intra-visit LCI CV of 5.2% compared 
to 6.2% in those with CF (43). In their study of preschool children the mean within subject 
intra-visit CV of LCI was 5.2% in healthy children compared to 7.8% in children with CF 
(39). This was thought to be due to variable mucus plugging in the CF lung. 
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1.4.1 Cystic Fibrosis 
 
CF is the most common inherited cause of early mortality. One in 2500 babies of Northern 
European descent are affected. The disease is a result of mutations in the gene that codes for 
the Cystic Fibrosis Transmembrane Regulator (CFTR) protein. CF is variable, depending on 
genetic and environmental factors. The pathology is characterised by collection of thick mucus 
in the lungs, sinuses, intestine, pancreas and reproductive organs. 
 
Approximately 2000 mutations of the CFTR gene have been identified. There are 6 classes of 
mutation that either affect the quantity or function of the CFTR protein. Mutations that effect 
the quantity of CFTR include those that cause defective or reduced protein synthesis (classes 
I and V respectively), defects in folding and trafficking (class II) or reduced stability of the 
protein on the cell surface (class VI). Class III and IV mutations affect CFTR function by 
reducing channel opening (III) or ion transit (IV). F508del is the most common mutation with 
more than 91% of the UK CF population having at least one allele (CF Trust Registry Annual 
Data Report 2012). It causes severe CF disease by producing problems with CFTR trafficking, 
channel opening and stability. 
 
Figure 12: Proposed 3D model of the CFTR protein (http://www.cfgenetherapy.org.uk) 
 53
CFTR is a cyclic adenosine monophosphate (cAMP) regulated chloride channel which is 
expressed in the apical surface of epithelium. The channel regulates chloride secretion but also 
other membrane proteins including the epithelial sodium channel (ENaC). CFTR and ENaC 
control the movement of water across the epithelium; faulty CFTR leads to fluid hyper-
absorption and dehydration of the epithelial surface. This leads to abnormal thick mucus with 
altered biophysical properties. 
 
CFTR is expressed in many tissues, including the lung, pancreas, intestine and reproductive 
tract. Defective mucus production in these tissues causes blocked ducts and impaired mucosal 
defence. CFTR is involved in the secretion of bicarbonate; lower pH due to reduced 
bicarbonate secretion has been shown to impede bacterial killing. CFTR malfunction is also 
thought to cause abnormal epithelial inflammation. 
 
Lung disease is the most significant cause of morbidity and mortality in CF (67); lungs of 
infants appear largely normal shortly after birth, but pulmonary disease starts to develop within 
the first few months of life (68) and 90% of patients eventually die from respiratory 
complications. Pulmonary disease is characterised by persistent infection and exaggerated 
inflammation leading to chronic airways disease and progressive decline in lung function.   
 
People with CF are living longer. A review of mortality in the US, between 1993 and 2002, 
found median survival for people with genotypes associated with little to no CFTR activity 
had increased to 36.3 years and for those with genotypes associated with residual CFTR 
activity it was 50 years (69).  This has been achieved through more intensive monitoring and 
earlier treatment, delaying lung disease progression (70). Early lung disease is thought to 
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develop first in small peripheral airways (10, 12); more sensitive methods of detecting this are 
sought to detect earlier disease and delay progression (71, 72).  
 
1.4.1.1 Lung function testing in CF 
 
In CF, measurement of lung function is routinely performed in patients from the age of 4-5 
years. This is typically done by performing spirometry which requires a coordinated expiratory 
manoeuvre on behalf of the patient. As discussed the feasibility of spirometry is limited in 
very young children due its volitional nature. It is well established that lung disease in CF can 
be present from as early as the first few months of life and an alternative method of detecting 
early disease is required (73). 
 
FEV1 is the most repeatable and referenced spirometric measure; it has proven to be a good 
predictor of outcome in patients with moderate to severe disease (74). However, FEV1 is 
insensitive in detecting early CF pulmonary disease (12, 53) as it measures medium to large 
airways obstruction. CF lung disease is patchy and normal function in some regions may mask 
diseased regions. Many children with CF have normal FEV1 (9, 10); however some of these 
children will have lung disease detected using CT scanning or MBW (10, 12, 39, 43). FEF25-
75 is more sensitive to small airways disease but is also highly variable, particularly in 




1.4.1.2 MBW in CF  
 
CF lung disease is thought to exist before symptoms develop or spirometry is abnormal. In 
comparison with FEV1, LCI is more sensitive to early lung function abnormalities (10, 26, 35, 
38, 39, 43, 75) and correlates better with airway damage seen on CT imaging (76). In children 
with CF, MBW derived indices correlate with FEV1 (43, 77) and FEF25-75 (39). However, 
MBW is often abnormal in children with normal spirometry and children are very unlikely to 
have normal MBW if spirometry is abnormal (10, 35, 39, 43, 75, 78). In addition LCI has been 
shown to be more sensitive in detecting abnormal lung function in pre-school children with 
CF than plethysmography (39).  Ventilation heterogeneity has been detected using MBW in 
infants with CF (53, 79).  
 
Children with CF who have chronic bacterial colonisation are known to have significantly 
worse lung function (MBW and spirometry) than non-colonised patients (10). Aurora et al 
found in their study of preschool children with CF, that children infected with pseudomonas 
aeruginosa had significantly higher LCI than uninfected patients despite non-significant 
differences in spirometry or plethysmography (39). Kraemer et al found LCI was higher in 
children (aged 6-16 years) with Allergic Bronchopulmonary Aspergillosis (ABPA) and that 
compared to indices of plethysmography and spirometry, LCI was the best discriminator 
between Aspergillus sensitisation and ABPA (80).  
 
LCI has also been shown to predict pulmonary exacerbation in CF. A prospective study of 63 
children (aged 5-19 years) over one year found the rate of exacerbations (requiring IV 
antibiotics) correlated with baseline LCI and that the time to first exacerbation decreased with 
increasing LCI (81). This effect was seen even in patients with normal FEV1. LCI was also 
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found to correlate with the respiratory domain of the standardised CF Questionnaire- Revised 
(r=-0.43, p=0.04). 
 
LCI is repeatable in children with CF. Aurora et al measured spirometry and MBW in school 
and preschool aged children with and without CF (22 children aged 6-16 years and 40 aged 2-
5 years with CF and 33 healthy children aged 6-16 years and 37 aged 2-5 years). MBW was 
performed using 4% SF6 and a RMS. They found that in school aged children the intra subject 
LCI CV was 6.2% (43) and in preschool children it was 7.8% (39). These CVs are higher than 
those of healthy children; school and preschool age LCI CVs were both 5.2% (39, 43). Poorer 
repeatability of MBW in children with CF may be due to variable mucus plugging.  
 
Children with CF have been shown to have abnormal Scond and Sacin suggesting disease of both 
conducting and acinar airways (48). In a Swedish study using N2 MBW in 15 patients with 
CF, aged over 6years, mean (SD) Scond was 0.151(0.071)L-1 compared to 0.045(0.021)L-1 in 
healthy children (p<0.001) and Sacin was 0.307(0.207)L-1 in CF patients and 0.090(0.022)L-1 
in healthy controls (p<0.01)(48). When compared to moderately severe asthmatic children, 
children with CF were shown to have significantly higher LCI and Sacin, but similar Scond (48). 
 
Horsley et al compared 0.2% SF6 MBW derived indices (using the modified Innocor) and 
spirometry in 22 adults and 18 children with CF, 17 healthy adults and 29 healthy children 
(82). LCI was significantly higher in children with CF compared to healthy controls (7.3 vs 
6.2, p=0.022) and in CF adults compared to controls (12.8 vs 6.7, p<0.0001). Sacin was 
significantly higher in children with CF compared to controls (0.192 L-1 vs 0.117 L-1, p=0.007) 
and in adults with CF compared to controls (0.366 L-1 vs 0.112 L-1, p <0.0001). Scond was also 
significantly higher in children with CF (0.068 L-1 vs 0.015 L-1 p<0.0001) and adults with CF 
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(0.086 L-1 versus 0.010 L-1, p<0.0001). FEV1 z score was significantly lower in adults with CF 
compared to controls (-3.03 vs 0.04, p<0.0001) but there was no difference between children 
with and without CF. Sacin and LCI were significantly higher in CF adults compared to CF 
children (p=0.0036 and p<0.0001) but there was no difference in Scond between the age groups 
in CF. Scond was elevated in several CF patients with normal LCI suggesting that it might be 
an early marker of disease. Scond did not however rise with rising LCI or correlate with FEV1 
and therefore might not be a good indicator of severity. The authors postulate that Scond has a 
ceiling value of 0.150L-1 which is reached relatively early in CF. Sacin did correlate with LCI 
(r=0.86, p<0.0001) and FEV1 (r=0.73, p=0.0002) but remained within the normal range until 
LCI exceeded 10.  
 
1.4.1.3 CF MBW and Imaging 
 
Computed tomography of the chest is the gold standard in identifying structural changes in 
CF. Disease can be seen in patients with apparently normal spirometry (12). However, the use 
of CT exposes the patient to radiation, thereby limiting its use as a monitoring tool. In addition 
CT does not provide information regarding the functional impact of disease. Structural lung 
disease, detected using CT, can exist in patients with normal spirometry (83, 84). As discussed 
in the following paragraphs LCI may be more sensitive than spirometry in predicting structural 
change seen on CT and may therefore serve as a useful monitoring tool to limit radiation 
exposure.  
 
In a retrospective study by Gustafsson et al, HRCT scan scores, LCI and spirometry obtained 
from 44 CF patients (aged 5-19 years) over a 30 month period were compared (76). LCI was 
found to be more sensitive a predictor of abnormal structure seen on CT than FEV1 or FEF75; 
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sensitivity for LCI was 85-94% compared to 19-26% for FEV1 and 62-75% for FEF75. LCI 
also correlated better with HRCT scores (r=0.85) than FEV1 (r=-0.62) or FEF75 (r=-0.66) 
(p<0.001). Normal LCI made the presence of structural disease unlikely; abnormal structure 
was only found in 2 (15%) patients with a normal LCI. LCI was abnormal in some children 
with a normal CT; it was speculated that LCI may be more sensitive to disease than CT. 
Alternatively this may have been due to a HRCT protocol which limited radiation exposure 
reducing sensitivity compared to standard protocol.  
 
Ellemunter et al investigated the accuracy of LCI in predicting CT diagnosed structural disease 
in a prospective study of CF patients with FEV1 >80% (85). They recruited 34 patients aged 
6-26 years, who underwent an ultra-low dose chest CT and then performed SF6 USFM MBW. 
MBW and CT detected disease in almost 80% of the study population. LCI was abnormal 
(>7.0) in 76.5% of patients and correlated with CT findings in 82.3% (i.e. both either normal 
or abnormal). LCI had sensitivity for predicting the presence of structural lung changes of 
88%. Only 3 patients had a normal LCI in the presence of disease on CT, indicating that 
patients with normal LCI are unlikely to have structural changes. However, these results may 
have been limited because patients did not have their CT and MBW performed on the same 
day; in fact some patients had up to almost 8 months between each test. 
 
A prospective study performed by the London Cystic Fibrosis Collaboration found that LCI 
correlated better with CT than spirometry or plethysmography (78). The group studied 60 
children with CF, aged 6-10 years; they had a HRCT (with a complete inspiratory volumetric 
dataset) and lung function testing on the same day. Eighty four percent of the children had 
abnormal LCI (>7.5), 58% abnormal plethysmographic lung volumes, 35% abnormal sRaw 
and 47% abnormal spirometry (FEV1 or FEF25-75); CT scans were abnormal in 85%. Total CT 
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score correlated best with LCI (r=0.77), compared to FEV1 (r=-0.43), or indices of 
plethysmography. However, concordance between LCI and CT scores were not absolute, 5 
out of the 9 children who had normal LCI had abnormalities on CT and 5/9 children with a 
normal CT had abnormal LCI. This small degree of discrepancy is possibly not surprising 
given the two tests identify different entities; CT defines structural disease whilst LCI 
demonstrates ventilation inhomogeneity. 
 
More recently a German study by Stahl et al found that LCI correlated with MRI findings of 
airway wall abnormalities, mucus plugging and abnormal lung perfusion in infants (p<0.05), 
toddlers (p<0.001) and older children (p<001) (86).  
 
Correlation between MBW derived indices and structural changes on imaging have been 
demonstrated in cross sectional studies of patients with CF. More recent studies have 
investigated the progression of ventilation heterogeneity and its relationship with CF disease 




1.4.1.4 Longitudinal change of MBW derived indices in CF 
 
In Aurora et al’s study of school age children, LCI in children with CF correlated with age 
(43). This relationship is thought to be due to progressive lung disease seen with increasing 
age in CF. In the same group’s study of pre-school children however there was no correlation 
between LCI and age (39). To try to definitively determine the relationship between LCI and 
age in CF, longitudinal studies have been performed. 
 
The London CF Collaboration undertook a study examining the changes in LCI, 
plethysmographic functional residual capacity (FRCpleth) and FEV0.5 in infants with and 
without CF over the first year of life (79). Seventy two infants diagnosed with CF by new born 
screening and 44 controls were recruited. Testing was performed at 3 and 12 months of age. 
At 3 months infants with CF already had significantly worse lung function for all tests 
compared to healthy controls; the mean (95% CI) difference in LCI z-score was 0.5 (0.1 to 0.9), 
p=0.02 (87). LCI remained stable throughout the first year of life whereas FEV0.5 improved. 
LCI at 3 months predicted poorer lung function at 1 year. LCI was significantly higher (0.6 to 
2.1 z-scores) and FEV0.5 significantly lower (-1.5 to -0.1) at 1 year in the group of infants who 
had had abnormal LCI at 3 months compared to the control group. However there was no 
difference in FEV0.5 or LCI at 1 year in infants who had normal LCI at 3 months compared 
to controls. 
 
Kraemer et al assessed 142 children and adolescents with CF aged 6 – 20 years at annual 
intervals with spirometry, specific airway resistance, plethysmography, p aeruginosa infection 
status and LCI (using N2 MBW) (75). They found that LCI was the first outcome to deteriorate, 
followed by FEF50, FVC and finally FEV1. The median age of onset for abnormal LCI was 6.4 
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years compared to 8.4 years for FEV1. LCI continued to increase, along with pulmonary 
hyperinflation and trapped gas volume, beyond the age of 12 years. Progression in female 
patients was significantly higher than in male patients. The mean (SE) annual change in LCI 
was 0.58 (0.06), p<0.0001 and FEV1 was -0.18 (0.01), p<0.0001. The slope of longitudinal 
progression of LCI was greatest in those chronically infected with pseudomonas aeruginosa 
(80). In this study changes in lung function over time were not related to structural changes on 
CT. 
 
Figure 13: Progression of LCI in Kraemer’s longitudinal study of children with CF depending 
on ABPA, A fumigatus sensitisation and intermittent or chronic infection with pseudomonas 
aeruginosa. Regression lines of mean values of repeated annual measurements presented as 
z-scores (80).    
 
In another study, by Aurora et al, preschool LCI was shown to predict school age lung function 
in children with CF (88). Forty five healthy children and 48 children with CF underwent MBW 
testing and spirometry on two visits. The first visit occurred when the children were aged 3-5 
years and the second when the children were 6-10 years of age. The average interval between 
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tests was 3.7 years. LCI was abnormal in 35 out of 48 children with CF at the first visit; only 
5 of these children had abnormal FEV1. Thirty three out of the 35 children with early abnormal 
LCI also had abnormal LCI at school age, and 15 had abnormal FEV1. Eleven out of 48 
children had normal LCI at school age, nine of whom had had normal LCI at pre-school 
testing; 32 had normal FEV1 at school age, of which 12 had normal LCI at preschool. The 
positive predictive value for pre-school LCI predicting either abnormal LCI or FEV1 was 94%, 
the negative predictive value was 62%. Preschool FEV1 PPV was 100%, however NPV was 
only 25%. These results tell us that LCI can detect abnormalities earlier than FEV1, early 
abnormalities in LCI persist and predict school age abnormalities in both LCI and FEV1.  
 
Fuchs et al prospectively tracked annual MBW, spirometry and ultra-low dose HRCT findings 
over a 3 year period in a group of 36 patients, aged 6-53 years with mild CF (89). Patients 
were included if their FEV1 z-score was >-2; four data sets were recorded at times of clinical 
stability. MBW was performed with 4% SF6 and a side-stream USFM. CTs were scored with 
a modified Bhalla score. At the start of the study all patients had an FEV1 of ≥80% but most 
had abnormal CT scores and LCI results (29/36 and 30/36 patients respectively). LCI and CT 
scores correlated at baseline (r = -0.565, p<0.001) and at last visit (r = 0.547, p=0.001); FEV1 
did not correlate with CT score. CT scores and spirometry remained stable throughout the 
study. Mean LCI improved from 8.0 to 7.2 (p=0.001), 6 patients had normal LCI (<7.0) on 
their first visit which remained <7.0 throughout the remaining visits. Of the 22 patients with a 
baseline LCI of between 7.0 and 9.0, LCI improved in 77% and deteriorated in 23%. Eight 
patients had an initial LCI of >9.0 and LCI in all of these patients improved by a mean (SD) 
of 2.0 (0.54). Change in LCI did not correlate with change in CT score over the study. It was 
possibly surprising that LCI improved in CF patients over time, however this may be explained 
by the fact that regular hypertonic saline was commenced in the majority of patients during 
the study period. Possibly as a result of this there was a reduction in mucus plugging seen on 
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CT in some patients. Otherwise the general improvement may have been an effect of increased 
motivation to comply with therapy secondary to study involvement. It is possible the 
improvement seen was an artefact due to the small cohort coupled with variability of LCI, 
however this is contradictory to evidence of limited variation in LCI in stable patients with CF 
already presented (39, 43).  
 
In Fuchs study, initial LCI correlated with CT scores 3 years later (r = -0.554, p <0.001), FEV1 
did not (29/36 with normal initial FEV1 had abnormalities on CT 3 years later) (89). 4 out of 
6 patients with normal initial LCI had normal final CTs and 27/30 patients with abnormal 
baseline LCI had abnormal final CTs.  The authors concluded that in 86% baseline LCI was 
indicative of the presence or absence of structural changes on final HRCTs. However as 
previously described, the correlation between CT findings and LCI was not absolute; 2/6 
patients with normal initial LCI had mildly abnormal CTs and 3/30 who had abnormal initial 
LCI had normal CTs 3 years later. As previously discussed neither modality could replace the 
other as each examines different aspects of CF lung disease but routine use of MBW could 
reduce the frequency of CT and thereby radiation exposure. This study supports the findings 
of Aurora et al in that LCI does appear to be able to predict later disease. 
 
LCI appears to correlate with age in cross sectional studies of patients with CF and is sensitive 
to, correlates with and predicts structural change found on CT. Results of longitudinal studies 
have shown conflicting results with regard to longitudinal change in LCI, possibly related to 
the introduction of new therapies. Larger studies are required to clarify this discrepancy. 
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1.4.1.5 Interventions in CF and MBW 
 
MBW derived indices have been shown to deteriorate during CF exacerbation and improve 
following treatment, suggesting MBW is a useful clinical test. MBW has been used as an 
outcome measure in clinical trials but is not as yet used in routine clinical management.  
 
Data from the UKCFGT Consortium have shown significant improvement in LCI (measured 
with the modified Innocor) between the start and end of intravenous (IV) antibiotics for CF 
exacerbation (90). Forty four patients over 10 years of age with CF who were treated for 
physician diagnosed exacerbations were assessed at the beginning and immediately after a 
course of IV antibiotics. Patients were assessed by MBW and 45 other measures including 
symptom scores, spirometry, CT and inflammatory markers. LCI fell in 69% of subjects, the 
mean fall in LCI was 0.8 (p=0.003). The patients in this study had significant lung disease, the 
lowest LCI post antibiotics was 9.4. The variable treatment response seen in LCI may have 
been due to opening up of previously obstructed severely diseased lung units. There were 
statistically significant improvements in FEV1 (p<0001); symptoms; CT scores for airway wall 
thickness, air trapping and large mucus plugs; serum CRP, IL-6 and calprotectin. 
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Figure 14: UKCFGT exacerbation study: Change in FEV1 z-score and LCI with treatment in 
individual patients. The horizontal dotted lines represent the normal range. Horizontal grey 
lines indicate the group means (90).  
 
Robinson et al also showed a significant, but variable, improvement in LCI in children treated 
with IV antibiotics for a pulmonary exacerbation (91). Twenty eight children, aged 8-17 years, 
were recruited with an admission mean (range) FEV1 of 61.4 (28-92)% predicted, LCI of 10.1 
(6.87 - 14.83) and peak VO2 of 31.2 (23.4 - 45.4)ml/kg/min. Patients were given 2 weeks of 
IV antibiotics. Mean LCI decreased by 3.8% (p=0.03) from admission to discharge, FEV1 
increased by 7% (p<0.01) and peak VO2 increased by 6.6% (p<0.01). LCI mean (SD) CV was 
4.4(3.8%) in the children at admission and 4.9(3.8) % on discharge, which is higher than the 
mean observed improvement in LCI. In 14 out of 28 patients LCI improved by more than 5%, 
but in 5 out of 28 children LCI deteriorated by more than 5%. The deterioration in LCI in some 
children, which was also seen in the UKCFGT study, was thought to be due to recruitment 
through treatment of previously obstructed lung units and this was supported by a decrease in 
FRC seen in 3 out of these 5 patients. Change in LCI and peak VO2 correlated with changes 
in a CF specific clinical severity score (CFCS) (r=0.480, p=0.01 and -0.50, p=0.02 
respectively). Change in FEV1 did not correlate with the CFCS. 
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A systemic literature review of studies examining LCI following treatment of CF pulmonary 
exacerbations with IV antibiotics was published in 2015 (92). Seven studies which included 
SF6 and N2 washout systems and over 176 pulmonary exacerbations were reviewed. Overall 
absolute LCI decreased by 0.4 (95% CI -0.6 - -0.19, p=0.004) or by 2.5% following treatment. 
The fall in N2 and SF6 generated LCI generally agreed apart from in one study in which SF6 
LCI fell more significantly. In one unpublished study in which patients performed both SF6 
and N2 washouts before and after treatment there was no difference in the relative fall in LCI 
between the 2 systems. The degree of improvement in LCI following treatment was small but 
as described LCI response was heterogeneous and treatment may have opened obstructed 
airways. Higher LCI was associated with greater improvements in LCI suggesting that LCI 
could be useful in the study of severe disease. 
 
Yammine et al examined the reasons behind the heterogeneous response of LCI to IV 
antibiotics in CF exacerbation using parallel plethysmography and MBW. By using 
multivariate regression analysis they found that improvement in LCI was partly explained by 
reduced gas trapping (as measured by change in FRCMBW minus residual volume derived from 
plethysmography) (93). Less gas trapping might occur secondary to less secretions and airway 
obstruction, better lung ventilation and less hyperinflation.  
 
There is some evidence from single breath washout that ventilation heterogeneity improves 
during the treatment of an acute exacerbation (94). In a study of 58 patients with CF, 
improvement in phase 3 slope was more sensitive to patient improvement at discharge than 
the change in FEV1 FEF2575, VC, maximal voluntary ventilation or oxygen saturation 
(p=0.005) (94).  
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MBW has potential as an outcome measure in trials of treatments designed for use in early CF 
disease, in which FEV1 is insensitive. Amin et al showed that LCI could detect improvement 
with hypertonic saline in children with CF and normal FEV1 (95). Twenty children aged 6 to 
18 years who had a baseline FEV1 of ≥80% were studied. The study was a crossover trial with 
two 4 week treatment periods of either hypertonic (7%) or isotonic (0.9%) saline and a 4 week 
washout phase. Treatment with hypertonic saline resulted in significantly lower mean (SD) 
LCI (7.86(1.71)) compared to isotonic saline (8.89(2.1); p=0.016). Baseline LCI was no 
different between the treatment groups. There was no significant differences in FEV1 or CFQ-
R respiratory domain scores following treatment with either hypertonic or isotonic saline. The 
study demonstrated that LCI is both sensitive and responsive and can be used in interventional 
studies of early CF disease in children. 
 
Ellemunter et al detected a long term treatment response with LCI to hypertonic saline in 
patients (aged 6 to 53 years) with CF (96). 34 patients with an FEV1 of ≥70% participated. 
Following a mean of 39.7 months after starting hypertonic saline, LCI had improved from 
mean (SD) 7.89 (1.35) to 6.96 (1.03), p=0.0001; FEV1 did not improve.   
 
In another study by Amin et al, LCI detected a treatment response following dornase alpha in 
children with CF and normal spirometry (97). Seventeen children aged 6-18 years with an 
FEV1 ≥80% predicted were recruited. They were given either dornase alfa or placebo for 4 
weeks with a 4 week washout period and then the alternate treatment. Absolute LCI decreased 
by a mean (SD; 95%CI) of 0.71 (1.23; 0.12-1.3) in the dornase alfa group and 0.31(1.36; -
0.33-0.95) in the placebo group. The relative improvement in LCI was 0.90 (1.44) with 
dornase alfa compared to placebo, p=0.022. FEF25-75 also improved by 6.1(10.34) % with 
dornase alfa but there were no differences in FEV1, FVC or the CFQ-R respiratory domain 
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between the treated and placebo groups. Change with dornase alfa treatment in LCI correlated 
with change in FEF25-75% predicted (r=-0.43, p=0.0001). 
 
LCI has also been used as an outcome measure in infants and pre-school children with CF in 
an interventional trial (98). The Infant Study of Inhaled Saline trial used LCI to detect a 
difference in a multicentre randomised, controlled trial of hypertonic (7%) versus isotonic 
(0.9%) saline. Twenty seven children, aged 0.34-4.95 years, performed MBW before and after 
48 weeks of twice daily nebulised treatment (hypertonic or isotonic saline). MBW was 
performed using 4% SF6 and a RMS. Twenty five out of twenty seven children had acceptable 
baseline and follow up LCI measurements (with at least 2 technically acceptable tests). LCI 
detected a significant treatment effect in the hypertonic saline group (p = 0.025). 
 
LCI was used as a secondary outcome measure in the UKCFGT consortium’s recently 
published trial of gene therapy (99). The trial was a randomised double blind, placebo 
controlled trial of non-viral CFTR gene therapy. Patients were aged 12 years and older, had 
any combination of CFTR mutations and an FEV1 of 50-90%. They were randomised to either 
receive nebulised pGM169/GL67A gene-liposome complex or 0.9% saline every 28 days for 
1 year. The primary endpoint was the relative change in percent predicted FEV1. At 12 months 
there was a modest treatment effect in the gene therapy group versus placebo (3.7%, 95% CI 
0.1-7.3; p=0.046). Response to treatment was heterogeneous, the FEV1 treatment effect was 
seen due to stabilisation with gene therapy compared to deterioration in the placebo group. 
There was no significant difference in LCI between the groups at the end of the trial, the 
treatment effect was -0.28 (95% CI -0.71-0.14), p=0.187. LCI may not have detected a 
difference due to the heterogeneity of the group, severely diseased lungs at baseline or varied 
response to treatment.  
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Studies have demonstrated that LCI can be used as a responsive outcome measure in studies 
involving patients with mild CF. There is less evidence regarding the use of LCI in 
interventional trials in more advanced disease. Evidence obtained from observational studies 
suggest that LCI response following treatment of exacerbation is variable, possibly due to the 
recruitment of previously obstructed lung units, however larger improvements do appear to 
correlate with worse baseline LCI and LCI may have a role in trials involving more severe 
disease. A minimal clinically important difference in LCI has not been established to guide 
interpretation and changes in management in an individual patient. Most studies have used 
non-commercially available equipment and standardisation to ensure reliability of MBW for 
use in a wider clinical setting is required. 
 
1.4.1.6 Multi-centre MBW trials 
 
In multi-centre trials, standardisation of MBW is important because normal ranges of results 
differ depending on set up and equipment. Comparable results also depend on consistent 
methodology across sites. An independent expert can be used to objectively determine site 
competency to qualify for study participation. As far as I am aware I was chosen as the first 
international verification expert for a multi-centre MBW trial because of my experience in 
performing MBW testing. Standardisation of testing for site verification has now become 
standard in both European and US CF trials (Saline Hypertonic in Preschoolers study, clinical 
trials.gov). 
 
The multicentre trial in which I acted as the independent expert used LCI to detect a treatment 
response to ivacaftor in children with CF, a G551D-CFTR mutation and normal spirometry 
(100). The study was published in The Lancet Respiratory Medicine Journal and has been 
included with permission at the end of this thesis.  
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Prior to the initiation of the study I was chosen to assess and improve the quality of MBW 
testing in each centre. Equipment was standardised, 0.2% SF6 and the modified Innocor were 
used. Quality of testing was assessed through analysis of qualification MBW tests, performed 
on healthy volunteers. I identified, communicated and helped resolve problems with testing at 
each centre. I then qualified centres for inclusion into the study only once all technical issues 
had been resolved. During the study I was the blinded central investigator and analysed all 
study MBW tests. 
 
The study was a multicentre, placebo-controlled, double blinded crossover study. Children 
were aged 6 years or older, with an FEV1 of >90% predicted, LCI of >7.4, and weighed at 
least 15kg at a screening visit.  By the time of testing FEV1 had fallen <90% in some patients. 
There were two treatment phases each lasting 28 days, consisting of either 150mg ivacaftor 
(Vertex Pharmaceuticals, USA) or placebo twice daily. Patients were randomly allocated to 
receive either ivacaftor or placebo followed by a 28 day crossover period between treatment 
phases.  The patients and all study personnel were blinded to treatment assignment. Twenty 
one patients were recruited and 17 of these completed the trial. Treatment with ivacaftor led 
to larger improvements in LCI compared to placebo. The average relative improvement in the 
treatment group compared to placebo group was -2.16 (95% CI -2.88 to -1.440, p<0.0001). 
FEV1 also showed improvement in the ivacaftor group compared to placebo, the average 
difference in mean FEV1 change was 8.67% (95% CI 2.36-14.97, p=0.0103). However, if 
patients in whom baseline FEV1 had fallen below 90% at baseline testing were excluded, there 
was no detectable difference in FEV1 between treatment groups, LCI still showed significant 
improvement. Post hoc analysis determined that LCI required a three to four times smaller 





Asthma is a chronic inflammatory condition of the lung which is common throughout 
childhood.  In the UK 1.1 million children (1 in 11) have asthma (www.asthma.org.uk). The 
condition is heterogeneous; its natural history and clinical manifestations vary dramatically. 
Children may suffer daily symptoms or occasional exacerbations. Exacerbations may be life 
threatening, in the UK in 2015 21 children and young people under the age of 20 years died 
from asthma. 
 
The aetiology of asthma is poorly understood but it is believed to be caused by a combination 
of environmental exposures with a background of genetic susceptibility. Inappropriate 
immune response to inhaled aeroallergens, viruses or pollutants cause inflammation, which 
leads to airway hyper-responsiveness and obstruction. There is evidence that inflammatory 
disease early in childhood affects the growth and differentiation of the lung leading to 
structural abnormalities. 
 
Airflow obstruction is caused by smooth muscle constriction and airway inflammation leading 
to oedema, basement membrane thickening, sub epithelial collagen deposition, smooth muscle 
and mucous gland hypertrophy and mucus hypersecretion. Smooth muscle in asthmatic 
patients is hypersensitive; numerous provocation factors including aeroallergens, exercise, 
cold air, and pollutants can trigger bronchoconstriction.  
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Symptoms include intermittent dry cough and expiratory wheeze. There is often diurnal 
variation, symptoms are typically worse at night. Other symptoms include exercise limitation 
and fatigue.  
 
Treatment involves reducing environmental exposure to stimuli, anti-inflammatory 
medications, treatment of co-morbid conditions including rhinitis, sinusitis and 
gastroesophageal reflux and management of acute exacerbations. The pharmacological 
management of chronic asthma involves a step wise approach depending on symptom severity. 
Assessing asthma control is difficult; reported symptoms often define levels of asthma control 
but symptom reporting is subjective. Objective measures of control are limited in children (13, 
101). Medication requirements often define levels of asthma severity (102), but medication 
requirements are dependent on many factors including symptom perception and reporting, the 
physician and compliance with treatments. Identification of patients with severe disease who 
may be at risk of exacerbation is important so that preventative treatment can be optimised.  
 
Asthma exacerbation treatment is dependent on severity as determined by the clinician. 
Children receive salbutamol and ipratropium multi dose inhalers (MDIs) via a spacer device 
or in more severe cases nebulised salbutamol, ipratropium and magnesium (at the time of my 
research children were not receiving nebulised magnesium in Edinburgh). Children tend to 
receive a short course of oral corticosteroids unless chronically very unstable in which case a 
longer course may be prescribed. If there is no improvement with inhaled bronchodilators 
children may also receive intravenous (IV) medications including hydrocortisone, magnesium, 
salbutamol or aminophylline. In Edinburgh if children require continuous IV medication they 
are admitted to the high dependency unit. In rare cases children may require intubation and 
ventilation while medications take effect. 
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1.4.2.1 Lung Function testing in Asthma 
 
Currently spirometry is used in asthma clinics to assess asthma control. Spirometry is used to 
obtain maximal expiratory flow volume curve parameters such as FEV1, FVC and FEF25-75 
and to measure reversibility following bronchodilator. Fractional exhaled Nitric Oxide (FeNO) 
is a biomarker which is thought to reflect airway and tissue eosinophilia and is measured in 
some tertiary centres.  
 
Figure 15: Flow Volume loops illustrating airways obstruction (http://www.morgansci.com). 
 
FEV1 has been shown to be associated with past and future serious asthma exacerbations, 
symptoms and persistent wheeze in studies of children; these observations are most marked in 
patients with an FEV1 of <80% (103-106). Better correlations between FEV1 and symptoms 
are seen when the population FEV1 is predominately abnormal (107). FEF25-75 has been found 
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to be worse in children who report chronic persistent symptoms (108). FEF25-75 is possibly 
more sensitive than FEV1 in detecting reversible airway obstruction (19); however its high 
variability has limited its clinical use. High bronchodilator response (BDR) has been 
associated with poor asthma control, increased airway inflammation, bronchial hyper-
responsiveness, good response to inhaled corticosteroids and worse future lung function in 
children (109).  
 
Other evidence suggests that there is poor correlation between FEV1 and symptoms in 
asthmatic children (13, 15, 110), possibly because the majority of children with chronic 
persistent asthma will have normal FEV1 (13, 14). In studies in which correlations between 
FEV1 and symptom scores are found, they are generally weak (111, 112).  
 
Persistently high FeNO might suggest severe airways inflammation, poor treatment adherence, 
poor inhaler technique or ongoing allergen exposure. FeNO has been shown to correlate with 
markers of inflammation in asthma (110) but only with symptoms in some studies (112). 
Studies of FeNO in children have had variable results as the technique has not been 
standardised; the ERS have not recommended its use as a routine monitoring tool in asthma 
until further evidence is available (109). 
 
Peak Expiratory Flow Rate (PEFR) measures the maximal expiratory flow following 
inhalation to vital capacity. It does not require expensive equipment and can be performed at 
home, regular PEFR monitoring may be advocated for patients with poor perception of 
symptoms. Evidence suggests however that using PEFR to guide treatment is no better than 
symptom guided management (109). 
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There is conflicting evidence concerning the utility of spirometry in the stable asthmatic child. 
Although abnormal FEV1 is associated with poorer asthma outcomes it appears insensitive to 
disease in many children. In addition testing may not be feasible in pre-school children as 




1.4.2.2 Asthma and the Small Airways 
 
Small airway disease in asthma is increasingly being recognised as a major determinant of 
control and exacerbation. Studies of histopathology (113-115), High Resolution CT (116, 117) 
3Helium weighted MRI(118) and PET (119) have all demonstrated small airways disease in 
asthma. The degree of small airways associated ventilation defect on 3He MRI has been shown 
to correlate with medication requirement, eosinophil count and symptom scores in asthmatic 
children (120). Spirometry can be insensitive in detecting early small airways disease; MBW 
is more sensitive whilst also being non-invasive, safe and inexpensive (45, 50, 121-123).  
 
1.4.2.3 MBW testing in Asthma 
 
MBW has been shown to identify abnormalities in ventilation heterogeneity in well controlled 
asthmatic patients with normal FEV1 (50, 124, 125). The most common abnormality found is 
elevation of Scond, localising disease to the small conducting airways (48, 126, 127). Sacin has 
also been shown to be abnormal in some patients indicating the involvement of very peripheral 
airways (45, 127, 128). Ventilation heterogeneity appears to be associated with inflammation 
in some studies (125, 127). However abnormalities in MBW derived indices have been found 
to persist after inhaled corticosteroid treatment and despite normal FeNO, indicating the 
absence of inflammation (47, 50). Abnormalities have also been shown to persist despite 
salbutamol (48, 50, 126). Persistent abnormalities may be secondary to airway remodelling. 
Specimens taken at biopsy and autopsy from asthmatic children have shown marked changes 
in lung structure (113) and airway biopsy of even preschool children with wheeze have 
revealed thickened reticular basement membranes compared to healthy children (129).   
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In Edinburgh significant differences in LCI between healthy and asthmatic groups of children 
were demonstrated despite no difference in FEV1 or FeNO (50). Thirty one children aged 5-
15 years attending a tertiary asthma clinic and 29 healthy controls, aged 5-16 years participated 
in the study. Asthmatic patients were on different steps of the 2003 BTS treatment ladder; 6% 
were on step 2, 68% step 3 and 26% step 4; all patients were clinically stable at testing. MBW 
testing was performed using the modified Innocor and 0.2% SF6. Asthmatic patients attended 
2 study visits, MBW and spirometry were performed before and 20 minutes after 200µg 
inhaled salbutamol or placebo, FeNO was measured before treatment on each occasion. 
Healthy controls attended one visit in which they performed MBW, spirometry and FeNO. 
Mean LCI in both groups was within the normal range but was significantly higher in the 
asthmatic group compared to the control group (6.69 versus 6.24, p = 0.02), despite no 
differences in FEV1 or FeNO. There was a non-significant trend to higher Scond in the asthmatic 
group (0.026L-1) versus the control group (0.017 L-1), p = 0.06. There was no difference in 
Sacin between the asthmatic and control groups (0.14 L-1 versus 0.12 L-1 respectively, p = 0.23). 
The CV of LCI in the asthmatic group was 4.2%. There was no significant change in LCI, Scond 
or Sacin following salbutamol despite significant increases in FEV1. Abnormalities detected by 
LCI could not fully be explained by inflammation, as there was no correlation with FeNO, or 
bronchospasm as there was no improvement following salbutamol.  
 
In Sigurs et al’s study of asthma and allergy patterns in childhood following RSV positive 
bronchiolitis LCI was significantly elevated in asthmatic children (n=21) compared to non-
asthmatic children (n=117) at 18 years of age (125). However they found that LCI did correlate 
with FeNO (r2 =0.29, p=0.003) indicating inflammation may play a role in ventilation 
heterogeneity. LCI also correlated with airway hyper-responsiveness after dry air challenge 
(r2 = 0.26, p=0.005). Asthmatic patients in this study were different from Macleod’s study; 
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asthmatic children were not necessarily attending a tertiary asthma clinic and had to have 
persistent episodes of physician diagnosed wheeze. 
 
Gustafsson studied N2 MBW in 15 asthmatic children (aged 12.3-18.6 years) and 11 healthy 
controls (48).  The mean pre-bronchodilator FEV1 % predicted of the asthmatic group was 
77% indicating relatively severe disease. LCI and Scond were significantly abnormal compared 
to healthy controls but there was no difference in Sacin. LCI fell following bronchodilator so 
that there was no difference with the control group. Post bronchodilator Scond did fall but 
remained significantly abnormal compared to the control group.  
 
Sonnappa et al compared the repeatability of LCI, Scond and Sacin in 62 children with stable 
recurrent wheeze (mean (SD) age 5.4 (0.6) years) to 28 healthy controls (6.1 (0.7) years old) 
(130). Children attended 2 visits, on one visit children repeated 2 sets of MBW (performed 
with 4% SF6 and a RMS) with a 20 minute interval without intervention and on another 
occasion they were given 200µg salbutamol after the first set of MBW. Visits occurred a 
median of 5.3 months apart in the wheezy children and 9 months in the healthy children. 
Details of symptom frequency and severity were not reported and spirometry was not 
performed, applicability of results to other populations may therefore be limited. There were 
no significant differences in the short term (within visit) variability of LCI, Scond or Sacin 
between the healthy and wheezy groups at baseline. Scond and Sacin had larger baseline 
variability than LCI; higher variability reduces the ability to discriminate between health and 
disease and to determine significant change. There were no changes in any outcome over the 
2 visits and the variability of LCI and Sacin were similar in both groups. Scond was significantly 
more variable over the 2 visits in the group with recurrent wheeze compared to the healthy 
group but did detect a bronchodilator response, which was not detected by LCI. 
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Verbanck et al detected ventilation inhomogeneity in adults with mild asthma; they also found 
that abnormalities in Scond representing ventilation heterogeneity in the small conducting 
airways were not completely reversible with salbutamol (126). The same group found that Sacin 
was higher in stable asthmatic patients receiving ≥500µg beclomethasone dipropionate 
equivalent compared to patients receiving smaller doses and that Sacin correlated with alveolar 
nitric oxide (r=0.61, p=0.015) (128). Patients with abnormal Sacin were also shown to have 
lower FEV1 compared to patients with normal Sacin (131). Verbanck’s group studied adults in 
whom asthma pathophysiology may differ from children. Unlike in Macleod and Gustafsson’s 
studies, Verbanck asked patients to achieve a set tidal volume, which may have aided detection 
of abnormalities in Sacin. 
 
Farah et al also found that Sacin and Scond were both abnormal in stable asthmatic adults and 
that both indices were associated with asthma control assessed using the Asthma Control 
Questionnaire - 5 (ACQ-5) (132). MBW was performed in 105 asthmatic adults using N2 and 
a set tidal volume protocol. Patients were categorised as poorly controlled if their ACQ-5 score 
was ≥1.5 and well controlled if their score was ≤0.75. Poorly controlled patients had worse 
FEV1, FeNO, Scond and Sacin values than the well-controlled group. However Scond and Sacin 
were not independent predictors of ACQ-5 scores, unlike FEV1 and FeNO. Baseline FEV1 was 
low in both the well and poorly controlled groups (83 and 73% predicted respectively) which 
indicates a group of adults with relatively severe disease.  
 
In Keen et al’s study of asthmatic children LCI, Scond and Sacin were all significantly elevated 
in asthmatic patients compared to controls, but Scond was the most common abnormality in 
asthmatic children (abnormal in 31/47 children); in contrast only 7/47 children had abnormal 
LCI (127). Children who had uncontrolled asthma (based on an asthma control score of >20) 
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had significantly higher LCI (p=0.04) and Scond (p=0.04); there was no significant difference 
in FEV1 between groups with uncontrolled and controlled asthma. LCI and Scond were found 
to correlate with FeNO and alveolar NO, whereas Sacin only correlated with alveolar NO. 
Airway hyper responsiveness was associated with higher Scond but not Sacin. 47 atopic asthmatic 
children and 74 healthy controls were studied using 4% SF6 and a RMS, airway hyper 
responsiveness was assessed using a dry air hyperventilation challenge. Quality control criteria 
required for reporting of Scond and Sacin were regular tidal breathing with a tidal volume of 10-
15ml/kg. Only 36/74 healthy children performed MBW well enough to fulfil these quality 
criteria, all the asthmatic patients managed. The correlations between Scond and Sacin with FeNO 
and alveolar NO suggest that small airways disease in asthmatic children is associated with 
inflammation. LCI appeared less sensitive than Scond in detecting disease in stable asthmatic 
patients, in whom the small conducting airways appear to be the major site of the disease 
process.  However very peripheral airways may also be abnormal, reflected in the elevation of 
Sacin in some children. 
 
Indices of MBW have been shown to correlate with evidence of small airways disease in 
asthma detected using different imaging techniques. Baseline Scond in 14 asthmatic adults 
correlated with airway closure secondary to methacholine challenge, detected using combined 
SPECT and HRCT scans (133). In 37 asthmatic adults Sacin correlated with abnormalities in 
acinar diffusion identified during 3He MRI scanning (134).  
 
Evidence suggests that MBW can detect small airways disease in asthma and could be used to 
further our understanding of the disease. However its clinical utility in monitoring asthma still 
has to be established. Indices are often abnormal in more severe disease but in these children 
FEV1 may be sufficiently sensitive. In mild disease results have been higher than in control 
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groups but have fallen within normal ranges rendering their use as a marker for an individual 
less clear. MBW may be more useful in detecting bronchial hyper-responsiveness in 




1.4.2.4 Asthma and Exercise 
 
The clinical presentation of exercise induced asthma (EIA) includes cough, wheezing, 
shortness of breath and/or chest tightness. The reported prevalence varies; it affects 
approximately 80-90% of people with asthma and 5-20% of the general population (135, 136). 
Asthma medications can prevent EIA; however in some patients, symptoms persist despite 
medication.  
 
Exercise induced bronchoconstriction (EIB) can occur during or up to 30 minutes after 
cessation of exercise (137, 138). The mechanism by which EIB is caused is unclear and may 
vary between individuals. Many experts speculate that EIB is due to changes in airway 
physiology, including increased airway osmolarity, caused by hyperventilation (136, 138, 
139). There is an inflammatory response associated with EIB, which is thought to be caused 
by this change in airway osmolarity (136, 138). Inflammatory mediators interact with smooth 
muscle cells to cause bronchoconstriction. In addition airway cooling during hyperventilation 
stimulates cholinergic receptors to increase airway tone and secretions. Inhalation of cold air 
also causes pulmonary vasoconstriction, then when exercise stops, secondary reactive 
hyperaemia occurs; this causes vascular bronchial congestion, oedema and further airway 
narrowing(136). Rapid rewarming is not thought to contribute to EIB in children(140). 
 
An exercise challenge test is used to diagnose EIA in patients with symptoms during or after 
exercise. Standard practice is to perform spirometry before and after 4-6 minutes of vigorous 
exercise, a deterioration in FEV1 of at least 10% is diagnostic of EIA (136, 138). Correlation 
between reported symptoms and clinical testing is poor; many children who experience 
exercise related symptoms do not demonstrate a fall in FEV1 on exercise testing (135).  
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Bronchial provocation studies, examining airway hyper-reactivity have involved examination 
of ventilation heterogeneity.  Indices of ventilation heterogeneity obtained through SBW have 
been shown to deteriorate with cold dry-air hyperventilation challenge in children and adults 
with asthma (121, 122). SBW and MBW indices have been shown to correlate with bronchial 
hyper-responsiveness measured following methacholine (47) and cold dry-air hyperventilation 
challenges (47, 122, 127).  
 
Exercise induced symptoms represent a more 'natural' phenomenon compared to events 
precipitated by pharmaceutical agents. Studies of hyperpolarised helium MRI have 
demonstrated heterogeneous ventilation in asthmatics following exercise testing (141). Indices 





1.4.2.5 Asthma Exacerbation 
 
Asthmatic exacerbations increase steroid burden, reduce school attendance, cause 
hospitalisation and at worst can be fatal. The risk of exacerbation is increased in children with 
poor adherence to treatment, poor asthma control, frequent exacerbations and elevated FeNO 
(109). In exacerbation of asthma, hyper-responsive airways constrict due to inflammation, 
bronchospasm and mucus plugging, causing breathlessness. There is evidence that much of 
the dyspnoea is caused by constriction of small terminal airways (119).  
 
Venegas et al used positron emission tomography (PET) to show that bronchoconstriction 
induced by methacholine leads to patchiness in ventilation in asthmatic patients (119). 
Ventilation heterogeneity occurred due to clustering of constricted terminal bronchioles and 
was independent of large airway disease. The group then used a computational model to 
explain how even minimal heterogeneity in ventilation disrupts the symmetry of the bronchial 
tree due to short and long range feedback mechanisms  to cause large clusters of poorly 
ventilated lung units.  
 
Zeidler et al performed HRCT imaging, spirometry and closing volumes in 10 patients with 
cat induced asthma before and 6 and 23 hours post exposure to cat allergen (117). All patients 
had an acute drop in FEV1 of ≥20% but by 6 hours FEV1 had returned to baseline, there was 
no further change in FEV1 at 23 hours. FEF25-75 was abnormal at 6 hours but returned to 
baseline by 23 hours. End expiratory HRCT scans and closing volumes demonstrated 
increased air trapping at 6 and 23 hours following exposure, indicating the persistence of small 
airways disease once larger airways obstruction had resolved. At 23 hours post exposure, 
HRCT image analysis revealed increased small airways hyper-responsiveness to methacholine 
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challenge compared to before allergen exposure. The implications of this study were that small 
airways may be significantly involved in late asthmatic responses to allergens and small 
airway associated bronchial hyper responsiveness may persist long after exposure.  
 
In Zeidler’s study small airways disease during asthmatic exacerbation was detected using 
multiple HRCT scans. As previously discussed ventilation inhomogeneity detected using 
washout techniques deteriorates following bronchial provocation challenges and can predict 
bronchial hyper-responsiveness (47, 121, 122). MBW may offer a way of detecting small 
airways disease during asthmatic exacerbation without exposure to radiation. 
 
Thompson et al studied the effects of asthmatic exacerbation on indices of phase III slope 
analysis in 18 adults (142). The group used N2 MBW with a fixed tidal volume protocol and 
compared results to those of 19 stable asthmatic patients. Patients were included if their PEFR 
was ≤50%  of their personal best on admission, testing occurred within 48 hours of admission 
but a minimum of 4 hours after salbutamol. Predicted values of Scond and Sacin were derived 
from a previous study of 180 healthy adults (40). In patients suffering exacerbation, the median 
FEV1 was 59% of predicted value, Scond 185% and Sacin 225%. FEV1 correlated with Sacin (r=-
0.67, p=0.006) but not Scond. Sacin also correlated with the level of pre admission treatment 
(r=0.59, p=0.016). Median Scond and Sacin normalised within the 11 patients who attended 
follow up at 4 weeks post discharge. LCI was not presented. A fixed breathing pattern was 
adopted to aid measurement of phase III slopes, but a fixed tidal volume is not feasible in many 
children and severely breathless adults. The authors concluded that acinar disease was an 
important determinant of airways obstruction as measured by FEV1. However this was an 
observational study and causation could not be established.   
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MBW can detect asthmatic exacerbation in adults and may offer a method of detecting 
persistent abnormalities following normalisation of FEV1. Persistent small airways disease 
may indicate ongoing bronchial hyper responsiveness. There are no published studies 
regarding the effects of asthmatic exacerbation on MBW indices in children.  
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1.4.2.6 Asthma Medications and MBW 
 
The small airways have been shown to be involved in the pathophysiology of asthma, the 
effects of some asthma treatments on small airways have been investigated with imaging and 
MBW.  Studies using MBW have shown that salbutamol does not completely normalise 
ventilation inhomogeneity in asthma (48, 50, 126). The incomplete resolution of changes seen 
on MBW testing after salbutamol inhalation has been hypothesised to be due to structural 
changes within the small conducting airways and mechanical obstruction of inhaled therapies. 
Inhaled therapies may not reach the most diseased areas of the lung and settle instead in well 
ventilated areas exacerbating ventilation inhomogeneity. This could explain why intravenous 
therapies are required in severe asthmatic exacerbations.  
 
There is evidence of improvement in ventilation inhomogeneity following inhaled 
corticosteroids (IHC). Goldin et al used HRCT to demonstrate improvements in gas trapping 
following a 4 week double blind, randomised trial of extra fine IHC versus standard IHC (143). 
The group treated with extra fine IHC had better improvement in gas trapping and less air 
trapping on methacholine challenge after treatment than the standard IHC group. 
 
MBW derived indices have been shown to predict and correlate with symptomatic 
improvement of asthmatic adults following inhaled corticosteroids. Farah et al studied 105 
asthmatic adults before and 3 months after high dose ICS treatment and correlated changes in 
symptom control questionnaire with Scond (r=0.32, p=0.02) and Sacin (r=0.41, p<0.01)(132). 
The same group found that baseline Scond correlated with improvement in patient symptom 
scores following upwards titration of ICS treatment after 8 weeks (r=-0.64, p<0.01) (144). 
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Moreover, Sacin correlated with deterioration in patient symptom score following downwards 
titration of ICS treatment (r=0.40, p<0.01) (144). 
 
Downie et al studied 18 sub-optimally controlled asthmatic adults who were given a 3 month 
course of inhaled beclomethasone dipropionate (47). Ventilation heterogeneity, assessed using 
N2 MBW, improved following inhaled corticosteroid treatment. LCI improved from 8.54 to 
7.78, Scond from 0.067 to 0.052 and Sacin from 0.159 to 0.142 (p=0.001, 0.009 and 0.035 
respectively). FEV1 also improved from 80.1 to 85.9% predicted (p<0.001). After treatment 
abnormal Scond (>0.037 L-1) had a high sensitivity and specificity for the presence of persistent 
airway hyper responsiveness (90.0% and 87.5% respectively). Airway hyper-responsiveness 
was assessed using a methacholine dose response ratio (DDR), percentage fall in 
FEV1/methacholine dose. In a multiple linear regression model following IHC treatment Scond 
was the only predictor of log DRR (r2=0.64, p=0.004).  
 
A study by Zeilder et al. examined the effect of montelukast on gas trapping on HRCT as a 
measure of small airways disease in 16 mild-to-moderate steroid-naïve asthmatics (116). The 
study was a double-blind crossover study comparing the effect of montelukast versus placebo 
after 4 weeks of treatment; HRCT was performed at residual volume, before and after 
methacholine at the end of each study period. Montelukast resulted in significantly less 
regional air-trapping on HRCT on the pre-methacholine images when compared with placebo, 
as well as improvement in total quality of life scores and symptom sub-scores. This difference 
was not detected with spirometry. However, montelukast treatment had no effect on increases 
in regional air-trapping on HRCT in response to methacholine.  
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The effects of treatments on small airways disease in asthma needs further evaluation. If small 
airways disease persists despite current treatments new therapies which target this disease 
should be sought and could improve asthma care. 
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1.5 Limitations of MBW 
 
Many of the limitations of the MBW test have been discussed throughout this introduction. 
Primarily the minimal clinically meaningful differences in indices of MBW have not been 
determined and are required so that MBW can be used in a clinical setting.  
 
As discussed in depth testing has not been standardised and this is necessary to produce valid 
comparable results. A variety of different analysers, gases and software systems have been 
used, which have an effect on indices. A commercially available device produced with a view 
to optimise accurate concentration and flow alignment which would be acceptable for use 
across all age ranges and allow calculation of phase III slope indices is required. This would 
allow studies to produce and collate data to produce universal reference equations. 
 
The value of LCI is becoming well established in interventional trials in mild lung disease. 
However in more marked disease there are concerns that washout traces from patients with 
partial lung collapse or widespread peripheral airway closure secondary to atelectasis may be 
misleading.  
 
Indices of phase III slope appear dependent on tidal volume and in the paediatric population 
achieving set tidal volumes is more challenging. In addition phase III slope indices are time 
consuming to produce and dependent on the skill of the investigator in their measurement. 
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Lastly MBW is more time consuming than performing spirometry, particularly in patients with 
more severe disease and this might not be appropriate in the clinical setting. In addition 
although most children tolerate the test very well some young children may become restless.  
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1.6 The UK Cystic Fibrosis Gene Therapy Consortium  
 
The UK Cystic Fibrosis Gene Therapy Consortium (UKCFGT) was formed in 2001 from the 
UK’s three leading CF gene therapy groups at Edinburgh and Oxford University and Imperial 
College London (www.cfgenetherapy.org.uk). The consortium’s aim is to develop gene 
therapy for CF into a clinical reality. The consortium is funded by the CF Trust 
(www.cysticfibrosis.org.uk), Flutterby Fundraisers, Just Gene Therapy and private donations. 
 
 
Figure 16: UK Cystic Fibrosis Gene Therapy Consortium 
 
The consortium has recently published a multi-dose gene therapy study in which patients in 
Edinburgh and London participated, the results are reported earlier in this thesis and show 
some promising results (99).  
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Prior to the clinical trial the consortium ran a “tracking study” and a “run-in” study to select 
the best assays for detecting change in CF disease with treatment. The tracking study identified 
assays that could detect improvement following treatment of CF exacerbation with IV 
antibiotics (90).  The run-in study was designed to identify which assays could sensitively 
detect CF disease progression. Some patients who participated in the run-in study were 
selected for gene therapy trial.  The run-in study involved approximately 200 children and 
adults who attended visits in London and Edinburgh. Methods of assessing lung disease 
included lung function tests (LCI and spirometry), imaging, laboratory tests, quality of life 
measures and exercise testing.  
 
Once the gene therapy product had been developed and its safety assessed in animal models, 
a pilot study was performed to assess safety and efficacy (145). The vector used in the 
aforementioned multi dose gene therapy study was GL67A/pGM169, a combination of 
cationic liposome (GL67A) and plasmid DNA expressing CFTR (pGM169). The consortium 
is now working towards developing a lentiviral vector for gene therapy (146). 
 
1.6.1 Previous CFGT Consortium Clinical Research Fellows 
 
The development of the MBW test in Edinburgh was well established prior to my post because 
of the work of previous CFGT Consortium Research Fellows. Dr Alex Horsley and Dr 
Kenneth Macleod adapted the Innocor to perform MBW and validated its use in clinical studies 
(26). With Dr Nick Bell they produced a standard operating procedure for performing the test 
and a spreadsheet for determining indices of phase III slopes. Dr Macleod and Dr Bell taught 
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me how to perform the test and analyse the data on software we had courtesy of Professor Per 
Gustafsson (Department of Paediatrics, University of Gothenburg, Sweden).  
 
1.7 The Children’s Clinical Research Facility  
 
The Children’s Clinical Research facility is part of Edinburgh’s Clinical Research Facility 
based in the city’s Royal Hospital for Sick Children. It is part of both NHS Lothian and 
Edinburgh University and provides a child friendly environment in which to conduct paediatric 





Within this thesis I report 5 projects that were achieved during my period of research: 
1. The effect of body position on MBW derived indices in healthy children and children 
with cystic fibrosis (chapter 4) 
2. Longitudinal variability of MBW derived indices in children with cystic fibrosis 
(chapter 5) 
3. Assessment of MBW in children with stable asthma (chapter 6) 
4. The effects of exercise on MBW derived indices in healthy children and children with 
asthma (chapter 7) 
5. Evaluation of MBW derived indices in asthmatic children during and after 
exacerbation requiring corticosteroids (chapter 8) 
 
The projects had many common methodologies, these will be described together, with 
additional project specific methods provided within relevant sections. 
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2.1 Aims and Objectives of Projects 
 
2.1.1 The effect of body position on MBW derived indices in healthy children and 
children with cystic fibrosis 
To investigate the effect of posture (sitting vs. lying) on MBW derived indices in healthy 
children. 
To investigate the effect of posture (sitting vs. lying) on MBW derived indices in children with 
CF. 
To compare the effects of posture on MBW indices and spirometry in children with and 
without CF. 
 
2.1.2 Longitudinal variability of MBW derived indices in children with cystic 
fibrosis 
To assess the longitudinal variation in MBW derived indices in children with CF 
To investigate the correlation between MBW derived indices, spirometry and CT findings in 
children with CF. 
 
2.1.3 Assessment of MBW in children with stable asthma 
To assess whether indices of MBW are abnormal in children with stable asthma. 
To assess whether indices of MBW related to asthma control. 




2.1.4 The effects of exercise on MBW derived indices in healthy children and 
children with asthma 
To investigate changes in indices of MBW in asthmatic individuals following exercise. 
To relate the changes in MBW derived indices to changes in spirometry and reported exercise 
induced symptoms. 
To determine whether baseline indices of MBW can predict exercise induced lung function 
responses. 
To investigate the effects of salbutamol on MBW derived indices following exercise in 
asthmatic children. 
 
2.1.5 Evaluation of MBW derived indices in asthmatic children during and after 
exacerbation requiring oral corticosteroids. 
To determine whether MBW derived indices are abnormal during an exacerbation of asthma. 
To investigate the effects of salbutamol multi-dosing on MBW indices during an exacerbation. 
To measure indices of MBW in children 4-6 weeks after discharge from hospital. 
To relate persistent abnormalities in MBW to symptoms, characteristics of the child and 
severity of exacerbation. 
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3 Common Methods 
 
3.1 Multiple Breath Washout (MBW) 
 
3.1.1 Equipment 
3.1.1.1 Innocor (Innovision, Denmark) 
The Innocor is a device designed originally to measure cardiac output. It uses photoacoustic 
spectroscopy technology to measure the concentration of specific gases in exhaled breath. The 
patient interface that comes with the Innocor was not used and was replaced with a custom 
made set up with a flow meter, gas sampling line, bacterial filter and mouthpiece. 
 




3.1.1.2 Pneumotach/Flowmeter (Hans Rudolph USA) 
The pneumotach was used to measure flow. It has a small dead space to prevent rebreathing 
of exhaled air. The dead space of the mouth piece, pneumotach and bacterial filter was 
36mls.  
 
A gas sampling line consisting of a 20G needle attached to nafion tubing was inserted into the 
distal part of the flow meter and connected to the Innocor.  
 
3.1.1.3 Mouthpiece (Hans Rudolph, USA), nose clip and bacterial filter (Air Safety, 
UK) 
A mouthpiece was used to deliver gases directly to the mouth. A nose clip was essential in 
preventing escape of gas. An inspiratory leak during wash-in phase prevents equilibration of 
the inert gas and an expiratory leak during washout will cause inaccuracies in expired volumes. 
A bacterial filter was necessary for infection control. 
 
3.1.1.4 Interface Positioning Stand 
The mouthpiece and flow meter were positioned in front of the patient using a goose necked 
microphone stand. The flow meter was positioned so that the gas sampling needle and flow 
transducer lines were not pointing downwards in case moisture should collect and travel down 
the lines. These lines were positioned between 9 and 3 o’clock. 
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3.1.1.5 Sulphur Hexafluoride (SF6) (BOC Ltd) 
SF6 was the inert gas that was used throughout MBW testing during my research. Being 
completely inert it is neither absorbed nor excreted by the body. It is however a potent 
greenhouse gas. It can be supplied at different concentrations. I used 0.2% (2000ppm) SF6 
concentration in medical quality dry air, supplied by BOC Ltd.  
 
3.1.1.6 Flow past Circuit 
The SF6 canister was connected to a rebreathing bag (to maximise availability of SF6 during 
inspiration) which was connected to approximately 0.5m of tubing. The tubing connected to a 
T-piece, on the other end of which was another length of tubing, approximately 1-2m long. 
This longer section of tubing functioned as the exhaust. The T-piece was attached to the flow 
meter during the wash-in phase and then removed during washout.  
 
Figure 18: Flow-Past Circuit (UKCFGT consortium SOP) 
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3.1.1.7 Data Analysis Software 
The raw flow and gas concentration data was required to be converted into volume and end-
tidal gas concentration for each breath of the washout. Custom software was available for data 
analysis, courtesy University of Gothenburg, Dept. Paediatric Physiology, Gothenburg, 
Sweden. A spreadsheet designed by Dr Alex Horsley (previous Research Fellow with the 
UKCFGT consortium) was used to calculate phase III slope indices. 
 
I also had the use of a second more automated software package “Simple Washout” designed 
by Dr Nick Bell (previous Research Fellow with the UKCFGT consortium), however it could 
only be used to calculate LCI and not phase III slope indices.  
 
3.1.2 Technique 
As described MBW testing throughout this thesis was performed using the modified Innocor 
and exogenous 0.2% SF6. In exogenous gas MBW there are 2 phases, wash-in and washout. 
Throughout testing the patient was encouraged to breathe regularly, through a mouthpiece, 
with a nose clip on. The test was performed with the patient sitting and watching television (as 
a distraction).  A pneumotach attached to the mouthpiece measured respiratory flow and gas 
samples were taken from the pneumotach at 10ms intervals for analysis of concentration by 
the Innocor gas analyser. The Innocor displayed online SF6 concentration with an approximate 
1.5 second delay. Displayed numerical concentration values were only updated every second 
so actual peak values may have differed. Data were extracted after testing for offline 
integration of flow and concentration signals and generation of MBW indices.  
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The set-up of equipment and testing room were standardised to maximise reliability. The room 
in which testing was performed was large and well ventilated to minimise SF6 rebreathing by 
the subject during the washout. In addition exhaled SF6 was cleared from the immediate area 
surrounding the subject by a fan. Ambient temperature and humidity were recorded each day 
testing occurred. 
 
Testing was explained to participants. Patients were shown the equipment and the 
disconnection of gas supply was demonstrated. Patient positioning was adjusted to avoid 
slouching and crossing of legs was discouraged. Patients were given time to get used to the 
mouthpiece and nose clip and any potential leaks were corrected before testing began. Patients 
were asked to breathe regularly and avoid breaking the mouth piece or nose clip seal. Patients 
were warned that they might get a dry mouth and that water would be available after each test. 
 
During the wash-in phase, the patient breathed in 0.2% SF6 until it was evenly distributed 
throughout the lung. The gas flow was set at between 10-15L/minute depending on the size of 
the patient and a reservoir bag was placed in line with the tubing to maximise the volume of 
SF6 available during inhalation. Wash-in was determined as complete when the maximum and 
minimum concentrations of SF6 displayed on the Innocor were within 0.003% for 3 successive 
breaths.  
 
Following equilibrium of gas concentration the gas supply was disconnected during an exhaled 
breath, by removal of the T piece, and the washout phase began. Identification of exhalation 
was done by watching the chest rise and fall and was difficult in some children. The T piece 
was covered immediately after removal to prevent escape of SF6 into the immediate vicinity 
of the patient and the SF6 supply was turned off. The patient continued to breathe regularly 
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through the mouthpiece until maximum SF6 concentration fell to less than 0.003% for 3 
successive breaths. MBW derived indices are derived after end tidal SF6 concentrations (Cet) 
falls to 1/40th of that at the end of the wash-in phase (Cinit). The cut off of 0.003% is less than 
1/40th of 0.2% but it allowed a margin of error to prevent premature termination of tests being 
discovered on subsequent offline analysis. 
 
 
Figure 19: Innocor online signal concentration display 
 
Each test took approximately 5-10 minutes, with slower wash-in and washout phases in more 
diseased lungs. MBW derived indices are reported as the mean of 2-3 acceptable tests. Testing 
was performed a minimum of three times, but was repeated more often if tests were technically 




3.1.3 Quality Control 
 
Calibration of the Innocor with the flowmeter and calculation of the Innocor’s flow-gas delay 
occurred before testing and was repeated at 4 hourly intervals. If the flowmeter was cleaned 
or replaced the ability of the Innocor to interpret pressure changes to linear flow at the flow 
meter was calibrated and corrected through a process of linearization. Calibration was 
performed with a bacterial filter in place as a filter can affect the flow through the flowmeter. 
In addition, the Innocor was serviced annually by Innovision. 
 
Flowmeter calibration and linearization were performed using a 3 litre calibration syringe at 
room temperature. Linearization involved filling and emptying the calibration syringe into the 
flowmeter at a range of different rates to simulate different respiratory flow rates. This was 
continued until the error in each manoeuvre across the range of flow rates was less than 1%. 
The daily flowmeter calibration involved a more limited number of filling and emptying 
manoeuvres at different rates to ensure that accuracy was within 2%. If accuracy was out with 
2%, equipment was checked and linearization repeated.  
 
To calibrate flow gas delay, eleven slow exhaled breaths followed by sharp inspirations were 
performed into the flowmeter via a filter. This was done to obtain a sudden transition from 
expiration to inspiration and a sharp fall in CO2 at the flowmeter. The Innocor calculated the 
delay from change in flow to drop in CO2 concentration within the analyser. Flow-gas delay 
was recorded for later use in the analysis of raw data. During analysis an additional 50ms was 
added to the calculated flow gas delay to correct for the Innocor’s response time to changes in 
SF6 concentration as discussed previously. Flow gas delay variation was within 20-40mls on 
testing days. 
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Only technically acceptable tests were accepted for analysis. SF6 was required to be adequately 
washed in, disconnection had to occur during expiration and washouts had to be complete to 
be analysed. Children were distracted throughout testing with a DVD and encouraged to 
maintain a relaxed regular breathing pattern. Tests were not excluded on the occasion that a 
child exhibited erratic breathing patterns so long as other quality control criteria were met. 
 
Care was taken to ensure that 0.2% SF6 was adequately washed in. This was checked during 
testing by ensuring that the difference between inhaled and exhaled SF6 concentration was 
<0.003% for 3 successive breaths. During analysis this difference was checked and tests in 
which wash-in was >0.003% were discarded. Insufficient wash-in reduces the volume required 
to wash out the lungs, hence invalidating results. Failure of SF6 to equilibrate during wash-in 
may have been caused by insufficient wash-in time (in more severe disease), insufficient gas 
flow in the flow past circuit (causing rebreathing of exhaled air) or a leak within the patient 
interface (at the mouth or nose). 
 
Disconnection of SF6 at the start of the washout phase had to occur during expiration. If 
disconnection occurred during inspiration an unquantifiable volume of additional inhaled SF6 
would be added to the exhaled SF6 volume of the first breath and would invalidate the washout. 
In a correctly disconnected test, SF6 concentration fell to (almost) zero on the first inspiration 
post disconnection. Tests in which SF6 disconnection occurred during inspiration were easily 
identified as SF6 concentration did not fall to zero and were excluded from analysis.  
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Figure 20: Washout trace illustrating almost complete equilibrium of SF6 concentration during 
wash-in and disconnection of SF6 supply during expiration causing fall in SF6 to almost zero 
with first inspiration (courtesy Dr Bell’s Simple Washout SOP). 
 
The Innocor reset every 300 seconds or 5 minutes to maintain accuracy. During resets there 
was a one second loss of flow data during which the Innocor recorded flow as -100L/s. In 
offline analysis resets were flattened by using the flow immediately prior to the reset, however 
this may have slightly distorted gas volumes. Resets were particularly important to avoid in 
the first 10 breaths of the washout when the largest SF6 volumes were being expired. If the test 
was approaching 5 minutes at the end of wash-in, disconnection was delayed until after the 
reset.  
 
Only tests in which SF6 was sufficiently washed out were analysed. To terminate a test 
maximum end tidal SF6 concentration (Cet) had to be less than one 40th of end tidal 
concentration at the end of wash-in Cinit). As discussed during testing the maximum SF6 
concentration displayed on the Innocor had to be less than 0.003% for 3 successive breaths 
before the test was terminated. On offline analysis, tests were termed completed and therefore 
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acceptable if Cet fell below the termination concentration (1/40th Cinit), the breath volume was 
larger than a stipulated minimum termination volume (MTV) and that breath was followed by 
another breath which met both criteria. MTV was set to avoid terminating washouts on the 
basis of an aberrantly small breath in which end tidal concentration was not reflective of 
peripheral gas concentration. MTV (ml) was calculated by doubling the predicted airway dead 




Gas concentration and flow data for each test was recorded by the Innocor and could be 
accessed through a Microsoft Windows program. Tests were accessed through Windows, 
saved on a memory stick and analysed offline using software provided courtesy of University 
of Gothenburg. Software incorporated the flow and gas concentration data using the flow gas 
delay and produced graphic illustrations of SF6 concentration versus expired volume for each 
breath.  
 
Analysis involved determining when disconnection of SF6 occurred, checking to ensure each 
breath and end tidal concentration were correctly identified and determining when the wash 
out terminated. Functions on the software allowed manual override to correct errors. 
Identification of phase III slope was set for between 65 and 95% of expired breath volume but 
required manual correction in most washouts. 
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Figure 21: SF6 expirogram; phase III slope identified in red by altering breath volume 
percentage at which phase III slope starts and finishes. 
 
Analysis using University of Gothenburg software produced LCI and FRC values. Indices of 
phase III slopes were determined following input of analysed washouts into a UKCFGT 
consortium spreadsheet. UKCFGT consortium software did not allow exclusion of breaths in 
which there was no clear SIII (due to a cough or small tidal volume). 
 
The calculation of MBW indices has been discussed in detail. The following calculations were 
used within this thesis. 
 
Lung Clearance Index (LCI) was calculated by dividing the total amount of expired gas during 
a washout (CEV) by the functional residual capacity (FRC).  
  LCI = CEV / FRC 
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FRC was calculated during a washout by dividing the volume of expired inert gas (Vgas) by 
the difference between end tidal gas concentrations at the start (Cinit) and end (Cend) of washout.  
  FRC = VGAS / CINIT- CEND 
LCI in this thesis is reported as the mean of at least 2 tests in which LCI differed by no more 
than 20% and FRC by less than 10%.  
 
In phase III slope analysis SIII was divided by mean slope SF6 concentration to produce a 
normalised slope (SnIII). SnIII was multiplied by expired breath volume to correct for the 
effects of variable breath volume. 
 
Scond was calculated by determining the slope of the graph of SnIII vs number of lung turnovers 
(TO) from TO=1.5 to TO=6. (TO at each point in washout calculated by dividing the 
cumulative expired volume at that time by FRC).  
Scond = delta SnIII (1.5-6.0 TO) 
Sacin was calculated by subtracting Scond multiplied by the number of lung turnovers at the first 
breath from SnIII at the first breath. 
Sacin = SnIII breath 1 – (Scond x TObreath 1)  
 
Scond and Sacin were reported in this thesis as the mean of at least 2 tests not excluded for excess 






The EasyOne™ Spirometer uses digital ultrasonic flow measurement technology to measure 
spirometric volumes. Ultrasonic spirometers do not cause resistance to air flow and have no 
moving parts which may be easily broken. However ultrasonic spirometers may record slightly 
lower volumes than heated wire spirometers (147).  
 
The EasyOne™ is portable and has inbuilt software to calculate whether technically acceptable 
tests have been achieved. Tests can be stored on the meter and downloaded after testing. The 
Easyone is calibrated with a 3 litre syringe and has been shown to remain accurate for 
prolonged periods of time (148, 149). The patient blows into a disposable spirette which is 
changed between patients for infection control.  
 
Figure 22: Easyone portable spirometer (http://www.nddmed.com) 
 
3.2.2 Technique 
Spirometry required the child to inhale to total lung capacity and then to perform a full forced 
expiratory manoeuvre. Testing complied with ATS/ERS standards(3), which were discussed 
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in the introduction. If the child had no experience of spirometry then they were shown what to 
do and allowed to practice. Unless otherwise stated children stood during testing and wore 
nose clips. The child was asked to repeat testing to try to achieve 3 technically acceptable tests 
but testing did not exceed 8 manoeuvres. The difference between the largest and next largest 
FVC and FEV1 had to be ≤0.150L unless FVC was less than 1.0L in which case the difference 
had to be ≤0.10L. The best FEV1 and FVC and the FEF25-75 of the manoeuvre with the best 
combined FEV1 and FVC were recorded. 
 
Indices generated by spirometry including FVC, FEV1 and FEF25-75 have already been 
discussed. Standard deviation scores and percent predicted FEV1, FVC and FEF25-75 were 
calculated for each patient using GLI equations (16). 
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4 Project: The effect of body position on MBW derived 




Standardisation of MBW testing is important in order to produce valid results. For effective 
standardisation it is important to establish the factors that affect MBW results within an 
individual over time. One factor that theoretically might affect MBW derived indices is 
posture, which is significant because infants undergo MBW testing in a supine position, 
whereas in older children measurements are made in a sitting position. It is therefore important 
to understand whether changes in posture influence measures of MBW and if so the degree of 
effect, and the difference in effect in health and disease. 
 
There is evidence that posture affects lung volumes (56, 57) and ventilation distribution (58) 
and imaging has demonstrated atelectasis in the lungs of supine children (59, 60). However 
studies assessing the effects of posture on indices derived from MBW have been contradictory. 
One small study has shown no change in LCI in asthmatic and healthy children on lying supine 
(57). Other small studies of healthy men have demonstrated rises in Scond (58) and LCI in the 
supine position (61). We sought to clarify how posture affects MBW derived indices in healthy 




To investigate the effect of posture (sitting vs. lying) on MBW derived indices in healthy 
children. 
To investigate the effect of posture (sitting vs. lying) on MBW derived indices in children with 
CF. 




4.3.1 Inclusion/Exclusion Criteria 
Patients with cystic fibrosis (CF) and healthy volunteers were studied. Participants were aged 
5−16 years. Healthy volunteers had no significant medical history, no history of respiratory 
disease and did not smoke. Patients had a confirmed diagnosis of CF by either sweat or genetic 
testing, were clinically stable (no exacerbations requiring antibiotics in the previous 4 weeks) 
and had an FEV1 of greater than 40% predicted. 
 
Healthy volunteers were excluded if they had a past history of recurrent wheezing episodes, 
pneumonia, cystic fibrosis, pertussis or tuberculosis; a previous diagnosis of asthma or were 
taking asthma medication; or a previous hospitalisation for respiratory infection. Patients with 
CF were excluded from the study if their FEV1 was less than 40% of predicted or if they had 
had an exacerbation requiring antibiotics in the previous four weeks. Volunteers from both 
groups were excluded if they were born before 34 weeks gestation; if they had any 
neuromuscular weakness or bone disease likely to affect respiration; or if they had any 




The group of healthy volunteers had either participated in a previous MBW study, were family 
members of hospital staff or siblings of patients. Initial notification of the pending study was 
sent out by email with an invitation to contact the research team. Patient information sheets 
were then sent out to interested families, followed by telephone calls to arrange testing. 
 
Patients with CF were first approached at out-patient clinic appointments. Information sheets 
were given to interested families, who were contacted by telephone at least 24 hours later to 




4.3.3 The Visit 
 
Testing was performed in the Children’s Clinical Research Facility (CCRF) of the RHSC, 
Edinburgh. Consent was obtained from parents and children prior to testing. Children were 
asked screening questions to ensure they complied with entry criteria and they were well 
enough to participate. Subsequently their weight and height were measured. They then 
underwent three MBW tests followed by standard spirometry (as described earlier). Children 
were then asked to lie down for 30 minutes after which testing was repeated in the same order 
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MBW raw data was extracted from the Innocor and analysed as described earlier to produce 
values for LCI, Scond and Sacin.  Z-scores and percent of predicted values for FEV1, FVC and 
FEF25-75 were calculated. 
 
Data were analysed using Minitab Version 17 statistical software (Minitab, USA). Data are 
presented as mean with standard deviation (SD) or median with interquartile range (IQ). 
Demographic and lung function results were compared between CF and healthy groups with 
either 2 sample t tests or Mann-Whitney tests depending on distribution. Changes in lung 
function on lying flat were analysed using paired t or Wilcoxon signed rank tests. Pearson or 
Spearman correlation coefficients were used to assess relationships between sitting lung 
function and change after lying. Significance was assumed at p=0.05. 
 
4.3.5 Ethical Approval 
The study was approved by the Lothian Research Ethics Committee. Written consent was 
obtained from parents and capable children, verbal assent was obtained from all children. 
 
4.3.6 My Involvement 
This study was designed and started by my predecessor Dr Kenneth Macleod. I was involved 
with recruiting and testing patients. I have analysed of all the washouts collected in the study 




4.4 Project Results 
 
4.4.1 Differences between CF and healthy groups 
 
20 children with CF and 20 healthy controls were recruited between August 2008 and May 
2011. Controls were significantly, older, taller and heavier than patients with CF (table 1). 
 
 Healthy CF P value 
Number 20 20  
Gender 12 M: 8 F 8 M: 12 F  
Age (years) 10.8(3.7) 8.5 (2.8) 0.03 
Height (cm) 145.5(21.6) 127.6 (17.3) <0.01 
Weight (Kg) 40.3 (15.4) 29.5 (12.3) 0.02 
Table 1: Demographics of healthy and CF groups. Mean (standard deviation SD). 2 sample t 
tests used to compare age, height and weight. 
 
4.4.2 Sitting Lung function 
 
Table 2 shows the lung function results of the children while in the sitting position. Data were 
normally distributed for FEV1, FVC, FEF25-75 and Scond, and so are presented as mean (SD); 
LCI, FRC and Sacin were not normally distributed and are therefore presented as median (IQ).  
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Healthy children had normal lung function with a mean (SD) FEV1 percent predicted of 97.6% 
(11.7), a FVC of  99.5% (10.5) and FEF25-75 of 93.8% (20.5); LCI was also normal, median 
(IQ) 6.1 (5.8, 6.3).   
 Healthy CF P value 
FEV1 % predicted 97.6 (11.7) 81.8 (17.7) <0.01 
FEV1 z-score -0.2 (1.0) -1.4 (1.5) <0.01 
FVC %predicted 99.5 (10.5) 90.8 (16.1) 0.05 
FVC z-score -0.1 (0.9) -0.8 (1.3) 0.07 
FEF25-75 %predicted 93.8 (20.5) 68.1 (24.6) <0.01 
FEF25-75 z-score -0.3 (1.0) -1.6 (1.3) <0.01 
LCI 6.1 (5.8, 6.3) 7.6 (6.6, 8.7) <0.01 
FRC (L) 1.7 (1.3, 2.2) 1.0 (0.9, 1.3) <0.01 
Scond (L-1) 0.02 (0.02) 0.06 (0.02) <0.01 
Sacin (L-1) 0.10 (0.09, 0.13) 0.13 (0.10, 0.25) 0.04 
Table 2: Sitting lung function in healthy and CF groups. Mean (SD) displayed and 2 sample t 
tests used for FEV1, FVC, FEF25-75 and Scond. Median (IQ) displayed and Mann-Whitney test 
used for LCI, FRC and Sacin. 
The CF group had significantly lower lung function compared to controls demonstrated in all 
indices except FVC z-score. Mean (SD) FEV1 was 81.8% (17.7), FEF25-75 68.1% (24.6), and 
median (IQ) LCI 7.6 (6.6, 8.7). Comparison between the 2 groups was done using 2 sample t 
or Mann-Whitney tests. 
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4.4.3 Effects of change in posture 
In the healthy group, FEV1, FVC and FEF25-75 % predicted and z-score significantly fell on 
retesting in the supine position. LCI and FRC also deteriorated; there was a significant rise in 
LCI from 6.1 to 6.4 (p<0.01) and a fall in FRC from 1.7 to 1.1 (p<0.01). Scond and Sacin did not 
change. Variability in MBW derived indices were similar in both positions. LCI showed good 
repeatability, the mean coefficient of variation (CV) for LCI was 5.3% sitting and 4.5% supine. 
Phase III slope variation was much higher, mean CV for Scond was 188% sitting and 142% 
supine and for Sacin it was 34% sitting and 34% supine.  
 Posture Mean change (95% CI), P value 
Sitting Supine 
FEV1 % pred 97.6 (11.7) 90.8 (10.6) -8.4 (-12.3, -4.4), p <0.01 
FEV1 SDS -0.2 (1.0) -0.8 (0.8) -0.7 (-0.9, -0.4), p<0.01 
FVC % pred 99.5 (10.5) 96.1 (10.5) -5.0 (-8.4, -1.6), p<0.01 
FVC SDS -0.1 (0.9) -0.4 (0.9) -0.4 (-0.7, -0.2), p<0.01 
FEF25-75 % pred 93.8 (20.5) 81.9 (17.7) -13.8 (-19.6, -7.9), p<0.01 
FEF25-75 SDS -0.3 (1.0) -0.8 (0.8) -0.6 (-0.9, -0.3), p<0.01 
LCI 6.1 (5.8, 6.3) 6.4 (6.2, 6.5) 0.3 (0.1, 0.4), p<0.01 
FRC (L) 1.7 (1.3, 2.2) 1.1 (0.8, 1.5) -0.6 (-0.7, -0.4), p<0.01 
Scond (L-1) 0.02 (0.02) 0.02 (0.02) <-0.01 (-0.01, 0.01), p=0.91 
Sacin (L-1) 0.10 (0.09, 0.13) 0.10 (0.08, 0.16) <0.01 (-0.02, 0.04), p=0.70 
Table 3: Table 3: Healthy children’s lung function sitting and lying. Mean (SD) FEV1, FVC, 
FEF25-75 and Scond and median (IQ) LCI, FRC and Sacin. Change in lung function presented 
as a mean with 95% CIs and P value. Paired t or Wilcoxon Signed rank test used. 
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In the CF group, FEV1 and FVC % predicted and z-score significantly fell on retesting in the 
supine position, the change was not significant for FEF25-75. LCI rose significantly from 7.6 to 
7.8 (p<0.03) and FRC fell from 1.0 to 0.8 (p<0.01). In the CF group Scond and Sacin did not 
significantly change. See table 4. The repeatability of LCI in the CF group was good in both 
positions, mean CV for LCI was 5.2% while sitting and 5.7% supine. Phase III slope variability 
was high, Scond CV was 51.4% sitting and 51% supine and for Sacin CV was 28% sitting and 
40% supine. 
 Posture Mean change (95% CI), P value 
Sitting Supine 
FEV1 %pred 81.8 (17.7) 75.1 (15.3) -6.8 (-12.2, -1.4), p=0.02 
FEV1 SDS -1.4 (1.5) -1.9 (1.3) -0.5 (-0.9, -0.1), p=0.02 
FVC %pred 90.8 (16.1) 83.8 (14.7) -7.0 (-11.1, -3.0), p<0.01 
FVC SDS -0.8 (1.3) -1.3 (1.3) -0.5 (-0.8, -0.2), p<0.01 
FEF25-75 %pred 68.1 (24.6) 61.3 (21.8) -6.8 (-14.1, 0.5), p=0.07 
FEF25-75 SDS -1.6 (1.3) -1.9 (1.3) -0.3 (-0.7, 0.1), p=0.08 
LCI 7.6 (6.6, 8.7) 7.8 (7.0, 10.3) 0.5 (0.05, 0.9), p=0.03 
FRC (L) 1.0 (0.9, 1.3) 0.8 (0.7, 1.1) -0.3 (-0.4, -0.2), p<0.01 
Scond (L-1) 0.06 (0.02) 0.07 (0.05) 0.01 (-0.01, 0.03), p=0.42 
Sacin (L-1) 0.13 (0.10, 0.25) 0.15 (0.10, 0.20) <-0.01 (-0.04, 0.02), p=0.71 
Table 4: CF children’s lung function sitting and lying. Mean (SD) FEV1, FVC, FEF25-75 and 
Scond and median (IQ) LCI, FRC and Sacin. Change in lung function presented as a mean with 
95% CIs and P value. Paired t or Wilcoxon Signed Rank tests used. 
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4.4.4 Relationship between change in FRC and LCI with postural change 
 
There was no relationship between change in FRC and change in LCI in either group. The 
spearman correlation coefficients comparing change in FRC and LCI in the heathy group 





Figure 23: Scatterplot of change in LCI from sitting to supine versus change in FRC from 






























4.4.5 Difference in posture related changes between CF and healthy cohorts 
 
The mean group change in each test are presented for the healthy and CF cohorts in table 5. 
Two sample t tests were used to compare the changes between groups. The only significant 
difference between the two groups was seen in a greater fall in FRC in the healthy group 
compared to the CF group (mean change -0.6 vs -0.3, p<0.01). 
 
 Sitting to lying mean change (95% CI) P value 
Healthy CF 
FEV1 %pred -8.4 (-12.3, -4.4) -6.8 (-12.2, -1.4) P=0.62 
FEV1 SDS -0.7 (-0.9, -0.4) -0.5 (-0.9, -0.1) P=0.53 
FVC %pred -5.0 (-8.4, -1.6) -7.0 (-11.1, -3.0) P=0.43 
FVC SDS -0.4 (-0.7, -0.2) -0.5 (-0.8, -0.2) P=0.51 
FEF25-75 %pred -13.8 (-19.6, -7.9) -6.8 (-14.1, 0.5) P=0.13 
FEF25-75 SDS -0.6 (-0.9, -0.3) -0.3 (-0.7, 0.1) P=0.26 
LCI 0.3 (0.1, 0.4) 0.5 (0.05, 0.9) P=0.36 
FRC (L) -0.6 (-0.7, -0.4) -0.3 (-0.4, -0.2) P<0.01 
Scond (L-1) <-0.01 (-0.01, 0.01) 0.01 (-0.01, 0.03) P=0.44 
Sacin (L-1) <0.01 (-0.02, 0.04) <-0.01 (-0.04, 0.02) P=0.33 
Table 5: Mean change in lung function from sitting to lying in healthy and CF groups with 95% 
confidence intervals. 2 sample t test used to compare changes in healthy and CF groups. 
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4.4.6 Posture related changes compared to baseline lung function 
 
Baseline LCI did not correlate with the change in LCI on lying supine. In the CF group in 
particular, lying had a very variable effect on LCI, which could not be predicted from baseline 
testing. See Figure 24, which shows a scatterplot of individual baseline LCI against the change 
on adopting the supine position. 
 
 

























Scatterplot of change in LCI versus baseline sitting LCI
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Baseline FEV1 % predicted for both groups did correlate with change in FEV1 % predicted on 
lying (Pearson correlation coefficient -0.49, p<0.01). Patients with better FEV1 had larger 
drops in their FEV1 on lying supine. See Figure 25. 
 
 

































Scatterplot of change in versus baseline FEV1 % predicted
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4.5 Project Discussion 
 
This study has shown that MBW derived indices are abnormal in children with CF compared 
to healthy controls and that supine posture affects FEV1, FVC, LCI and FRC in both groups. 
FRC was more affected by posture in healthy individuals compared to CF patients. LCI 
deteriorated equally in CF patients and controls despite a smaller fall in FRC in the CF group 
demonstrating that increased ventilation inhomogeneity was not entirely due to reduction in 
FRC. A postural difference in Scond and Sacin could not be detected, possibly because of high 
variability.  
 
Children with CF in this study had significantly reduced baseline lung function when 
compared to a healthy group with no respiratory disease. All spirometry and MBW derived 
indices with the exception of FVC z-score were significantly worse in the CF group. Healthy 
children’s lung function fell within the normal range. Most but not all of the children with CF 
had abnormal lung function. The variability of lung function within the group with CF was 
larger than the healthy group as reflected by the higher standard deviations for % predicted 
FEV1 (11.7 in healthy group compared to 17.7 in the CF group) and interquartile ranges for 
LCI (5.8, 6.3 in healthy children compared to 6.6, 8.7 in children with CF). This suggests that 
the group of children with CF had varying degrees of lung disease which was not surprising 
given that only severely diseased children with an FEV1 of less than 40% were excluded. 
 
Supine posture caused a reduction in FEV1, FVC and FRC and a small rise in LCI in healthy 
children and children with CF.  It is well established that posture effects residual lung volumes 
(56). Bouhuys et al had previously found that LCI increased on lying flat in a small study of 
healthy adults (61). A rise in LCI was predicted on lying supine because FRC was expected to 
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fall and LCI is calculated using FRC to divide the total volume of gas expired during the 
washout. However in our study change in LCI in individual patients did not correlate with 
change in FRC suggesting that the rise in LCI was due to other factors. The rise in LCI may 
have been due to increased ventilation heterogeneity secondary to atelectasis or the effects of 
gravity on ventilation distribution. Atelectasis has been demonstrated in children’s lungs on 
lying flat using MRI and CT imaging (59, 60). The results of our study that was performed 
without anaesthetic suggest that not all of the atelectasis seen on imaging studies was likely to 
be due to the use of anaesthetic and artificial ventilation. Gravity dependent changes in 
ventilation distribution which shift ventilation to more diseased regions of the lung on lying 
supine may also increase ventilation inhomogeneity. 
 
The results of this study contrast to the findings of some published studies of posture and 
MBW. Gustafsson et al found that LCI did not change in the supine position in healthy children 
(57). Differences in methodology may be to blame for the contrasting results as in this Swedish 
study spirometry was performed before MBW and only one MBW test was performed at each 
time point (0, 30 and 60 minutes following assuming the supine position). Lum et al also found 
no difference in LCI measurements in erect and supine positions, however they compared LCI 
between two very different groups of patients (a group of <2 year olds with a group aged ≥3 
years) (41). In addition the two groups Lum et al studied performed MBW differently, the 
infants were sedated and used a face mask and the older children were not sedated and used a 
mouthpiece. 
 
The effects of posture are different in CF lungs compared to healthy lungs. FRC fell 
significantly more in the healthy group compared to the CF group (mean change -0.6L versus 
-0.3L respectively (p<0.01)). Despite the smaller drop in FRC, the rise in LCI appeared larger 
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in the CF group, with a mean increase in LCI of 0.5, compared to 0.3 in the healthy group, 
however this difference was not significant. The variation in change of LCI was much more 
marked in the CF group; the 95% CIs for change in the CF group were 0.05 - 0.9 compared to 
0.1 - 0.4 in the healthy group. The effect of posture could not be explained by baseline LCI 
because change on moving supine did not correlate with initial LCI. In fact several patients 
with abnormal initial LCI had an improvement in their LCI on lying supine. Improvement in 
LCI in these patients could have been caused by complete obstruction of peripheral regions of 
diseased lung on lying supine. CF patients with normal LCI appeared to follow a similar 
pattern to the healthy children with regard to their change in LCI on lying. These observations 
need clarification in larger groups of patients with categorised disease severity.  
 
Indices of phase III slope were almost identical in sitting and supine postures, suggesting that 
they may be useful when comparing the lung function of patients in different positions. 
However the very high variability, reflected in the CV, in Scond and Sacin may be the reason a 
difference could not be detected. In Gronkvist’s study of 11 healthy men there was a rise in 
Scond in the supine position (no change in Sacin) (58). The methodology in this study differed 
from our own, helium was used as well as SF6 which will have altered the density of gas being 
inhaled; subjects were also asked to breath to a set tidal volume, which will have affected FRC 
and also reduced variability in phase III slopes.  
 
Adoption of the supine posture reduced FEV1 and FVC in healthy and CF groups, drops 
appeared greater in the healthy group but the differences were not significant. There was a 
significant correlation between baseline FEV1 %predicted and change in FEV1% predicted on 
lying supine, p<0.01. Patients with better initial FEV1 had larger falls in FEV1 on lying supine. 
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This effect means that it is not possible to compare spirometry across different postures. 
Standardised spirometry guidance has been published to ensure consistency (3). 
 
The results of this study have been combined with a similar study performed by Horsley et al 
in Sheffield in which another 15 children with CF and 8 healthy controls were recruited. In 
this group MBW was repeated as soon as the patient was supine and the equipment was ready, 
unlike in our study in which we waited 30 minutes after the patient adopted the supine position 
before testing. The results were similar with a larger fall in FRC in healthy children compared 
to controls (28.4% vs 24.0% respectively, p<0.001). LCI rose from 6.25 to 6.47 in the healthy 
group and from 7.72 to 8.22 in the group with CF. Combined results of these studies have been 
submitted for publication. 
 
This study was limited by a number of factors. A larger more diverse group of healthy children 
across all ages would be required for results to be applicable to all healthy children. The group 
of children with CF was limited and had varying disease severity, more information may be 
discerned from studying children in categories of disease severity. Assumptions with regard 
to why ventilation inhomogeneity increases on lying supine have been made. Incorporating 
imaging with MRI or CT within the study protocol could have allowed us to compare changes 
in functional ventilation heterogeneity with structural changes. This comparison would have 
allowed us to determine more definitively why children with CF had such a variable response 
to lying supine. In our study derived indices of phase III slope analysis were highly variable, 
this may have been due to not having a set tidal volume protocol during testing which is 
difficult for many children. However the software I had to my disposal meant that I could not 
exclude breaths in which the phase III slopes were indiscernible and this may have increased 
the variability of my results. 
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This study demonstrates that LCI is affected by posture and for comparison of results posture 
should be standardised. In addition the study demonstrated that the effects of a variable on 
MBW derived indices can be different in diseased lungs compared to healthy lungs. 
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5 Project: Longitudinal variability of MBW derived indices in 
children with cystic fibrosis 
 
5.1 Introduction 
It is well established that cystic fibrosis (CF) is a progressive disease, most evident for changes 
in lung function with age. There is however limited data on longitudinal measures in larger 
cohorts that not only provide evidence for individual measures of disease progression, but also 
the inter-relationship of these measures for anatomical, physiological and inflammatory 
markers. This work was developed within the UK CF gene therapy consortium as part of the 
requirement to be able to adequately measure response to new therapies that may be more 
sensitive to change than the current standard (accepted by the FDA and EMA) FEV1.  
 
FEV1 is understood to decline with progressive disease severity (74), but has been shown to 
be insensitive in detecting early disease (12, 83, 84). LCI appears to correlate with age in cross 
sectional studies of patients with CF (43) and may be more sensitive to early disease than FEV1 
(76, 85). There is evidence that LCI correlates with structural changes found on CT (78, 89) 
suggesting that LCI may be a marker of severity, however studies have shown conflicting 
results with regard to longitudinal change in LCI (75, 89). If indices of MBW relate to disease 
severity a decline over time would be expected, determining the rate of decline might allow 
assessment of the efficacy of new therapies in the future. This could be especially helpful in 
patients with mild disease to which FEV1 is insensitive. However if MBW indices vary 
significantly over repeated testing visits the ability of MBW to detect a meaningful change in 
lung function will be limited. This study was performed to examine the variability of MBW 
derived indices in children with CF over multiple visits and determine whether MBW could 
detect change in lung function over time. 
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5.2 Aims 
To assess the longitudinal variation in MBW derived indices in children with CF 
To investigate the correlation between MBW derived indices, spirometry and CT findings in 
children with CF. 
 
5.3 Methods 
A “Run-In” study was performed by the UK CF gene therapy consortium. It was designed to 
assess the stability and repeatability of a wide range of clinical and laboratory assays over time 
in patients with Cystic Fibrosis, at times of clinical stability. The study was a precursor to a 
multi dose gene therapy trial (99) in which some participants of this study subsequently 
volunteered. One of the methods that was studied was MBW.  
 
Adults and children with CF were recruited from across Scotland and London. My work in the 
study involved running the clinical aspects of the Scottish children’s visits; I will present only 
the data from their visits. I started work with the study midway through the children’s third 
visit but have analysed and presented data from all 4 visits. 
 
5.3.1 Inclusion/Exclusion Criteria 
Patients were eligible to take part in the paediatric group if they were aged 10-16 years, with 
a diagnosis of CF on sweat or genetic testing. They were excluded if they had an FEV1 below 
40%, a chronic day time oxygen requirement, were awaiting, referred for or post lung 
transplant, had a history of previous spontaneous pneumothorax (unless subsequent 
pleurodesis), recurrent severe haemoptysis, colonisation with MRSA or B. cepacia complex, 
advanced liver disease (varices or significant, sustained elevation of transaminases: ALT/ 
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AST>100 IU/l), significant renal impairment (serum creatinine > 150 μmol/l), significant 
coagulopathy, requirement for immunosuppressive agents (methotrexate, cyclosporine or 
intravenous immunoglobulin), were taking part in another interventional trial,  pregnant or 
were a current smoker.  
 
5.3.2 Recruitment 
Children, aged 10-16 years were recruited from Edinburgh, Glasgow, Dundee and Stirling. 
Meetings were held to present and discuss the study at each site. Suitable children were 
identified by local clinical teams. Patients were sent information about the study, some were 
approached by a CF nurse and others attended a parent education event. This was followed up 
with telephone calls. Full information sheets were then distributed to interested families. 
 
5.3.3 Study Visits 
At the time I completed my research fellowship all patients had completed four study visits 
spaced at 4-6 monthly intervals. Patients were asked to attend at times of clinical stability and 
appointments were rescheduled if symptoms indicated exacerbation, the patient had been 
prescribed antibiotics in the past 2 weeks or their regular CF medications had changed over 
the preceding 4 weeks. 
 
At each visit patient’s height and weight were measured, baseline observations were taken, 
including temperature, respiratory rate, heart rate, blood pressure and oxygen saturations. A 
physical examination of the chest was performed. Patients and their families then completed a 
quality of life questionnaire. Subsequently the children performed MBW testing (as detailed 
earlier) followed by spirometry using the EasyOne spirometer. Patients performed exhaled 
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breath condensate testing and had blood, urine and sputum taken for multiple laboratory 
assays. Finally patients performed a shuttle walk test.  
 
In between each visit, patients were asked to keep a diary of their symptoms, perform weekly 
forced expiratory manoeuvres into an electronic peak flow meter and wear a pedometer for a 
week.  
 
At their first visit patients underwent a low dose high resolution CT chest scan using a Siemens 
64 slice scanner. Each examination exposed the patient to an effective radiation dose of 1.4 
mili Sieverts. The scan included an inspiratory volumetric and an expiratory limited 
interspaced high resolution CT. The scans were anonymised and then assessed by two 
independent radiologists (at the Royal Brompton Hospital, London). Scans were scored using 
a previously reported scoring system (150). Each lobe was scored for extent of bronchiectasis 
(0-3), severity of bronchiectasis (0-4), bronchial wall thickness (0-4), presence of small and 
large airway plugs (0-2), consolidation (0-4) and gas trapping (percentage basis). A mean of 
the scored lobes was then recorded for each feature. 
 
5.3.4 Analysis  
MBW raw data were extracted from the Innocor and analysed as described earlier to produce 
values for LCI, Scond and Sacin.  Z-scores and percent of predicted values for FEV1, FVC and 
FEF25-75 were calculated. 
 
Data were analysed using Minitab Version 17 statistical software (Minitab, USA). Data are 
presented as mean with standard deviation (SD). Pearson correlation coefficients were used to 
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examine relationships between MBW and spirometric indices and between these indices and 
CT scores. Significance was assumed at p = 0.05. Intra and inter visit coefficient of variation 
(CV) was used to describe variability of tests. 
 
5.3.5 Ethical Approval 
The study was approved by the National Research Ethics Service. Written consent was 






5.4.1 Baseline Demographics 
 
Thirty four children (12 girls and 22 boys) with CF made up the subset within the CFGT 
Consortium Run- In study who attended the Royal Hospital for Sick Children. All children 
attended the first visit at which time the group’s mean age was 13.0 years (range from 10.1 to 
17.5 years) and mean (SD) height was 152.6 (10.8) cm . The group comprised children with 
varied genotypes and disease severity. 
 
Lung function varied within the group, mean (SD) and the range of values obtained are 
displayed in table 6. The group’s mean LCI and Scond were abnormal whereas mean FEV1, 
FVC, FEF25-75 and Sacin fell within 1.64 standard deviations of healthy mean values.  
Variable Mean (SD) Min Max 
FEV1 % predicted 81.0 (15.3) 39.1 105.3 
FEV1 SDS -1.6 (1.3) -5.2 0.4 
FVC % predicted 87.5 (11.2) 58.8 104.8 
FVC SDS -1.1 (1.0) -3.8 0.4 
FEF25-75 % predicted 69.3 (25.7) 15.3 107.7 
FEF25-75 SDS -1.6 (1.5) -5.3 0.3 
FRC (L) 1.9 (0.5) 1.2 3.4 
LCI 9.0 (1.8) 6.7 14.2 
Scond (L-1) 0.08 (0.03) 0.02 0.15 
Sacin (L-1) 0.19 (0.09) 0.06 0.52 
Table 6: Run-In Study Visit 1 lung function 
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Age at first visit correlated with FEV1 and FVC z-scores (r = -0.41 (p = 0.02) and r = -0.51 (p 
< 0.01) respectively) and mean LCI and FRC (r = 0.34 (p = 0.048) and r = 0.39 (p = 0.02) 
respectively). Age did not correlate with FEF25-75, Scond or Sacin. 
 
5.4.2 Correlation between FEV1, LCI, Scond and Sacin 
 
Figures 26 and 27 (scatterplots of visit 1 LCI versus FEV1 percent predicted and z-score 
respectively) demonstrate the range of FEV1 and LCI within the group. Reference lines 
indicate the 1.64 standard deviation limits of healthy children, FEV1 values below the 
horizontal line and LCI values to the right of the vertical line are out with 95% of healthy 
values. The limit for LCI of 7.01 was taken from the mean (6.24) plus 1.64 standard deviations 
(1.64 x 0.47) of LCI obtained in a previously published study of MBW in 29 healthy children 
in Edinburgh using the same equipment and methodology (50). FEV1 and LCI correlated 
within individual patients (Pearson r = 0.64, P<0.01), patients with CF lung disease are 
expected to develop abnormal lung function. However, LCI was abnormal (>7.01) in the 
majority of patients (71%) with a normal FEV1 (>80% or >-1.64 SDS) possibly indicating that 
LCI is more sensitive to early disease. There were no patients with a normal LCI (< 7.01) 
despite an abnormal FEV1 (<80%). 
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Figure 26: Visit 1 FEV1 % predicted vs LCI. . Reference lines at 80% predicted FEV1 and LCI 
= 7.01 (mean + 1.64 SD in healthy children). 
 
Figure 27: Visit 1 FEV1 z-score vs LCI. Reference lines from mean +/- 1.64 SD in healthy 








































Figure 28 shows a scatterplot of individual FEV1 z-score versus Scond. The reference lines show 
the 1.64 standard deviation limits for FEV1 and Scond. Values below the FEV1 limit and to the 
right of the Scond limit are out with 95% of values in healthy children. The 1.64 standard 
deviation limit for Scond was taken from the mean (0.017 L-1) and standard deviation (0.02) of 
Scond in a previous study of 29 healthy children in Edinburgh using the same equipment and 
methodology (50). 28 out of 33 children had a Scond above 1.64 standard deviations of the 
mean. Only 13 of these patients also had FEV1 below 1.64 standard deviations of the healthy 
mean. Sixteen patients had a normal FEV1 (>-1.64 SDS) but abnormal Scond (>1.64 SDS), 
suggesting that Scond may also be a sensitive marker of early lung disease in CF. Scond did not 
correlate with FEV1 z-score. There was one patient with an abnormal FEV1 and a Scond within 
the 1.64 standard deviation limit.  
 
Figure 28: Visit 1 FEV1 z-score versus Scond. Reference lines from mean + 1.64 SD in healthy 



















Figure 29 shows a scatterplot of individual FEV1 z-score versus Sacin and 1.64 standard 
deviation limits. The 1.64 standard deviation limit for Sacin was taken from the mean (0.12 L-
1) and standard deviation (0.06) of Sacin in healthy children using the same methodology (50). 
Sacin did weakly correlate with FEV1 (Pearson r= -0.34, p=0.049). However there were seven 
patients with abnormal FEV1 and a normal Sacin and seven patients with normal FEV1 an 
abnormal Sacin suggesting that neither test is more sensitive to early disease and that the tests 
possibly identify different processes.  
 
 
Figure 29: Visit 1 FEV1 z-score versus Sacin. Reference lines from mean + 1.64 SD in healthy 






















Figures 30 and 31 show scatterplots of individual Scond and Sacin against LCI with reference 
lines marking the previously described 1.64 standard deviation limits. LCI values to the right 
of the vertical reference line and Scond or Sacin values above the horizontal reference line are out 
with 95% of values previously obtained in healthy children. Scond did not correlate with LCI. 
Only 5 patients had a Scond within 1.64 standard deviations of the healthy mean, three of these 
patients had a normal LCI and the other two had Scond values that were approaching the cut-
off value. Six patients had normal LCI and three of these patients had abnormal Scond, 
suggesting that Scond may be even more sensitive to early disease than LCI. 
 
Figure 30: Visit 1 Scond vs LCI. Reference lines from mean + 1.64 SD in healthy children (Scond 






















Sacin correlated with LCI (Pearson r=0.68, p<0.01) and FEV1, suggesting that Sacin may be a 
marker of disease severity. However there were 16 patients with a normal Sacin but abnormal 
LCI suggesting that Sacin may not be as sensitive to early disease as LCI. 
 
Figure 31: Visit 1 Sacin vs LCI. Reference lines from mean + 1.64 SD in healthy children (Sacin 




















5.4.3 Intra-visit variability of MBW derived indices 
 
Intra visit coefficients of variation (CV) for MBW indices at visit 1 are detailed in table 7. LCI 
and FRC have CVs of 5.4 and 3.5% respectively but Scond and Sacin have CVs of greater than 
25%. 
 
 Mean CV (SD) 
LCI  5.4% (3.2) 
FRC 3.5% (2.3) 
Scond  29.8% (22.6) 
Sacin  25.4% (22.0) 
Table 7: Intra visit coefficient of variation for LCI, FRC, Scond and Sacin at Visit 1 
 
5.4.4 CT scores 
 
Every child who attended visit 1 had a CT on the same day. CTs were scored as described in 
the methodology by two independent radiologists. Each lobe was scored for extent of 
bronchiectasis (0-4), severity of bronchiectasis (0-4), bronchial wall thickness (0-4), presence 
of small and large airway plugs (0-2), consolidation (0-4) and air trapping (percentage basis). 
A mean of the scored lobes was then recorded for each feature. The results are shown in figures 





Figure 32: CT scores at visit 1 
 






























































Individual Value Plot of air trapping
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FEV1, FVC and LCI correlated with the extent and severity of bronchiectasis, wall thickness, 
small and large plugs and air trapping. Sacin correlated with extent and severity of 
bronchiectasis, large plugs and airway trapping. Scond only showed moderate correlation with 
wall thickness (r=0.34, 0=0.05) and large plugs (0.38, p=0.03).  No lung function measure 
correlated with consolidation. LCI correlated most strongly (compared to the other lung 
function indices) with extent and severity of bronchiectasis and wall thickness (r=0.66, 0.69 
and 0.58, p<0.01). Of the six patients with normal LCI (<7.01) five (83%) had no 
bronchiectasis on CT, of the 28 patients with abnormal LCI, 27 (96%) had bronchiectasis on 
CT. FEV1 correlated best with large plugs and air trapping (r=0.62 and 0.45, p<0.01). FVC 





























































Table 8: Correlation between lung function and CT scores. Pearson correlation coefficients 
and p values displayed. Strongest correlation for each CT feature in bold. 
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5.4.5 Variability of lung function over time 
 
Thirty two children subsequently attended 3 further visits, one withdrew after the first visit 
due to Burkholderia cepacia complex, and another after the third visit for personal reasons. 
The visits occurred at intervals of 3 to 10 months, over a period of 19 months. The median 
gaps (and IQ ranges) between visits 1 and 2, 2 and 3 and 3 and 4 were 3.9 (3.7-4.3) months, 
3.5 (3.2-4.2) months and 5.9 (5.6-7.0) months respectively. 
 
There were no consistent trends in lung function for the whole group over time. Table 9 shows 
the mean (SD) for each measure of lung function of the group at each visit. 
 
Variable Visit 1 (n=34) Visit 2 (n=33) Visit 3 (n=33) Visit 4 (n=32) 
FEV1 % predicted 81.0 (15.3) 82.3 (17.1) 79.5 (20.0) 79.3 (15.6) 
FEV1 SDS -1.6 (1.3) -1.5 (1.4) -1.8 (1.7) -1.8 (1.3) 
FVC % predicted 87.5 (11.2) 89.3 (13.6) 86.5 (16.4) 86.7 (13.7) 
FVC SDS -1.1 (1.0) -1.0 (1.2) -1.2 (1.5) -1.2 (1.2) 
FEF25-75 % predicted 69.3 (25.7) 70.9 (27.4) 68.8 (32.2) 67.6 (26.0) 
FEF25-75 SDS -1.6 (1.5) -1.5 (1.6) -1.7 (1.8) -1.7 (1.5) 
FRC (L) 1.9 (0.5) 1.8 (0.5) 1.9 (0.6) 2.0 (0.6) 
LCI 9.0 (1.8) 9.3 (2.4) 9.7 (2.1) 9.2 (2.1) 
Scond (L-1) 0.08 (0.03) 0.07 (0.03) 0.08 (0.03) 0.07 (0.03) 
Sacin (L-1) 0.19 (0.09) 0.19 (0.11) 0.21 (0.13) 0.20 (0.09) 
Table 9: Lung function across all visits. Mean (SD) displayed. 
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There was no group difference over time in any mean lung function result. Between visits 1 
and 4 LCI rose in 21 patients by a mean (SD) of 0.95 (0.86) but fell in 11 patients by a mean 
(SD) of -1.14 (0.98). FEV1 z-score fell in 21 patients by a mean of -0.76 (0.60) and rose in 11 
patients by a mean (SD) of 0.65 (0.44). The change in LCI between visits 1 and 4 correlated 
with change in FEV1 z-score (Pearson r = -0.421, p=0.017).  Changes in Scond and Sacin did not 
correlate with either FEV1 or LCI. 
 
 

































Lung function varied over time for each patient. FVC varied the least with the lowest inter-
visit CV across the 4 visits of 6.8%. FEV1 had a CV of 8.1% and LCI 9.1%. FEF25-75% 
predicted had a CV of 19.0%, Sacin varied by 29.5% but Scond varied the most with a CV of 
31.2%. See table 10. 
 
Variable V1-4 Mean V1-4 Inter-Visit CV 
FEV1 % predicted 80.0 (16.0) 8.1% 
FVC % predicted 87. 4 (12.3) 6.8% 
FEF25-75 % predicted 68.0 (25.4) 19.0% 
FRC (L) 1.9 (0.5) 9.5% 
LCI 9.3 (1.9) 9.1% 
Scond (L-1) 0.07 (0.02) 31.2% 
Sacin (L-1) 0.20 (0.09) 29.5% 




Figures 35-37 demonstrate how patients’ LCI varied over time. The patients are split 
depending on LCI at first visit. Figure 33 shows patients with a normal LCI (<7.01) at visit 1, 
figure 34 shows patients with an LCI of between 7.01 and 9.5 and figure 35 shows patients 
with an initial LCI of greater than 9.5. Variability of LCI appeared greater if baseline LCI was 
above 9.5. Mean inter-visit CV was 7.7 if initial LCI was <7.01, 8.2 if initial LCI was 7.01-
9.5 and 10.7 if LCI was >9.5.  
  
 
Figure 35: Individual variation in LCI over visits 1-4 in patients with an initial LCI of <7.01 











Initial LCI < 7.01
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Figure 36: Individual variation in LCI over visits 1-4 in patients with an initial LCI of 7.01-9.5 
 
Figure 37: Individual variation in LCI over visits 1-4 in patients with an initial LCI of >9.5 
 











Initial LCI 7.01 - 9.5











Figures 38 and 39 show how FEV1 percent predicted varied across the visits. Patients were 
split depending on whether their initial FEV1 z-score was less than -1.64. 
 
Figure 38: Line plot of individual FEV1% predicted over the 4 visits when initial FEV1 was >-
1.64 
 
Figure 39: Line plot of individual FEV1% predicted over the 4 visits 



















Initial FEV1 >-1.64 SDS
























This study detected no significant deterioration in LCI, Scond, Sacin or FEV1 over a period of 19 
months in children with CF. LCI and Scond were abnormal in several children in whom FEV1 
was normal suggesting LCI and Scond may be more sensitive to early disease than FEV1. There 
were significant correlations between LCI and structural changes on CT scanning, LCI showed 
the strongest correlation of any lung function parameter with severity and extent of 
bronchiectasis. The repeatability of LCI over multiple visits was similar to FEV1 but Scond and 
Sacin were highly variable over multiple test visits. 
 
The ages of the children in this study ranged from 10.1 to 17.5 years, age positively correlated 
with worse FEV1, FVC and LCI. Aurora et al published similar findings regarding correlation 
between age and LCI in CF in school age children (43). This relationship may be due to the 
progressive nature of CF lung disease. Correlations were not strong but it is well established 
that there may be multiple factors that determine lung disease severity in a group of children 
with different CF genotypes. Interestingly FEF25-75 and indices of phase III slopes did not 
correlate with age, this may be due to the intrinsic variability of the indices themselves and a 
larger group may be necessary to measure a correlation. 
 
Twenty one out of the 34 children in this study had normal FEV1 (>80% predicted). Sly et al 
found that lung disease was detectable in 80% of infants with CF using CT within the first few 
months of life (68). In addition bronchiectasis has been demonstrated with CT in children with 
CF who have normal FEV1 (72). Given that CF lung disease is known to be present so early 
in life and deteriorate with age it is unlikely that the children in our study had normal lungs. It 
may be more likely that FEV1 is insensitive in detecting early CF lung disease.  
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FEV1 and LCI correlated within individual patients (Pearson r=0.64, p<0.01). FEV1 is known 
to decline with deteriorating CF disease severity (74) and correlation with LCI suggests that 
LCI may also be useful as a marker of disease progression. In addition, LCI was abnormal 
(>7.01) in 15 of the 21 patients with normal FEV1 (>-1.64 SDS), in keeping with multiple 
published studies in which LCI detected abnormalities in CF when FEV1 did not (10, 35, 39, 
43, 75, 78) suggesting that LCI may be more useful in early disease than FEV1. Especially as 
abnormal LCI in childhood has been shown to persist through early childhood and even predict 
those who will develop abnormal FEV1 (88). 
 
Scond was abnormal in 29 of the 34 children in this study and did not correlate with FEV1 or 
LCI. Of the five patients with normal Scond four had normal FEV1 and three had normal LCI. 
The patients with normal Scond and abnormal FEV1 (n=1) and abnormal LCI (n=2) had a Scond 
just within the normal range. The normal range was formulated on the basis of a previous study 
in the same centre using identical equipment in 29 healthy children and may have been too 
small to accurately identify the normal range (which may be below the cut off used in this 
study (0.05L-1)). Three patients had abnormal Scond but normal LCI. Theoretically Scond will 
detect change in small conducting airways and be the first indicator of early disease. Horsley 
et al previously found that Scond was highly sensitive to early disease but that once a ceiling 
value of 0.150L-1 was reached it could no longer discriminate more severe disease (82). 
Gustafsson found that although Scond was abnormal in children with CF and asthma it could 
not discriminate between the groups (48). The use of Scond in CF may be limited to detecting 
the first signs of disease. 
 
Sacin was abnormal in 14 of the 34 children and correlated with both FEV1 and LCI (r=-0.34 
and 0.68 respectively) suggesting Sacin may be a marker of disease severity. The correlation 
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was much stronger for LCI which is logical as both indices are measures of ventilation 
inhomogeneity compared to FEV1 which is primarily a measure of larger airway obstruction. 
Horsley et al have previously demonstrated correlations between Sacin, FEV1, and Raw(0.5) in 
adults with CF and postulated that these correlations resulted from proximal displacement of 
the diffusion convection front secondary to obstruction of small conducting airways (82).  
Sixteen patients had a normal Sacin but an abnormal LCI suggesting that Sacin may be less 
sensitive to early disease than LCI. 
 
This study suggests that LCI appears to be repeatable within children with CF. The intra visit 
variability of LCI across the three MBW tests performed at visit one were similar to previously 
published figures in healthy children. The mean coefficient of variation for LCI in this study 
was 5.4% compared to reported CVs from groups of healthy children in Edinburgh, London 
and a German and Austrian collaboration which were 5.4% (26), 5.2% (43) and 5.1% (44) 
respectively.  
 
Intra-visit variability of Scond and Sacin were high with mean CVs of 29.8% and 25.4% 
respectively. In our study MBW was performed without targeted tidal volumes. During 
analysis tidal volumes were corrected however it is unclear exactly how tidal volumes effect 
phase III slopes. By not targeting tidal volume, phase III slopes may have been more variable. 
In addition I was unable to exclude breaths in which phase III slopes were indiscernible. 
Without targeted tidal volumes and the ability to exclude aberrant breaths it does not appear 
that measurement of phase III slopes in children with CF is repeatable. 
 
This study supports previous findings that LCI is highly sensitive to the presence of CF disease 
on CT (85) and correlates better with CF disease on CT than FEV1 (76, 78, 89). Both LCI and 
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FEV1 correlated with every aspect of the CT score but LCI correlated better than FEV1 with 
extent and severity of bronchiectasis and bronchial wall thickening. Eighty three percent of 
patients with normal LCI had no bronchiectasis on CT. Ninety six percent of patients with an 
abnormal LCI had bronchiectasis on CT scanning and unfortunately Fuchs et al showed that 
abnormalities on CT scanning in children with CF persist (89). FEV1 correlated better than 
LCI with large plugs and air trapping, illustrating that if regions of lung are obstructed they 
might not contribute to indices of ventilation heterogeneity. 
 
Scond only correlated weakly with bronchial wall thickness (r=0.34) and large plugs (r=0.38), 
it did not correlate with extent or severity of bronchiectasis, small plugs or air trapping. Scond 
was abnormal in our group of children with CF compared to our healthy controls but as with 
Horsley at al’s group it did not correlate with severity of disease (82). Sacin did correlate with 
extent and severity of bronchiectasis, large plugs and air trapping but correlations were weaker 
than for LCI.  
 
There were no overall statistically significant differences in any lung function parameter 
between the first and last visit. This differed from Kraemer et al who showed a deterioration 
in LCI and FEV1 over a much more prolonged period of time (75) and Fuchs et al who showed 
an improvement in LCI over a 3 year period (89). Our study group was a motivated group of 
children with varied genotypes and lung disease, who had families who were willing to attend 
regular prolonged study visits. Within this group there were some individuals in whom FEV1 
and LCI deteriorated and the change in these parameters correlated. No differences in overall 
FEV1 or LCI were seen probably due to the size, motivation and variation of the group in 
combination with the short time frame. 
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There was some variation in all lung function parameters over the four visits despite being 
performed at times of clinical stability. Mean inter-visit CV for individuals across the 4 visits 
was lowest for FVC at 6.8%, followed by FEV1 at 8.1% and then LCI at 9.1%. LCI was almost 
as reproducible as FEV1 despite the group including some severely diseased individuals, in 
whom CV was slightly higher, possibly because of intermittent obstruction of diseased lung 
sections secondary to mucus plugging. Low variability in LCI has meant that LCI has already 
been used to detect a treatment effect in clinical trials of hypertonic saline, dornase alpha, gene 
therapy and ivacaftor (95, 97, 99, 100). The inter-visit CV for Scond was 31.2%, Sacin was 29.5% 
and FEF25-75 was 19%. This was despite no difference in lung function from the start to the 
end of test visits.  The inherent variability of Scond, Sacin and FEF25-75 makes detecting a 
treatment effect during clinical trials or interpreting change in an individual patient very 
difficult. 
 
The study was limited by several factors. The relatively short time frame may have prevented 
significant change in lung function from being detected. Change may have been detected had 
the group been larger. A larger group may have also allowed categorisation of disease severity 
to assess the utility of MBW in detecting change in different stages of CF. Repetition of a 
HRCT at the end of the study period would have assessed whether there was deterioration in 
structural disease that was not detected using lung function. The variability of phase III indices 
might have been reduced with the use of a fixed tidal breathing protocol however this could 
have been impractical in some of our children. In addition analysis of phase III slopes would 
have been improved with the use of software allowing exclusion of breaths in which the phase 
III slope was difficult to determine.  
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Results from this study suggest that LCI is a more sensitive test of early CF lung disease than 
FEV1. LCI appears to be a repeatable and meaningful clinical test in CF, variability over time 
is limited and correlation with structural disease on CT is strong. Although Scond was abnormal 
in most children with CF, it did not correlate with FEV1, LCI or degree and extent of 
bronchiectasis. Although Sacin did correlate with markers of disease severity it did not appear 
as sensitive or correlate as well with CT changes as LCI. In addition Scond and Sacin were both 
extremely variable over multiple test visits limiting their utility.  
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The assessment of control in stable asthmatic children and decisions regarding changes in 
treatment are often made on the basis of subjective symptom reporting. Objective tools are 
limited (13, 101). Spirometry is the most commonly used lung function test in outpatient 
clinics, abnormal FEV1 has been shown to relate to symptoms and risk of exacerbation (103-
106), but most children with stable asthma have normal FEV1 (13, 14). FEF25-75 is possibly 
more sensitive than FEV1 in detecting reversible airways obstruction (19); however its high 
variability has limited its clinical use. FeNO, which is believed to be a marker of airway 
inflammation, does not appear to consistently correlate with symptoms (112). In addition 
spirometry and FeNO may not be achievable in pre-school children. 
 
MBW might offer an alternative option in the assessment of stable asthmatic children as it can 
be performed in children of all ages and can detect early small airways disease. Small airways 
disease has been shown to correlate with measures of asthma control (120) and MBW can 
detect abnormalities in well controlled asthmatic patients with normal FEV1 (50, 124, 125). 
This study sought to determine whether MBW derived indices are abnormal in asthmatic 
children and whether abnormalities relate to asthmatic control, in order to establish whether 





To assess whether indices of MBW are abnormal in children with stable asthma. 
To assess whether indices of MBW related to asthma control. 




6.3.1 Paediatric Asthma Genes and Environment Study  
 
The study population was a cohort of children (aged 5-16 years inclusive) within the Paediatric 
Asthma Genes and Environment Study (PAGES) attending the Royal Hospital for Sick 
Children, Edinburgh, UK. PAGES was designed to examine relationships between genetic 
variations and environmental factors in asthmatic children across Scotland (151). The Chief 
Investigator was Dr Stephen Turner based at the University of Aberdeen. Fifteen Scottish 
centres were involved, Edinburgh was the only centre to perform MBW. In Edinburgh 
recruitment and study visits were run by Debbie Miller, a senior research nurse at the 
Children’s Clinical Research Facility. 
 
My involvement was in the analysis of the MBW tests. I examined relationships between 




6.3.2 Recruitment and Inclusion/Exclusion Criteria 
Between October 2008 and November 2010 children with consultant paediatrician diagnosed 
asthma attending the RHSC Asthma Clinic were invited to participate in the study.  Exclusion 
criteria were any coexisting respiratory conditions, including cystic fibrosis or 
bronchopulmonary dysplasia (BPD), cerebral palsy, Down’s syndrome, gastro-oesophageal 
reflux (prescribed medications) and marked developmental delay.  
 
Children acting as controls were previously recruited for other studies from families of hospital 
staff and local schools and had no history of respiratory disease, prematurity (<34 weeks), 
congenital cardiovascular disease, neuromuscular or bone disease likely to affect respiration 
or viral symptoms at the time of testing. 
 
6.3.3 Study Visit 
Children with asthma were asked to attend on a day when they were not taking oral 
corticosteroids to treat an acute exacerbation. At the study visit assessments were performed 
in the following order; MBW, exhaled nitric oxide, spirometry, skin prick reactivity, collection 
of salivary samples and bronchodilator response. 
 
Parents were asked to complete questionnaires relating to their child’s asthma and environment 
either before or at the study visit. Questionnaires included an asthma questionnaire (available 
at http://www.asthma-pages.com/participants/what/); this included respiratory questions 
validated in the BREATHE study (152), asthma control questions (the Child Asthma Control 
Test®, used with permission) and details of environmental exposure (from Biobank). Parents 
were also asked to complete the Paediatric Asthma Quality of Life Questionnaire 
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(http://www.qoltech.co.uk/paqlq.html) and the Scottish Collaborative Group semi-
quantitative food frequency questionnaire version C1 (http://www.foodfrequency.org). 
 
Patients performed three MBW as described in the common methods section. 
 
Spirometry was performed in accordance with European Respiratory Society / American 
Thoracic Society guidelines using the portable ML3500 MicroLab Viasys spirometer. 
Bronchodilator response was measured by the change in FEV1 15 minutes after inhalation of 
200 micrograms salbutamol, delivered from a pressurised metered dose inhaler via a large 
volume spacer device (Volumatic, Glaxo Smith Kline, UK). Parents and children were asked 
to withhold short acting beta agonists for 6 hours and long acting beta agonists for 12 hours 
prior to testing. 
 
Exhaled NO was measured using a validated (153) portable NO analyser (NIOX MINO, 
Aerocrine, Solna Sweden). Measurements were performed in accordance with internationally 
recommended guidelines (154).  
 
Salivary samples were collected for cotinine with a sterile absorbent cotton wool swab 
(Salivette, Sarstedt Ltd, Leicester, UK). Samples were processed using ELISA (ABS 
laboratories, Welywn Garden City, UK). Levels below the limit of detection were assigned a 
value of 0.1 ng/ml. 
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Skin prick testing to assess sensitivity to Dermatophagoides pteronyssinus, cat dander, dog 
dander, whole egg, Alternaria alternans, Aspergillus fumigatus, peanut and grass was 
performed using standard methodology (155) (ALK, Northampton). Histamine 10mg/ml was 
used as a positive control and 0.9% saline as a negative control. Testing was withheld if a 
patient had taken antihistamines within 72 hours and peanut testing was withheld in patients 
with a history of peanut anaphylaxis. 
 
6.3.4 Analysis 
MBW raw data were extracted from the Innocor and analysed as described earlier to produce 
values for LCI, Scond and Sacin.  Z-scores and percent of predicted values for FEV1, FVC and 
FEF25-75 were calculated. 
 
Minitab Version 17 statistical software (Minitab, USA) was used for data analysis. Data are 
presented as mean with standard deviation (SD). Two sample T-tests were used to compare 
between groups. Pearson and Spearman correlation coefficients were used to compare 
variables. Significance was assumed at p=0.05. 
 
6.3.5 Ethical Approval 
The study was approved by the Cornwall and Plymouth Research Ethics Committee. Written 
consent was obtained from parents at completion of questionnaire and verbal consent was 




6.4.1 Differences between asthmatic and healthy children 
 
Sixty three children (51% male) with asthma aged 5.1-16.5 years (mean 10.3 years) were 
recruited.  The control group comprised 66 children (63% male) aged 5.0-16.1 years (mean 
11.2 years). The criteria for recruitment was inclusive of all types and severities of asthma. 
The cohort included patients on all levels of the BTS treatment ladder (BTS/SIGN Asthma 
guideline 2009) including two patients who were only receiving salbutamol as required and 
two patients who required maintenance oral prednisolone at the time of testing, see table 11. 
 
BTS Step Number of patients Percentage of group 
1 2 3% 
2 15 24% 
3 33 52% 
4 11 17% 
5 2 3% 
Table 11: Patients on each step of the BTS ladder 
 
Sixteen patients had had at least one admission to hospital in the year and eight patients were 
hospitalised in the six months prior to testing. Thirty four patients had had at least one course 
of prednisolone in the year and 25 patients had had oral steroids in the six months prior to 
testing.  
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Severity Indicator Percentage of asthmatic group 
Hospital admission in past year 25% 
Hospital admission in past 6 months 13% 
Prednisolone course in past year 54% 
Prednisolone course in past 6 months 40% 
BTS therapy ≥ 4 21% 
Continuous oral prednisolone 3% 
Wheeze only with colds 14% 
Table 12: Proportion of asthmatic group reporting severity indicator. 
Significant differences were observed between children with asthma and healthy controls for 
LCI and FEF2575, but not FEV1 (table 13). There were no significant differences in Scond or Sacin 
between the groups. Mean values for all lung function indices in the asthmatic group fell within 
healthy ranges. 
Table 13: Mean (SD) results for asthmatic and control groups with significance levels for 
comparisons using 2 sample t-tests. 
 
 Asthmatic Control Significance 
LCI 6.7 (0.9) 6.3 (0.5) P<0.01 
Scond (L-1) 0.03 (0.03) 0.03(0.02) P=0.21 
Sacin (L-1) 0.15 (0.07) 0.14 (0.07) P=0.60 
FEV1 z score -0.65 (0.8) -0.41 (1.0) P=0.16 
FEF2575 z score -1.20 (0.9) -0.51 (1.0) P<0.01 
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6.4.2 Correlation between lung function indices 
 
In children with asthma significant correlations were identified between LCI and Scond 
(Pearson r=0.37, P<0.01), Sacin (Pearson r=0.53, p<0.0001), FEF2575 (Pearson r=-0.31, p=0.04), 
bronchodilator response (Pearson r=0.33, p=0.03) but not FEV1. 1.64 SDS values were 
calculated using values obtained in the control group; the 1.64 SDS for LCI was 7.12, for Scond 
it was 0.06L-1 and for Sacin it was 0.25L-1. Figures 40-43 show scatterplots illustrating the 
correlation between different indices of lung function with reference lines at 1.64 SDSs. 
Values to the right of the vertical line show LCI values greater than 95% of normal values. 
Values below the horizontal line in the FEF25-75 graph and above the horizontal line in the Scond 
and Sacin graphs show values out with 95% of healthy values.  
 
Figure 40: Scatterplot of FEV25-75 z-score versus mean LCI in asthmatic patients. Reference 




















Figure 41: Scatterplot of Scond versus mean LCI in asthmatic patients. Reference lines at 1.64 
SDS. 
 




























Figure 43: Scatterplot of Bronchodilator Response versus mean LCI in asthmatic patients. 
Reference line at 1.64 SDS. 
       
FEV1 and FEF2575 z-scores and Scond correlated with exhaled nitric oxide, r=-0.39, (p=0.007), 
r=-0.33, (p=0.02) and r=0.29, (p=0.02) respectively (Pearson correlation coefficients). LCI 























6.4.3 Asthma Severity 
 
LCI, Sacin, FEV1 and FEF25-75 did not correlate with number of hospital admissions, or number 
of courses of steroids over the previous six months or year. Scond correlated with courses of 
prednisolone over the previous year (Spearman r=0.27, P=0.035) but not courses over the 
previous six months.  
 
Scond correlated with BTS score (Pearson r=0.30, p=0.02), patients on step 3, 4 or 5 had 
significantly higher Scond (0.034 L-1), than patients on steps 1 or 2 (0.021 L-1), p=0.04. LCI, 
Sacin, FEV1 and FEF2575 did not correlate with BTS score. 
 
6.4.4 Asthma Control 
 
In the asthma questionnaire parents were asked to report on how well they considered their 
child’s asthma to be controlled; options were “Not controlled at all”, “Poorly controlled”, 
“Somewhat controlled”, “Well controlled” or “Completely controlled”. Patients whose parents 
reported that their child’s asthma was either completely or well controlled had significantly 
lower LCI (6.4) than those whose parents described their asthma as somewhat controlled or 
worse (6.9, p=0.02). There were no differences in FEV1 or FEF2575 between these groups.  
 
Parents were also asked to grade the frequency of their child’s symptoms and their interference 
with daily life. LCI correlated with time that asthma affected school work, salbutamol use and 
perceived control (see table 14). FEV1 did not correlate with any parent reported factor. 



























































































Table 14: Spearman correlation r values (and p values) between lung function and reported 
symptoms. 
 
6.4.5 Atopy and Allergy 
Thirty six patients had eczema, 26 had rhinitis and 36 had food allergies at the time of testing. 
Twenty five patients had skin prick testing; only three patients were not reactive to any antigen. 
Two children were sensitive to Alternaria alternans, 17 to cat dander, 10 to dog dander, 17 to 
grass, 18 to house dust mite and three to peanut; no patients were sensitive to whole egg or 
Aspergillus fumigatus.  
 
No differences in LCI, Scond, Sacin or FEV1 corresponded to parent reported triggers including 
exercise or pets. Patients who reported dust as a trigger factor had a worse FEF2575 z score (-
1.46 vs -0.9, P=0.03). 
 
 169
There were no differences in LCI, Scond, Sacin or FEV1 between groups of children in whom 
salivary cotinine was either detected or not. Children in whom salivary cotinine was detected 
had significantly lower FEF25-75 z-score compared to those in whom cotinine was not detected 




In this study LCI in stable asthmatic children was significantly higher than in healthy children. 
LCI was significantly higher in patients whose parents reported poorer asthma control, 
something not evident for FEV1 or FEF2575. There was no difference in Scond or Sacin between 
asthmatic and healthy groups but within the asthmatic group Scond correlated with regular 
medications and courses of prednisolone over the preceding six months. 
 
The cohort of asthmatic children had a wide range of disease severity; current control was not 
a precondition of inclusion, however mean FEV1 and FEF25-75 z-scores fell within normal 
ranges. This is in keeping with evidence suggesting that most children with stable asthma have 
normal FEV1 (13, 14). No difference in FEV1 between the healthy and control groups could 
be detected. Mean FEF25-75 z-score was significantly lower in the asthmatic group compared 
to the control group. FEF25-75 has previously been shown to be worse in children reporting 
chronic persistent symptoms (108) and our group included some children who reported poor 
asthma control. 
 
Mean LCI, Scond and Sacin in the group of asthmatic children fell within previously reported 
healthy ranges (50, 54, 82) and within a standard deviation of the study control group. Mean 
LCI of in the asthmatic group was, however, significantly higher than in the control group. 
There was no difference in Scond or Sacin between the groups. Previous studies have 
demonstrated abnormalities in Scond and Sacin in asthmatic patients (45, 48, 126-128). 
Differences in Scond and Sacin were not found in this study, despite differences in LCI and FEF25-
75, possibly because the size of the study it was not possible to detect differences in these highly 
variable parameters.  
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Reported healthy values for Scond and Sacin in children vary, possibly due to methodology, 
choice of inert gas and equipment. In this and previous studies using the modified Innocor, 
0.2% SF6 and without a fixed tidal breathing protocol, reported values of phase III slopes in 
healthy children and adults are different than in other centres (1, 50, 82). For example, 
Verbanck described the upper limit of normal of Sacin as 0.11-0.13 L-1(45) which is below the 
healthy mean reported in this study. However, Verbanck used fixed tidal volumes and N2. N2 
is lighter than SF6 and might theoretically decrease Sacin, due to faster diffusion (58). In addition 
tidal volume is known to affect the phase III slope (21), fixed tidal volumes are likely to 
therefore have an effect on indices of phase III slope analysis. In studies in which tidal volume 
is not fixed, tidal volume is corrected but this adjustment has not been validated. 
 
In asthmatic children LCI correlated with Scond, Sacin and FEF25-75. However, eleven children 
had abnormal LCI and normal Scond, only two children had abnormal Scond and normal LCI. 
Ten children had abnormal LCI and normal Sacin and only two had abnormal Sacin and normal 
LCI. This might suggest that LCI is more sensitive to asthmatic disease than Scond or Sacin. Keen 
et al have previously published MBW data from asthmatic children in whom Scond was the 
commonest MBW abnormality (127). Keen et al required children to breath between 10-
15ml/kg, we did not set limits but encouraged children to breathe regularly. The limits of 
normality in both studies were calculated on the basis of the mean and standard deviation of 
the respective control groups. The variability within Scond and Sacin were much larger in our 
study compared to Keen et al’s (reflected by a larger standard deviation) and the limits of 
normality in our study were therefore greater. Sonappa et al also found higher variability in 
Scond and Sacin than in LCI (130). The higher variation in indices of phase III slopes in our study 
may have limited the ability to detect differences between groups. 
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In this study FEV1 and FEF2575 z-scores and Scond correlated weakly with exhaled nitric oxide 
(r=-0.39, p=0.007, r=-0.33, p=0.02 and r=0.29, p=0.02), LCI and Sacin and did not. Previous 
studies have been contradictory, some studies finding no correlation between FeNO and MBW 
indices (47, 50). In Keen et al’s study a correlation was found between Scond and FeNO, 
however LCI also correlated with FeNO (127). LCI was also shown to correlate with FeNO in 
a study investigating the effects of early severe bronchiolitis, in patients with asthma (125). In 
addition, correlations between Sacin and exhaled alveolar nitric oxide have also been found 
(127, 128). Airway remodelling in the small airways of asthmatic children is known to exist 
(113); and may be the reason why no correlation was found between LCI and exhaled NO, 
despite elevated LCI in the asthmatic group. 
 
LCI and Sacin did not correlate with recent courses of prednisolone or admissions to hospital. 
Since these factors indicate exacerbation, it appears that LCI and Sacin may not be higher in 
patients having frequent exacerbation. Or it may be that patients who experienced numerous 
recent exacerbations had increases in their daily medication and as a result were better 
controlled at the time of study testing. Neither LCI nor Sacin correlated with BTS score either 
but this is complicated because MBW indices have been shown to improve with inhaled 
corticosteroids (47). An earlier study of 31 asthmatic children within our department also 
found that LCI did not correlate with BTS step (50). However Verbanck found that Sacin was 
higher in adults receiving 500µg or more of beclomethasone dipropionate than those on 
smaller doses (128). Relationships between lung function indices and treatments appear 
complex, asthma is a heterogeneous condition and a larger study or more specified cohort may 
lead to better understanding. 
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Scond was significantly higher in patients on step three, four or five of the BTS ladder, than in 
patients on steps one or two. Scond also correlated with the number of courses of prednisolone 
over the year prior to testing. This could imply that Scond is an indicator of severity. However 
there were no significant correlations between Scond and reported recent hospital admissions or 
courses of prednisolone over the 6 months prior to testing. Although the asthmatic group as a 
whole did not have significantly higher Scond than the control group when the group with a 
BTS score of 3 or more was compared to the control group there was a significant difference 
(p=0.028). Other studies have found differences in Scond between healthy and asthmatic groups, 
we may not have in the whole asthmatic group because of the inclusion of mild asthmatic 
patients.  
 
Children who’s asthma was described as either completely or well controlled had significantly 
lower LCI (6.4) than those whose parents described their asthma as somewhat controlled or 
worse (6.9, p=0.02). LCI also correlated with time that asthma affected school work and 
salbutamol use (see table 14). Scond and FEF2575 also correlated with perceived control but did 
not correlate with any other parent reported factor, FEV1 did not correlate with reported 
symptoms. LCI and Scond have previously been shown to be significantly higher in patients 
with uncontrolled compared to controlled asthma (127, 132). This has implications for the 
routine monitoring of asthmatic patients. As symptom perception and reporting varies between 
individuals and families LCI may be of use in objectively assessing patients who might benefit 
from an increase in medication. This study was, however, subject to the same biases of 
symptom perception and reporting. 
 
This study was limited because it was not designed to examine relationships between MBW 
indices and asthma control and severity. The analysis has been performed on a group of 
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patients who were participating in a wider study regarding genetic and environmental 
influences in asthma. Multiple statistical tests were performed on the data to identify 
correlations between variables, some of which may have been coincidental. It would be 
interesting to further investigate some of the associations identified in a prospectively designed 
study with predefined hypotheses.  In addition recruitment of asthmatic children did not 
discriminate between phenotypes and in such a heterogeneous condition different 
abnormalities in lung function may be possible in different groups. More specified groups 
might detect more significant results. Data regarding asthma control was subject to bias 
because it relied on retrospective patient reporting, this could possibly have been reduced with 
symptom diaries. Lastly as described in previous studies the variability in phase III slopes may 
have been reduced with software allowing the exclusion of breaths in which phase III slopes 
were difficult to identify. 
 
Asthma is a heterogeneous disease and therefore lung function may be best interpreted by 
reference to change within the individual. LCI may be considered a better surrogate of 
symptom control than FEV1 and presents an alternative option for the objective assessment of 
the stable asthmatic child. Despite correlations with FeNO and regular treatments, Scond 
appeared too variable to discriminate between healthy and asthmatic patients. Further work to 
define the effects of different phenotypes of asthma on LCI and the benefits of LCI guided 
treatment is warranted. 
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7 Project: The effects of exercise on MBW derived indices in 




Many children with asthma suffer from exercise induced symptoms. However the sensitivity 
of detecting abnormalities in symptomatic children using conventional exercise challenge 
testing with spirometry is poor (135). MBW has been shown to detect abnormalities in 
asthmatic children with normal FEV1 (50, 124, 125), and may therefore also be more sensitive 
to exercise induced changes in lung function. MBW has not previously been performed 
following exercise in asthmatic children, but studies of hyperpolarised helium MRI have 
demonstrated heterogeneous ventilation in asthmatics following exercise (141).  MBW indices 
have also been shown to correlate with bronchial hyper-responsiveness (47), and therefore 
MBW might be able to predict children who develop exercise induced bronchoconstriction. 
The effects of salbutamol on MBW indices following exercise are unknown and are important 
to establish. Evidence suggests that salbutamol does not completely normalise ventilation 
inhomogeneity in asthma (48, 50, 126) and alternative treatments might reduce symptoms. 
 
This study was performed to determine the effects of exercise on MBW in asthmatic children 
in order to assess whether MBW could be a more sensitive way of detecting exercise induced 
asthma (EIA) than FEV1. This would be important in improving our understanding of EIA 
pathophysiology, detecting more children with exercise induced asthma and guiding clinical 
decision making in these children.     
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7.2 Aims 
To investigate changes in indices of MBW in asthmatic individuals following exercise. 
To relate the changes in MBW derived indices to changes in spirometry and reported exercise 
induced symptoms. 
To determine whether baseline indices of MBW can predict exercise induced lung function 
responses. 






7.3.1 Inclusion/Exclusion Criteria 
 
Children with respiratory physician diagnosed asthma and healthy controls recruited from 
local schools were invited to participate. Participants were aged 5-16 years.  
 
Asthmatic children had respiratory paediatrician diagnosed asthma and were currently or 
previously under the care of the respiratory physicians at the RHSC. They were clinically 
stable, with no exacerbations requiring oral corticosteroids or increased bronchodilator use in 
the two weeks prior to testing.  
 
Healthy children were excluded if they had any significant respiratory history including 
asthma or regular anti-asthma medications, previous hospitalisation for a respiratory infection, 
recurrent wheezing episodes, exercise related respiratory symptoms, pneumonia, cystic 
fibrosis, pertussis or tuberculosis. In addition they were excluded if they were born before 34 
weeks gestation, had neuromuscular weakness or bone disease likely to affect respiratory 
function, congenital cardiac defects requiring treatment or a history of atopy (including 
eczema, hay fever or allergic rhinitis).  
 






Asthmatic children were identified through the RHSC asthma out-patient clinic. Letters were 
sent to families inviting them to participate. Letters were followed up by telephone calls for 
discussion and to assess willingness to participate. 
 
Healthy volunteers were recruited by letters sent to parents through local schools. Families 
who replied were contacted by phone to confirm interest and provide further information 
regarding the study.  
 
7.3.3 Study Visit 
 
Each child attended one study visit at the RHSC. Participants followed the order of testing as 
illustrated in figure 44. Children were asked not to take bronchodilators for six hours prior to 
the study visit, all other medications were given as normal. 
 
Consent for study participation was taken on arrival and then children and their parents 
completed a symptom questionnaire. The questionnaires used in the study were designed using 
the International study of Asthma and Allergies in Childhood (ISAAC) study core 









Baseline exhaled NO (FeNO) testing using the NioxMIno (Aerocrine)/Niox) was performed. 
Patients were required to breathe out through a mouthpiece against partial pressure to obtain a 
steady state FeNO signal. Visual incentives were displayed for encouragement.  
 
Patients then performed a set of three MBW tests, followed by spirometry (in accordance with 
ERS/ATS guidelines using a CareFusion spirometer). 
 
Children subsequently performed an exercise challenge on a treadmill in accordance with ATS 
guidelines (157). A target heart rate was set for each child at 80% of their calculated maximum 
heart rate (220-age in years). Once this was achieved children under the age of 12 years ran 
for a further 4 minutes and those over 12, ran for a further 6 minutes. 
 
Following completion of the exercise challenge the child was asked to perform one forced 
expiratory manoeuvre within a minute, the aim of which was to record FEV1. This was 
followed by a single MBW test. This series was repeated to achieve a total of three FEV1 
measurements and three MBW tests. The child then performed a further full set of spirometry. 
 
Following post exercise testing, 400 micrograms of salbutamol was administered to both 
healthy and asthmatic children. This was delivered from a pressurised metered dose inhaler 
via a large volume spacer device (Volumatic, GlaxoSmith Kline, UK). After ten minutes a 
further set of three MBW tests and then spirometry were repeated. 
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If at any time a child’s FEV1 fell to below 20% of their baseline or if the child experienced 
significant discomfort, testing was stopped. Inhaled salbutamol was given if appropriate and 
the child was assessed 10 minutes later with spirometry. 
 
Asthmatic children were followed up by telephone 12-16 days after their visit. The call was 




MBW raw data was extracted from the Innocor and analysed as described earlier to produce 
values for LCI, Scond and Sacin.  Z-scores and percent of predicted values for FEV1, FVC and 
FEF25-75 were calculated. Exercise induced changes in lung function were calculated by 
dividing change by baseline value. 
 
Data were analysed using Minitab Version 17 statistical software (Minitab, USA). Two sample 
t tests were used to compare data between groups and paired t tests within groups before and 
after exercise or salbutamol. Correlations were assessed using Pearson correlation coefficients. 
Significance was assumed at p=0.05. 
 
7.3.5 Ethical Approval 
Ethical Approval was granted by the Lothian Research Ethics committee. Parents and where 






Twenty one asthmatic patients (eight girls, 13 boys), aged 7.8-15.9 years (mean 11.5 years)  
and 21 healthy controls (nine girls and 12 boys) aged 7.6-15.4 years (mean 12.1) were 
recruited. One healthy girl was excluded before testing as she was incidentally found to have 
complete heart block. 
 
All of the asthmatic patients were attending the RHSC asthma clinic. Nine children reported 
one admission to hospital over the preceding 2 years, twelve children reported no admissions. 
Most children had had courses of oral corticosteroids over the preceding 2 years, the numbers 
of children requiring multiple courses are illustrated in figure 45. Six patients had had at least 
one oral corticosteroid course in the 6 months prior to the study. Only two children had had an 
increase in their regular medications in the 6 months before their study visit. 
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Figure 45: Bar chart of the number of children requiring different numbers of steroid courses 
over the 2 years preceding the study. 
 
Eleven children had a history of food allergy, 16 allergy to animals, 15 children had a history 
of eczema, 16 reported hay fever and 17 reported rhinitis. Seven patients reported nocturnal 
symptoms and six reported early morning symptoms in the two weeks preceding their study 
visit. The number of 100mcg doses of inhaled salbutamol each child reported in the seven days 






















Figure 46: Bar chart illustrating the use of salbutamol over the 7 days preceding study visit 
 
The amount and type of regular exercise children reported varied but all children described at 
least one hour of exercise per week. Nine children reported prophylactically using salbutamol 
prior to exercise. Thirteen children reported using salbutamol during exercise, eight of whom 
said they needed salbutamol every time they exercised. Sixteen children said they experienced 
wheeze or difficulty breathing when they exercised, seven of whom said symptoms occurred 
every time they exercised. Only two children felt that their asthma prevented them from doing 


























7.4.2 Baseline Lung Function 
 
The initial mean (SD) LCI of the asthmatic group was 7.2 (0.7) which was significantly higher 
than the control group (6.8 (0.4)), p = 0.02. Initial FEV1 and FEF25-75 z scores and FeNO were 
also significantly worse in the asthmatic group (p = 0.01, p < 0.01 and p = 0.05 respectively). 
There were no significant differences in Scond, Sacin or FVC (see table 15). 
 Healthy Children Asthmatic Children Significance 
LCI 6.8 (0.4) 7.2 (0.7) p = 0.02 
Scond (L-1) 0.02 (0.03) 0.04 (0.02) p = 0.07 
Sacin (L-1) 0.18 (0.06) 0.17 (0.06) p = 0.40 
FEV1 z-score 0.08 (0.73) -0.58 (0.85) p = 0.01 
FVC z-score 0.18 (0.85) 0.36 (0.90) p = 0.53 
FEF25-75 z-score -0.33 (0.91) -1.43 (1.07) p = 0.001 
FeNO 19.7 (21.7) 37.7 (33.6) p = 0.05 
Table 15: Baseline mean (SD) lung function. 2 sample t tests used to compare healthy and 
asthmatic groups. 
 
In asthmatic patients LCI correlated with Sacin (Pearson r = 0.54, p = 0.02), but not Scond, FEV1 
z-score or FEF25-75 z-score. Neither Scond nor Sacin correlated with FEV1 or FEF25-75 z-score. No 
lung function parameter correlated with FeNO.  
 
FEF25-75 z-score correlated with the number of courses of oral corticosteroids children had had 
in the preceding two years (Spearman r = -0.57, p <0.01). No other lung function parameter 
correlated with number of oral corticosteroid courses or hospital admissions in the preceding 
two years. There were no correlations between baseline lung function and reported symptom 
frequency or salbutamol use in the period immediately preceding testing. 
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7.4.3 Changes in lung function following exercise 
 
Following exercise FEV1 fell by more than 20% in three of the asthmatic children. These 
children had abnormal baseline lung function with a mean (SD) LCI of 7.6 (0.8), FEV1 z-score 
of -1.7 (1.2) and FEF25-75 z-score of -2.7 (0.6). However FEF25-75 z-score was the only 
parameter to be significantly worse when compared to the group who did not experience a 
drop in FEV1 of more than 20% (p = 0.03). Baseline FVC z-score was normal (0.16 (1.1)).  
Scond 0.06 L-1 (0.02), Sacin 0.16 L-1 (0.03) were also within 1.64 standard deviations of healthy 
mean values. There are limited data on these three children following exercise as only one 
patient managed to perform MBW following exercise. These patients have had to be excluded 
from the following analysis. 
 
Following exercise, FEF25-75 was still significantly worse in the asthmatic group compared to 
the healthy group (p = 0.004). In addition Scond was now significantly elevated in the asthmatic 
group (p = 0.001). FEV1 and LCI were no longer significantly worse in the asthmatic group 
compared to the healthy volunteers. 
 
 Healthy Asthmatic Significance 
LCI 6.9 (0.4) 7.3 (1.0) p = 0.08 
Scond (L-1) 0.01 (0.01) 0.034 (0.026) p = 0.001 
Sacin (L-1) 0.21 (0.09) 0.19 (0.06) p = 0.36 
FEV1 z-score 0.07 (0.71) -0.39 (0.69) p = 0.051 
FVC z-score 0.03 (0.89) 0.19 (0.97) p = 0.61 
FEF25-75 z-score -0.10 (0.75) -0.98 (0.97) p = 0.004 
Table 16: Post exercise lung function. 2 sample t tests used to compare groups 
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Within the healthy children there were no significant changes in lung function following 
exercise. Table 17 shows baseline and post exercise lung function in the healthy group. 
 Initial Post exercise 95% CI for Change 
LCI 6.8 (0.4) 6.9 (0.4) -0.09, 0.26 (p = 0.31) 
Scond (L-1) 0.03 (0.03) 0.01 (0.01) -0.03, 0.0004 (p = 0.06) 
Sacin (L-1) 0.18 (0.07) 0.21 (0.09) -0.01, 0.07 (p = 0.15) 
FEV1 z-score 0.08 (0.73) 0.07 (0.71) -0.11, 0.10 (p = 0.90) 
FVC z-score 0.15 (0.84) 0.03 (0.89) -0.30, 0.07 (p = 0.21) 
FEF25-75 z-score -0.25 (0.93) -0.10 (0.75) -0.04, 0.35 (p = 0.11) 
Table 17: Initial and post exercise lung function Mean (SD in healthy children. Change 
determined using paired t tests. 
 
In the asthmatic patients there were significant changes in Sacin, FVC and FEF25-75 z-score 
following exercise. Sacin and FVC deteriorated (p = 0.02 and 0.004), but FEF25-75 actually 
improved following exercise (p = 0.001). LCI trended upwards but this was not significant (p 
= 0.14). 
 Initial  Post exercise  95% CI for Change 
LCI 7.1 (0.6) 7.4 (1.1) -0.11, 0.66 (p = 0.14) 
Scond (L-1) 0.04 (0.02) 0.04 (0.03) -0.02, 0.02 (p = 0.86) 
Sacin (L-1) 0.17 (0.06) 0.19 (0.05) 0.001, 0.045 (p = 0.04) 
FEV1 z-score -0.39 (0.66) -0.39 (0.69) -0.12, 0.12 (p = 0.99) 
FVC z-score 0.39 (0.88) 0.19 (0.97) -0.32, -0.07 (p = 0.004) 
FEF25-75 z-score -1.23 (0.99) -0.98 (0.97) 0.11, 0.38 (p = 0.001) 
Table 18: Initial and post exercise lung function Mean (SD) in asthmatic children. Change 




Children were asked if their exercise was limited by their asthma. Nine children said that their 
asthma did not affect how much exercise they did. Four children said that they could exercise 
as long as they took salbutamol. Only two children said that their asthma stopped them 
exercising even if they took salbutamol. One patient did not answer the question. If the children 
were divided into two groups depending on if they reported needing salbutamol (n=6) or not 
(n=9) the change in LCI following exercise appeared higher in the group requiring salbutamol. 
In the group who reported requiring salbutamol LCI increased by a mean of 6.6% compared 
to 2.7% in the group who did not, this trend was not statistically significant (p = 0.50). Table 
19 shows the percentage change in the other lung function parameters depending on whether 
children reported requiring salbutamol or if they were not limited by their asthma at all. There 
appeared to be a more marked deterioration in FEV1 in the group who reported requiring 
salbutamol to exercise, but again this was not significant.  
 
 No reported exercise limitation Exercise limitation without salbutamol Significance 
LCI 2.7 (8.5)% 6.6 (11.7)% p = 0.50 
Scond  25 (111)% -11.5 (43.2)% p = 0.40 
Sacin  29.9 (45.2)% 14.2 (29.1)% p = 0.43 
FEV1  0.26 (3.9)% -0.78 (2.4)% p = 0.51 
FEF25-75 5.6 (9.0)% 10.14 (8.1)% p = 0.31 
Table 19: Mean (SD) percentage change in lung function following exercise in groups that 
reported no exercise limitation and requirement for salbutamol. Two sample t tests used for 
comparison. 
 
In the asthmatic group change in lung function parameters following exercise did not correlate 
with each other. In addition there were no correlations between change in any lung function 
parameter and baseline FeNO, number of oral corticosteroid courses or number of hospital 
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admissions over the preceding two years or symptoms and salbutamol use in the weeks 
preceding testing. 
 
Figures 47 and 48 are line plots of individual LCI and FEV1 before and after exercise, the 
patients who demonstrated a fall in FEV1 of greater than 20% have been included (Patients 1, 
17 and 20).  The graph of LCI illustrates than in many individuals there is an immediate 
increase in LCI with the first MBW test that tends to fall by the second or third test. FEV1 
stayed relatively stable throughout post exercise testing (except in the three patients who were 
excluded due to dramatic falls in FEV1). 
 
Figure 47: Line plot of individual LCI from mean baseline, at each test post exercise and mean 
following salbutamol 
 


































Figure 48: Line plot of individual FEV1 from best at baseline, at each blow post exercise and 



































7.4.4 Changes in lung function following salbutamol 
 
Following salbutamol the only significant differences between healthy and asthmatic groups 
were in Scond and FEF25-75 z-score (p = 0.02 and 0.003 respectively). Mean LCI and FEV1 z-
score were not significantly different between groups. 
 Healthy Asthmatic Significance 
LCI 7.1 (0.4) 7.4 (0.6) p = 0.09 
Scond (L-1) 0.01 (0.03) 0.03 (0.02) p = 0.02 
Sacin (L-1) 0.25 (0.18) 0.17 (0.06) p = 0.08 
FEV1 z-score 0.23 (0.70) -0.10 (0.88) p = 0.18 
FVC z-score 0.03 (0.81) 0.25 (0.84) p = 0.40 
FEF25-75 z-score 0.15 (0.75) -0.69 (0.94) p = 0.003 
Table 20: Post salbutamol lung function. 2 sample t tests used to compare groups. 
 
Administration of salbutamol to healthy children caused an improvement in FEV1 z-score from 
0.07 to 0.23 (p=0.02) and FEF25-75 z-score from -0.10 to 0.23 (p=0.001). Paradoxically there 
was a deterioration in mean LCI from 6.9 to 7.1 (p=0.01).  
 Post exercise Post salbutamol 95% CI for Change 
LCI 6.9 (0.4) 7.1 (0.4) 0.05, 0.38 (p = 0.01) 
Scond (L-1) 0.01 (0.01) 0.01 (0.03) -0.01, 0.014 (p = 0.95) 
Sacin (L-1) 0.21 (0.09) 0.26 (0.18) -0.04, 0.13 (p = 0.27) 
FEV1 z-score 0.07 (0.71) 0.23 (0.70) 0.04, 0.30  (p = 0.02) 
FVC z-score 0.03 (0.89) 0.00 (0.83) -0.15, 0.09 (p = 0.59) 
FEF25-75 z-score -0.10 (0.75) 0.23 (0.75) 0.15, 0.50 (p = 0.001) 
Table 21: Healthy children changes in lung function following salbutamol (paired t tests used) 
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In the asthmatic group administration of salbutamol improved both FEV1 z-score from -0.39 
to -0.06 (P=0.006) and FEF25-75 z-score from -0.98 to -0.64 (P=0.03). There were no other 
significant changes. 
 
 Post exercise Post salbutamol 95% CI for Change 
LCI 7.5 (1.2) 7.3 (0.6) -0.62, 0.22 (p = 0.33) 
Scond (L-1) 0.04 (0.03) 0.03 (0.02) -0.03, 0.00 (p = 0.10) 
Sacin (L-1) 0.19 (0.05) 0.18 (0.06) -0.05, 0.01 (p = 0.20) 
FEV1 z-score -0.39 (0.69) -0.06 (0.72) 0.11, 0.56 (p = 0.006) 
FVC z-score 0.19 (0.97) 0.25 (0.83) -0.20, 0.32 (p = 0.63) 
FEF25-75 z-score -0.98 (0.97) -0.64 (0.87) 0.04, 0.65 (p = 0.03) 




Figures 49 and 50 illustrate the changes in LCI and FEV1 from baseline, following exercise 
and after salbutamol in both groups of children. 
 
Figure 49: Interval plot of baseline, post exercise and post salbutamol mean (plus 95% CI) 
LCI in the asthmatic and healthy (HV) groups.
 
Figure 50: Interval plot of baseline, post exercise and post salbutamol mean (plus 95% CI) 

































7.4.5 Symptoms following testing 
 
Twelve to 16 days after each visit families were called and asked whether they thought their 
child’s asthma was better, the same or worse. No family reported improvement in symptoms, 
13 said symptoms had been similar and four stated that symptoms had been worse than usual. 
There were no significant differences in exercise induced changes in any lung function 
parameter between the group with similar and the group who reported worse symptoms.  
 
 No change in symptoms Worse Symptoms Significance 
LCI 3.5 (11.1)% 3.53 (6.76)% p = 0.98 
Scond  31.0 (100)% -20.1 (40.2)% p = 0.20 
Sacin  26.0 (43.1)% 8.2 (30.5)% p = 0.40 
FEV1  0.6 (2.9)% -0.1 (2.2)% p = 0.65 
FEF25-75 7.2 (6.4)% 13.2 (8.1)% p = 0.25 
Table 23: Mean (SD) percentage change in lung function following exercise in groups with 





The group of asthmatic children in our study had significantly worse LCI compared to our 
healthy group. Baseline LCI was abnormal in children who experienced large falls in FEV1 
following exercise. There were trends towards an increase in LCI following exercise in the 
asthmatic group and a higher increase in the group who reported requiring salbutamol to 
exercise. 
 
The group of asthmatic children were varied and included a large proportion of patients who 
were asymptomatic in the period preceding testing. Twelve out of 21 children reported no 
symptoms in the previous two weeks, and nine children reported not using salbutamol for one 
week before their study visit. Eleven children had had fewer than two courses of oral 
corticosteroids in the previous two years and twelve children had not been admitted to hospital 
during this time. Four children denied ever suffering from exercise induced wheeze or 
breathlessness. 
 
The asthmatic group had significantly higher FEV1 and FEF25-75 values than the healthy group. 
However the mean values of each of these indices were within normal ranges. Studies have 
found that most children with stable asthma have normal FEV1 (13, 14) but that patients with 
low FEV1 may be more symptomatic and at greater risk of exacerbation (103). In addition 
FEF25-75 has previously been found to be lower in chronic persistent asthma compared to well 
controlled asthma (108) and in our study baseline FEF25-75 z-score correlated with the number 
of courses of oral corticosteroids received in the two years prior to testing. The phenotypes of 
children in our group were probably mixed. 
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The asthmatic group had significantly higher LCI than the healthy group but the asthmatic 
group mean fell within 1.64 standard deviations of the healthy mean (7.46).  Five patients had 
an LCI of greater than 7.46. There were no differences between the healthy and asthmatic 
groups in Scond or Sacin. Scond has previously been shown to be the most commonly abnormality 
of MBW in asthma (48, 126, 127) but in this study only two patients had a Scond out with 1.64 
standard deviations of the healthy mean. Sacin was only outside 1.64 standard deviations of the 
healthy mean in one asthmatic patient but did correlate with LCI. There were no other 
correlations between lung function parameters possibly because so many children had normal 
results. Indices of MBW did not correlate with FeNO, in keeping with previous studies 
suggesting that ventilation heterogeneity can be independent of airway inflammation (47, 50). 
 
In the children in whom FEV1 fell by more than 20% after exercise mean baseline FEV1, FEF25-
75 and LCI were abnormal. Baseline ventilation heterogeneity has been shown previously to 
correlate with airway hyper-responsiveness triggered by methacholine or cold-dry air 
hyperventilation challenges (47, 122, 127). In this study elevated LCI appeared to be 
associated with exercise induced bronchospasm (EIB) however the difference in baseline LCI 
between the groups who did and did not have large drops in FEV1 was not significant. The 
trend may have been significant in a group in which more patients experienced EIB. 
 
Following exercise mean LCI in the asthmatic children rose from 7.1 to 7.4 but the 95% CIs 
for change were -0.11, 0.66 (p = 0.14). The trend in rise in LCI following exercise occurred 
despite the group including children who did not report exercise induced symptoms and with 
the exclusion of children who experienced significant EIB. There was almost no difference in 
FEV1, (CIs for change -0.12, 0.12). Ventilation heterogeneity in asthmatics following exercise 
has been demonstrated by hyperpolarised helium MRI (141), the ability of this study to 
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significantly demonstrate increased heterogeneity using LCI may have been limited by its size. 
Scond which appeared significantly worse in the asthmatic compared to healthy groups 
following exercise did not actually change in the asthmatic group following exercise. The 
difference between the healthy and asthmatic groups is likely due to a slight fall in Scond with 
exercise in the healthy group. 
 
Sacin and FVC were the only assays that significantly deteriorated following exercise. Sacin has 
previously been shown to correlate strongly with FEV1 during exacerbation suggesting that it 
may be a major determinant of airflow obstruction (142); Sacin might therefore be used to detect 
EIB. However, despite the deterioration in Sacin following exercise, Sacin in the asthmatic group 
following exercise appeared lower than the healthy group (0.19 L-1 versus 0.21 L-1 
respectively) meaning that it could not discriminate between the two groups. It is possible that 
both the changes in FVC and Sacin relate to variation in breathing pattern as testing began 
immediately after exercise. Inhalation to full vital capacity may have been limited due to 
breathlessness, thereby reducing FVC. The change in Sacin may have been related to alteration 
of tidal volume and breathing rate, which are known to effect the phase III slope (21), as 
opposed to exercise induced peripheral ventilation heterogeneity. FEF25-75 z-score 
paradoxically improved with exercise in the asthmatic group (95% CI 0.11, 0.38 p < 0.01). 
FEF25-75 is more sensitive to small airways disease than FEV1 but is reliant on the validity of 
FVC and the level of expiratory effort (19). The apparent improvement in FEF25-75 following 
exercise is possibly a result of the change in FVC asthmatic patients had following exercise. 
 
Asthmatic children who reported exercise limitation or requirement for salbutamol to prevent 
limitation appeared to have greater increases in LCI than children who stated that their asthma 
did not limit their exercise (6.6% compared to 2.7%). The difference was not significant (p = 
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0.50) but the group was small and only six children stated that their exercise was limited or 
that they needed salbutamol to exercise. No significant difference in the fall in FEV1 z-score 
was observed either. Correlation between fall in FEV1 on exercise testing and exercise related 
symptoms is known to be poor (135). There are no previous studies regarding the effects of 
exercise on MBW derived indices or correlation with symptoms, a larger study of children 
with asthma is required to determine this relationship. 
 
There were no correlations between change in lung function and baseline FeNO. FeNO has 
previously been shown to be associated with bronchial hyper responsiveness (127). This 
relationship was not demonstrated in this group possibly because baseline FeNO was relatively 
low or because the group did not show significant deterioration in lung function with exercise. 
 
Post exercise lung function testing lasted up to 27 minutes following cessation of exercise. 
The individual line plot of LCI over the three MBW tests (figure 47) illustrates that in several 
children LCI deteriorated in the first test after exercise only to normalise on tests two and 
three. Analysis of the change in MBW derived indices used a mean of the three post exercise 
tests but heterogeneity may increase immediately following exercise and improve with time. 
 
Administration of salbutamol to the asthmatic group following completion of their post 
exercise testing caused significant improvements in FEV1 (95% CI 0.11, 0.56, p < 0.01) and 
FEF25-75 (95% CI 0.04, 0.65, p = 0.03). There were no significant changes in LCI, Scond or Sacin. 
Salbutamol has previously been shown to partially but not completely reverse abnormalities 
in MBW in asthmatic patients (48, 50, 126). The lack of effect seen in this study may have 
been due to poor peripheral deposition of inhaled salbutamol or the relative normality of LCI 
and Scond in the group.  
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This study was limited by size, patient selection and possibly subjective symptom reporting. 
Asthma is a heterogeneous condition, as demonstrated in the demographics of the cohort not 
all children with asthma have exercise induced symptoms. Exercise may have different effects 
on MBW derived indices in children with exercise induced symptoms than those without and 
results of either group may not be applicable to the other. This study did seek to determine 
whether there were different effects in groups categorised depending on symptoms but 
numbers were small and although trends were observed differences were not significant. 
Categorising children depending on reported symptoms depends on accurate reporting and 
awareness of symptoms. Although the majority of children said that their exercise was not 
limited by their asthma, some of these children still took salbutamol before or during exercise. 
Children in this study were not asked to keep a diary in the weeks prior to their visit, which 
may have improved the accuracy of symptom reporting. 
 
Mean LCI was higher in asthmatic children compared to healthy controls but LCI could not 
detect change following exercise in asthmatic children in whom FEV1 fell by less than 20%. 
The effects of exercise on MBW in asthmatic children who experienced large falls in FEV1 
could not be assessed as immediate treatment was the priority. However, the study was not 
designed to assess the effects of MBW derived indices in children with large falls in FEV1 but 
instead assess whether MBW could be more sensitive in detecting exercise induced changes 
in asthmatic children in whom there is no change in FEV1. It appeared that more symptomatic 
children had larger increases in LCI following exercise and either a larger study of asthmatic 
children or a study of children who all suffer from exercise induced symptoms is necessary to 
clarify these preliminary findings. 
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8 Project: Evaluation of MBW derived indices in asthmatic 




There is evidence to suggest that there is significant ventilation heterogeneity during 
exacerbation of asthma (119). Indices of phase III slope analysis have demonstrated 
abnormalities during exacerbation in adults (142) but there have been no studies of MBW in 
paediatric exacerbation. There have therefore been no studies assessing the effects of 
salbutamol on MBW derived indices in children during exacerbation. This is important 
because evidence suggests that salbutamol does not completely normalise ventilation 
inhomogeneity in asthma (48, 50, 126) and alternative treatments targeting the small airways 
may be beneficial. The natural history of ventilation heterogeneity following exacerbation is 
unknown. Following provoked exacerbation of asthma in adults, small airways disease was 
shown to persist after normalisation of FEV1 and correlated with bronchial hyper-
responsiveness (117). If ventilation heterogeneity persists following exacerbation and 
predisposes children to bronchial hyper-responsiveness, medication should possibly be altered 
in the period following exacerbation.  
  
This study sought for the first time to determine the effects of exacerbation and salbutamol 




To determine whether MBW derived indices are abnormal during an exacerbation of asthma. 
To investigate the effects of salbutamol multi-dosing on MBW indices during an exacerbation. 
To measure indices of MBW in children 4-6 weeks after discharge from hospital. 
To relate persistent abnormalities in MBW to symptoms, characteristics of the child and 







8.3.1 Inclusion/Exclusion Criteria 
Children aged 5- 16 years with previously diagnosed asthma (either attending primary care or 
hospital clinic) who were admitted to the RHSC with an exacerbation requiring corticosteroids 
were recruited. Children had to be well enough to attend the research facility within the 
hospital and at the time of testing did not require salbutamol more frequently than at two hourly 
intervals. Children who could not leave their bed as they were too unwell or required daytime 




Patients were identified through either the hospital’s general medical or respiratory teams. The 
family were approached and the study described; written information sheets were left if 
interest was shown. Consent was taken once the family had at least one hour to consider 
participation. Admission details were extracted from medical notes. The child was given an 
asthma severity score corresponding to the child’s pre admission BTS treatment step. The 
treatments prescribed during admission and the length of time between salbutamol 
administration and testing were recorded. The child was given a maximal therapy grade 
depending on treatments required for the exacerbation (mechanical ventilation = 5; 
intravenous (IV) therapy = 4; High Dependency Unit (HDU) care = 3; any nebulised 




8.3.3 Study Visits 
Testing was performed in the RHSC Children’s Clinical Research Facility (CCRF). The 
child’s first visit occurred as soon as practically possible after admission; when the patient no 
longer required salbutamol more frequently than at 2 hourly intervals. Testing was undertaken 
at least one hour after the patient’s last dose of salbutamol.  
 
At the first visit height and weight were measured. Baseline observations including heart rate, 
respiratory rate and oxygen saturations were recorded. The family were asked to complete a 
short questionnaire relating to the child’s asthma, including details such as normal 
medications, exacerbating factors, frequency of exacerbation and symptoms preceding 
admission. The patient underwent MBW and spirometry shortly before and 15 minutes after 
salbutamol (1000 micrograms via spacer). Timing of salbutamol coincided with the clinical 
team’s prescription. 
 
A second visit was scheduled for four to six weeks after discharge to coincide with a clinic 









                Patient spaced to 2 hourly salbutamol via Metered Dose Inhaler (MDI) 
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MBW raw data were extracted from the Innocor and analysed as described earlier to produce 
values for LCI, Scond and Sacin.  Z-scores and percent of predicted values for FEV1, FVC and 
FEF25-75 were calculated. 
 
Data were analysed using Minitab Version 17 statistical software (Minitab, USA). Paired t 
tests were used to assess change in baseline FEV1, LCI, Scond and Sacin following bronchodilator 
and after recovery. Pearson correlation coefficients were used to examine relationships 
between lung function indices. Significance was assumed at p = 0.05. 
 
8.3.5 Ethical Approval 
 
Ethical Approval was granted by the Lothian Research Ethics committee. Parents and where 







Nine children (six female) aged 6.4-13.6 years (median 9.0 years) were recruited. Children’s 
heights ranged from 132-163cm. Children all had a prior diagnosis of asthma before presenting 
to hospital. All children reported multiple triggers for their symptoms including viral upper 
respiratory tract infections (URTI), pets, dust, exercise, cigarette smoke, weather, emotional 
upset, hay fever and paint fumes.  
 
The group’s regular medications prior to exacerbation varied greatly; one child was on step 1 
of the BTS treatment ladder, two were on step 2, three were on step 3, two were on step 4 and 
one was on step 5 (BTS/SIGN Asthma guideline 2009). Three patients said that on average 
they used salbutamol more than once a day, four said they used salbutamol daily and only one 
patient said they used salbutamol occasionally. The number of courses of oral corticosteroids 
and hospital admissions children had over the previous 12 months are illustrated in figures 51 
and 52. Days of school absence due to asthma over the previous year varied from 0 - 50. 
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Figure 51: Frequency of Hospital Admission over the 12 months prior to study participation. 
 





































Exacerbation was reported as having started 17 to 72 hours prior to testing. Six patients 
reported they knew the trigger for their current exacerbation, triggers included URTI, weather, 
emotional upset, dust, hay fever and animals.  
 
The severity of exacerbation varied. All children received oral corticosteroids and inhaled 
bronchodilators; eight of the nine children also required nebulisers and three required high 





8.4.2 Baseline Lung function 
 
Children were tested at a mean (SD) of 36.6 (17.0) hours following admission. Seven of the 
children were receiving four hourly inhaled salbutamol by this time; the remaining two were 
at three hourly intervals. Testing began at a mean (SD) of 3.5(0.5) hours post last inhaled 
salbutamol. 
 
Baseline mean (SD) LCI was 8.5 (1.7), Scond was 0.06 L-1 (0.03), Sacin 0.19L-1 (0.10), FEV1 z-
score -3.4 (1.6) and FEF25-75 z-score was -3.0 (1.5). The upper limits of normal based on the 
mean plus 1.64 standard deviations of 66 healthy children involved in a previous study (page 
156) were an LCI of 7.12, Scond of 0.06L-1 and a Sacin of 0.25L-1. Intra-visit CV for LCI was 
4.4%, Scond was 15.2% and Sacin was 22.2%.  
 
Pre bronchodilator FEV1 z-score correlated strongly with LCI (r = -0.81, p = 0.008) and Sacin 
(r = -0.91, p = 0.001). FEF25-75 z-score also strongly correlated with LCI and Sacin (r = -0.92, p 
= 0.001 and r = -0.84, p = 0.004 respectively). LCI correlated with Sacin (r = 0.85, p = 0.004). 




Figure 53: Baseline FEV1 z-score vs mean LCI in asthmatic patients presenting with 
exacerbation 
 
































8.4.3 Pre Admission Asthma Control 
 
Children were divided into groups depending on the level of treatment they were receiving 
prior to hospital admission (BTS/SIGN Asthma guideline 2009). The mean (SD) lung function 
parameters for each group are displayed in table 24. 
 
BTS Step 1 2 3 4 5 
N 1 2 3 2 1 
LCI 9.3 7.8 (0.3) 9.8 (2.1) 6.7 (0.7) 8.6 
Scond (L-1) 0.04 0.07 (0.02) 0.08 (0.02) 0.04 (0.05) 0.04 
Sacin (L-1) 0.19 0.16 (0.09) 0.26 (0.11) 0.10 (0.01) 0.25  
FEV1 z-score -3.8 -2.6 (0.4) -4.3 (1.5) -1.5 (0.6) -5.3 
FVC z-score -2.4 -1.9 (0.3) -3.4 (1.4) -1.0 (0.2) -5.4  
FEF25-75 z-score -4.3 -2.6 (1.2) -3.6 (1.9) -1.5 (1.3) -3.2 
Table 24: Baseline mean (SD) lung function in groups divided by preadmission BTS treatment 
score (BTS/SIGN Asthma guideline 2009). 
 
Pre admission control was also assessed using symptom questionnaires, (although one patient 
did not complete a questionnaire). Patients were asked to report how frequently they used their 
salbutamol inhaler (0=never, 1=occasionally, 2=daily, 3=more than once a day), their 
responses related to their lung function are detailed in table 25. Scond tended to worse and FEV1, 
FVC and FEF25-75 tender to be better in patients taking more salbutamol. 
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Salbutamol Frequency 0 1 2 3 
N 0 1 4 3 
LCI  9.3 8.3 (2.4) 8.4 (1.7) 
Scond (L-1)  0.04 0.05 (0.02) 0.09 (0.01) 
Sacin (L-1)  0.19 0.22 (0.12) 0.14 (0.06) 
FEV1 z-score  -3.8 -2.8 (1.4) -1.9 (1.0) 
FVC z-score  -2.9 -2.0 (1.1) -1.3 (0.5) 
FEF25-75 z-score  -3.8 -2.7 (1.6) -1.8 (1.1) 
Table 25: Baseline mean (SD) lung function in groups divided by pre admission salbutamol 
use. 
Patients also reported how may courses of prednisolone they had used in the 6 months 
preceding admission. The results and corresponding lung function for each group are reported 
in table 26. 
Prednisolone  
(6 months) 
0 1 2 4 8 
N 1 2 3 1 1 
LCI 10.3 7.8 (0.3) 9.4 (2.1) 6.0 7.6 
Scond (L-1) 0.10 0.07 (0.02) 0.07 (0.03) 0.0001 0.06 
Sacin (L-1) 0.21 0.16 (0.09) 0.23 (0.14) 0.10 0.18 
FEV1 z-score -3.0 -1.6 (0.03) -3.1 (1.8) -1.6  -3.6 
FVC z-score -1.8 -1.1 (0.2) -2.2 (1.3) -1.1 -2.8 
FEF25-75 z-
score 
-3.1 -1.5 (0.3) -3.3 (2.0) -1.4 -2.7 
Table 26: Baseline mean (SD) lung function in groups divided by reported courses of 
prednisolone over preceding 6 months 
 
Patients also described their usual triggers, hospital admissions and school absences. There 
were no correlations between these indicators and lung function during exacerbation. 
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8.4.4 Exacerbation Severity 
 
Children were divided into groups depending on the maximal therapy they required during 
their exacerbation. Children were graded 1 if they only required MDIs and oral corticosteroids, 
2 if they were given nebulisers, 3 if they required IV medication, 4 if they were admitted to 
HDU and 5 if they were mechanically ventilated. Only one child admitted to hospital only 
needed MDIs and corticosteroids, 5 were given nebulisers in addition and 3 children were 
admitted to HDU. No children were given IV medications and not admitted to HDU and none 
were mechanically ventilated during this admission. The mean lung function of each group is 
displayed in table 27. 
Maximal therapy grade 1  2 3 4 5 
N 1 5 0 3 0 
LCI 7.4 8.6 (2.1)  8.6 (1.5)  
Scond (L-1) 0.07 0.05 (0.04)  0.07 (0.02)  
Sacin (L-1) 0.11 0.21 (0.12)  0.20 (0.02)  
FEV1 z-score -1.9 -3.7 (2.0)  -3.2 (0.3)  
FVC z-score -1.1 -3.1 (1.9)  -2.3 (0.8)  
FEF25-75 z-score -2.4 -3.1 (1.9)  -2.9 (1.1)  
Table 27: Baseline mean (SD) lung function in groups divided by maximal therapy required for 
admission. 
 
When the children were divided into two groups depending on whether or not they were 
admitted to HDU there were no differences in lung function. Mean (SD) LCI in the group 
admitted to HDU was 8.6 (1.5) compared to 8.4 (1.9) in the group who were not (p = 0.86); 
mean (SD) FEV1 z-score in the HDU group was -3.2 (0.3) compared to -3.4 (2.0) in the non 
HDU group (p = 0.85). 
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Two out of the nine children were on three hourly and seven of nine were on four hourly 
salbutamol MDIs by the time of testing. There were no differences in any assay between these 
two groups at the time of testing. 
 
8.4.5 Change in lung function following bronchodilator 
 
Post bronchodilator mean (SD) LCI was 8.3 (1.4), Scond was 0.06 L-1 (0.03), Sacin 0.17 L-1 
(0.06), FEV1 z-score -2.8 (1.4) and FEF25-75 z-score was -2.5 (1.3). Post salbutamol LCI 
correlated with post salbutamol FEV1 z-score (Pearson r=-0.83, P=0.005). 
 
 


























The change in each lung function parameter following bronchodilator is shown in table 28.  
The only significant difference following salbutamol was seen in the change in FEV1 z-score 
(P=0.04). No other significant changes were seen. 
 
 Baseline Post salbutamol Difference 
LCI 8.5 (1.7) 8.3 (1.4) P=0.41 
Scond (L-1) 0.06 (0.03) 0.06 (0.03) P=0.75 
Sacin (L-1) 0.19 (0.10) 0.17 (0.06) P=0.28 
FEV1 z-score -3.4 (1.6) -2.8 (1.4) P=0.04 
FVC z-score -2.6 (1.6) -2.2 (1.4) P=0.08 
FEF25-75 z-score -3.0 (1.5) -2.5 (1.3) P=0.14 
Table 28: Baseline and post salbutamol mean (SD) lung function in children admitted for 




In some children administration of salbutamol caused a deterioration (an increase) in LCI, see 
figure 56. Larger improvements in LCI appeared to occur if baseline LCI was worse but the 
correlation between initial LCI and change following salbutamol was not significant (Pearson 
r = -0.61, p = 0.08). Initial FEV1 z-score significantly correlated with bronchodilator change 
(Pearson r = -0.71, p = 0.03). 
 
 



















Change in LCI significantly correlated with change in FEV1 in individual patients (Pearson r 
= -0.71, p = 0.03). There were no significant correlations between changes in LCI and FEV1 
or FEF25-75 with Scond or Sacin. 
 
Figure 57: Percentage change in LCI following salbutamol versus percentage change in FEV1 
























8.4.6 Follow up after discharge 
 
Three patients returned 5-10 weeks after discharge. All three patients said that their asthma 
was either well or completely controlled at the time of follow up. The group had normal mean 
lung function with a mean (SD) LCI of 6.7 (0.6), Scond of 0.03 L-1 (0.02), Sacin of 0.13 L-1 (0.06), 
FEV1 z-score of -0.6 (0.6) and a FEF25-75 z-score of -1.2 (0.6). One patient (patient 5) had 
persistently abnormal LCI (7.36) and FEF25-75 z-score (-1.74), this patient had higher Sacin and 
lower FEV1 compared to the other two patients but the values were within 1.64 standard 
deviations of the healthy mean. Figure 58 illustrates individual LCI at baseline, post 
salbutamol and at follow up (in the 3 patients who attended). 
 
 
Figure 58: Individual line plot of LCI at baseline, post salbutamol and at follow up. 
 





















Patients 1 and 3 only required nebulised treatment during their hospital stay, patient 5 required 
HDU admission. All three patients were on four hourly salbutamol MDIs when they were 
initially tested. Patient 5 had been using salbutamol more than once daily prior to admission 
but was only on step 3 of the BTS treatment ladder and had not had any courses of oral 
corticosteroids or days of school absence in the preceding year.  
 220
8.5 Discussion 
This study has demonstrated for the first time that LCI is abnormal and repeatable in children 
during an acute exacerbation of asthma. During exacerbation LCI correlated with FEV1, but 
despite significant bronchodilator response in FEV1, salbutamol had a variable effect on LCI.  
 
LCI was abnormal (>7.12) in eight out of nine asthmatic children during exacerbation. The 
mean (SD) baseline LCI of the group was 8.5(1.7). The CV of LCI at baseline testing was low 
(4.4%) suggesting that LCI is repeatable during asthmatic exacerbations. There are no other 
studies detailing the effects of asthmatic exacerbation on LCI, however small airways disease 
has been detected using HRCT scanning in provoked exacerbation of asthmatic adults (117). 
 
Thompson et al reported abnormalities in Scond and Sacin during asthmatic exacerbation in adults 
(142). In our study mean Scond and Sacin were within 1.64 standard deviations of the healthy 
mean determined in our centre (using the same equipment and methodology). Throughout 
studies in this thesis, variability of Scond and Sacin have been high, in this study the CV of Scond 
was 15.2% and Sacin was 22.2%. The high variability in indices of phase III slope analysis has 
limited their ability to differentiate disease. The variability of phase III slopes in Thompson’s 
study was not specified, percentage of predicted values (derived from a study by Verbanck et 
al (40)) were presented but the limits of normality were not quoted. 
 
During asthmatic exacerbation FEV1 and FEF25-75 z-score strongly correlated with LCI and 
Sacin. There were no correlations between Scond and other lung function indices. Thompson et 
al showed similar correlations between Sacin and FEV1 with a lack of association between Scond 
and FEV1 during exacerbation (142). Verbanck had previously shown that patients with 
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abnormal Sacin had lower FEV1 z-scores (131). The correlations between Sacin, FEV1 and LCI 
might suggest that the acinar zone is a major determinant of ventilation heterogeneity and 
airflow obstruction in exacerbation of asthma. However a causal relationship has not been 
established, alternatively FEV1 may be a major determinant of acinar ventilation 
heterogeneity. 
 
There were no significant differences in LCI, Sacin, Scond, FEV1 or FEF25-75 between groups of 
children depending on pre admission BTS treatment step. In Thompson’s study of asthmatic 
adults they found a correlation between Sacin and pre admission treatment levels which they 
suggested proved a relationship between disease in the acinar region and asthma severity 
(142). Verbanck et al had previously found that Sacin was higher in patients receiving higher 
doses of inhaled corticosteroids (128) and Farah et al found that Sacin was associated with 
deterioration in symptoms following downwards titration of medication (144). The lack of 
correlation between MBW indices and pre admission treatment level in this study does not 
disprove a relationship between asthma severity and ventilation heterogeneity because 
treatment levels can be a poor measure of asthma severity (102), especially during 
exacerbation when pre admission treatment levels may be an underestimate of short term 
severity.  
 
The study group had a high rate of oral corticosteroid courses, school absence and salbutamol 
use indicating poor control in the period before admission to hospital. There appeared to be a 
trend of worse Scond but better FEV1, FVC and FEF25-75 in patients taking more salbutamol. 
Farah et al found worse FEV1, Scond and Sacin in patients with poorly controlled asthma, 
assessed on the basis of an asthma control questionnaire (132). My study numbers were too 
small to make any conclusions. 
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There were no differences between lung function parameters in relation to maximal grade of 
treatment received during exacerbation. Maximal therapy was intended to be used to indicate 
exacerbation severity. At the time of testing patients were almost all receiving the same 
treatment, 3 – 4 hourly salbutamol MDIs. I had hypothesised that abnormalities in ventilation 
inhomogeneity might persist because of obstruction preventing peripheral deposition of 
inhaled therapies. Abnormalities in indices of MBW have been show to persist despite inhaled 
salbutamol (48, 50, 126). However patients on higher maximal therapy grades received IV 
medication which will have bypassed airways obstruction. Persistent small airways disease 
despite salbutamol has been found and suggested to be due to small airways remodelling (113). 
However abnormalities of MBW indices found in stable asthmatics possibly reflecting 
remodelling have been small (47, 50) and probably masked by the large changes we found 
during exacerbations. There is evidence of persistent small airways disease demonstrated by 
HRCT scanning following normalisation of FEV1 and FEF25-75 in allergen induced 
exacerbation in which patients were not given medication (117). Persistence in small airways 
disease was postulated as being due to the inhalation of fine particulate antigens that were 
deposited in the lung periphery. The patients in my study were admitted with exacerbations 
caused by a variety of triggers and patients were given medications. 
 
Following salbutamol multi-dosing the only significant improvement in lung function was in 
FEV1 (p=0.04). There was no difference in LCI, Scond or Sacin but change in FEV1 correlated 
with change in LCI within individual patients (r = -0.71, p = 0.03). Children with higher LCIs 
tended to show more improvement following salbutamol, but this trend was not significant (r 
= -0.61, p = 0.08). Administration of salbutamol has previously been shown to at least partially 
reverse ventilation inhomogeneity in asthma (48, 50, 126).  Children in this study were 
receiving very regular salbutamol and tolerance to its effect may have developed, however 
effect was still seen in FEV1. The lack of effect may have been due to obstruction preventing 
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peripheral deposition of salbutamol. In this study salbutamol administration was associated 
with an increase in LCI in some children. Increases in LCI may have been caused by increased 
inhomogeneity following deposition of salbutamol in well ventilated regions of lung. The lack 
of significant effect from inhaled salbutamol on MBW derived indices suggests that outcomes 
in asthmatic exacerbation could be improved with alternative therapies targeting the small 
airways. 
 
In patients who attended follow up mean LCI fell to within healthy range, indicating that 
asthmatic exacerbation was the likely factor causing elevation in LCI. Only three children 
attended follow up but this group included the two patients who had had the most severely 
abnormal LCI at initial testing. One patient had persistently abnormal LCI and FEF25-75 and 
this child was the only patient out of the three who attended follow up who had required HDU 
care and IV medication. The abnormality in LCI in this patient may have been a persistent 
effect of the exacerbation, however the patient did not report worse symptoms than the other 
two patients following discharge. Abnormal LCI may have predated the exacerbation. There 
is evidence that suggests abnormal ventilation heterogeneity is associated with bronchial hyper 
responsiveness (47, 122, 127) and possibly this patient may have had a more severe 
exacerbation because of pre-existing ventilation heterogeneity. To prove this association a 
much larger prospective study would be required. 
 
This study had several limitations, partly associated with the difficulties of testing children 
during an acute illness. MBW testing could not be performed at the most severe stage of 
asthmatic exacerbation. Children could not undergo testing until they were stable and not 
requiring acute medical intervention. MBW testing could not be performed on a ward or in the 
Accident and Emergency department and could not be undertaken by a child receiving 
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supplemental oxygen. It was necessary for there to be at least an hour following administration 
of salbutamol before testing and therefore the interval between salbutamol doses had to be of 
a minimum duration of two hours. Testing was undertaken a mean of 36 hours following 
admission by which time seven of the nine children were only receiving four hourly inhaled 
salbutamol. The initial design of the study included testing patients twice during their 
admission, once as soon as they were clinically stable and again on the day of discharge. I 
found however that this was not possible because the patient was usually discharged on the 
same day they became stable enough to have their first study visit.  
 
Only a small number of children were recruited to this study because of practicalities and time 
constraints. Families and children were generally very happy to participate but involvement 
was limited by the availability of the research facility and the necessity to perform testing 
during standard working hours (due to staffing). The number of children may have limited 
detection of significant correlations between lung function with pre admission control and 
treatment, exacerbation severity and persistent abnormalities of lung function at follow up. 
Testing at follow up also proved to be difficult as follow up appointments either did not 
coincide with availability of myself or the clinical research facility, patients were not followed 
up in the hospital or families did not wish to miss further school because of an additional 
hospital visit. 
 
There was high within testing variability in asthmatic children’s Scond and Sacin results. High 
variability suggests poor repeatability and reduces the power of an assay to detect a change 
within an individual. In addition there was high variability of mean Scond and Sacin results across 
the control group of healthy children used for comparison. High variability across the control 
group caused a wide normal range and may have prevented these assays from differentiating 
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between healthy and diseased groups. As discussed in previous studies within this thesis, many 
published studies investigating Scond and Sacin have occurred in adults and have used a fixed 
tidal volume breathing protocol to reduce variability in the phase III slope. Detection of the 
phase III slope can be difficult in children with variable tidal volumes and I did not have the 
ability with the software to my disposal to exclude breaths with indeterminable phase III 
slopes, which will probably have increased variability.  
 
The study design could have been improved. FeNO was not tested, but may have allowed 
evaluation of the relationship between inflammation and ventilation heterogeneity during 
exacerbation and following recovery. FeNO may have helped to determine whether persistent 
abnormalities in lung function were secondary to ongoing inflammation or pre-existing small 
airways remodelling. Symptom data was collected by questionnaire and was subject to reporter 
error, symptom diaries following discharge may have been more useful. Attempts at relating 
lung function to pre admission treatments were made but there was no evaluation of 
compliance, this could have been attempted with review of repeat prescription records. 
 
LCI can detect increased ventilation heterogeneity during asthmatic exacerbation, it is 
repeatable during exacerbation and improves following recovery. No significant improvement 
in LCI was seen following administration of inhaled salbutamol during exacerbation, 
suggesting that treatments targeting the small airways could improve outcomes in asthmatic 
exacerbation. A larger prospective study is required to assess whether pre-existing 





MBW is a safe non-invasive method of detecting small airways disease through assessment of 
ventilation heterogeneity. It has been shown to be sensitive to disease in cystic fibrosis and 
asthma. However there was limited evidence regarding its variability in health and disease and 
my objective was to further define this. I used the modified Innocor to perform SF6 washouts 
in healthy children, children with CF and children with asthma in five different studies.  
 
Throughout, LCI was higher in children with disease compared to those without. In children 
with CF, LCI correlated with the extent and severity of bronchiectasis on CT scanning and in 
asthma LCI appeared to deteriorate during exacerbation. Children with poorer perceived 
asthma control had higher LCI, and we showed that children who had severe EIB had abnormal 
baseline LCI. LCI correlated with FEV1 in children with CF and in children experiencing an 
exacerbation of asthma, suggesting that LCI relates to disease severity. In addition, in CF and 
asthma, LCI appeared more sensitive to early disease than FEV1, FEV1 could not discriminate 
between and healthy and asthmatic groups and correlated less well with bronchiectasis on CT 
than LCI.   
 
LCI was found to be repeatable in healthy children and children with CF and asthma, with 
consistently low variation in intra-visit testing. The longitudinal study of children with CF 
demonstrated some variability in LCI over multiple visits despite no significant overall 
change, however this inter-visit variability was very similar to that of FEV1 suggesting it is 
unlikely to limit utility. Inter-visit variability of LCI was higher in children with more severe 
CF possibly reducing the sensitivity of LCI for detecting change in these patients.  In order to 
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compare LCI results, between tests or individuals, the posture study demonstrated that posture 
must be standardised during MBW testing. 
 
In contrast, indices of phase III slope analysis were highly variable both within and between 
visits. This high variability may have limited the ability of Scond and Sacin to differentiate 
between healthy and diseased groups and to detect postural or longitudinal change in CF and 
exercise or exacerbation induced changes in asthma. As described the variability of phase III 
slope indices in my studies may have been increased compared to other centres as I did not 
use a fixed volume tidal breathing protocol and could not exclude small breaths during 
analysis. 
 
There were some common limitations to the studies described in this thesis. Several studies 
were limited by sample size and subject selection. Possibly due to limited size and subject 
recruitment no change in LCI over time in patients with CF and no significant rise in LCI 
following exercise in asthmatic patients were detected. However, the statistical analysis 
throughout this thesis was performed without a professional statistician whom may have been 
able to define significant changes. In addition, multiple statistical tests were performed on 
some of the data, particularly in relation to asthma control and therefore some findings may 
have been coincidental. 
 
LCI has the potential to be clinically useful in the management of individual patients once 
testing and equipment are standardised. In CF LCI is sensitive to early disease, correlates with 
markers of severity and improves with treatments. However in patients with more severe CF 
lung disease, variability appears higher and further studies establishing the variability and 
treatment effects are required. In asthma, LCI may relate to asthma control and might predict 
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those who develop EIB and more severe exacerbation.  There are variable effects of salbutamol 
on LCI and the effects of many other treatments are unknown. A prospective longitudinal 
study is required to assess the relationship between LCI, symptoms, exacerbation and 
treatments to assess whether LCI could be used to guide asthma management in the future.  
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